US20020012680A1 - Compositions and methods for improved delivery of lipid regulating agents - Google Patents

Compositions and methods for improved delivery of lipid regulating agents Download PDF

Info

Publication number
US20020012680A1
US20020012680A1 US09/898,553 US89855301A US2002012680A1 US 20020012680 A1 US20020012680 A1 US 20020012680A1 US 89855301 A US89855301 A US 89855301A US 2002012680 A1 US2002012680 A1 US 2002012680A1
Authority
US
United States
Prior art keywords
peg
pharmaceutical composition
fatty acid
hydrophobic
acid esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/898,553
Other versions
US6451339B2 (en
Inventor
Mahesh Patel
Feng-Jing Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipocine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22981541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020012680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US09/898,553 priority Critical patent/US6451339B2/en
Publication of US20020012680A1 publication Critical patent/US20020012680A1/en
Priority to US10/074,687 priority patent/US7374779B2/en
Priority to US10/158,206 priority patent/US20030104048A1/en
Application granted granted Critical
Publication of US6451339B2 publication Critical patent/US6451339B2/en
Assigned to LIPOCINE INC. reassignment LIPOCINE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, FENG-JING, PATEL, MAHESH V.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Definitions

  • the present invention relates to drug delivery systems, and in particular to pharmaceutical compositions for the improved delivery of hydrophobic compounds.
  • Hydrophobic therapeutic agents i.e., therapeutic compounds having poor solubility in aqueous solution
  • a well-designed formulation must, at a minimum, be capable of presenting a therapeutically effective amount of the hydrophobic compound to the desired absorption site, in an absorbable form. Even this minimal functionality is difficult to achieve when delivery of the hydrophobic therapeutic agent requires interaction with aqueous physiological environments, such as gastric fluids and intestinal fluids.
  • Pharmaceutical compositions for delivery of such hydrophobic therapeutic agents must carry the hydrophobic compound through the aqueous environment, while maintaining the hydrophobic compound in an absorbable form, and avoiding the use of physiologically harmful solvents or excipients.
  • a number of approaches to formulating hydrophobic therapeutic agents for oral or parenteral delivery are known.
  • One well-known approach uses surfactant micelles to solubilize and transport the therapeutic agent.
  • Micelles are agglomerates of colloidal dimensions formed by amphiphilic compounds under certain conditions.
  • Micelles, and pharmaceutical compositions containing micelles have been extensively studied and are described in detail in the literature; see, e.g., Remington's Pharmaceutical Sciences, 17 th ed. (1985), the disclosure of which is incorporated herein in its entirety.
  • micelles can incorporate hydrophobic therapeutic agents in the hydrocarbon core of the micelle, or entangled at various positions within the micelle walls.
  • micellar formulations can solubilize a variety of hydrophobic therapeutic agents, the loading capacity of conventional micelle formulations is limited by the solubility of the therapeutic agent in the micelle surfactant. For many hydrophobic therapeutic agents, such solubility is too low to offer formulations that can deliver therapeutically effective doses.
  • Another conventional approach takes advantage of the increased solubility of hydrophobic therapeutic agents in oils (triglycerides). Hydrophobic therapeutic agents, while poorly soluble in aqueous solution, could be sufficiently lipophilic that therapeutically effective concentrations of the therapeutic agents can be prepared in triglyceride-based solvents.
  • one conventional approach is to solubilize a hydrophobic therapeutic agent in a bioacceptable triglyceride solvent, such as a digestible vegetable oil, and disperse this oil phase in an aqueous solution.
  • the dispersion may be stabilized by emulsifying agents and provided in emulsion form.
  • the therapeutic agent can be provided in a water-free formulation, with an aqueous dispersion being formed in the in vivo gastrointestinal environment.
  • the properties of these oil-based formulations are determined by such factors as the size of the triglyceride/therapeutic agent colloidal particles and the presence or absence of surfactant additives.
  • a triglyceride-containing formulation suitable for delivering hydrophobic therapeutic agents through an aqueous environment is an oil-in-water emulsion.
  • Such emulsions contain the hydrophobic therapeutic agent solubilized in an oil phase which is dispersed in an aqueous environment with the aid of a surfactant.
  • the surfactant may be present in the oil-based formulation itself, or may be a compound provided in the gastrointestinal system, such as bile salts, which are known to be in vivo emulsifying agents.
  • the colloidal oil particles sizes are relatively large, ranging from several hundred nanometers to several microns in diameter, in a broad particle size distribution. Since the particle sizes are on the order of or greater than the wavelength range of visible light, such emulsions, when prepared in an emulsion dosage form, are visibly “cloudy” or “milky” to the naked eye.
  • triglyceride-based pharmaceutical compositions are useful in solubilizing and delivering some hydrophobic therapeutic agents, such compositions are subject to a number of significant limitations and disadvantages.
  • Emulsions are thermodynamically unstable, and colloidal emulsion particles will spontaneously agglomerate, eventually leading to complete phase separation.
  • the tendency to agglomerate and phase separate presents problems of storage and handling, and increases the likelihood that pharmaceutical emulsions initially properly prepared will be in a less optimal, less effective, and poorly-characterized state upon ultimate administration to a patient.
  • Uncharacterized degradation is particularly disadvantageous, since increased particle size slows the rate of transport of the colloidal particle and digestion of the oil component, and hence the rate and extent of absorption of the therapeutic agent.
  • a further disadvantage of triglyceride-containing compositions is the dependence of therapeutic agent absorption on the rate and extent of lipolysis.
  • colloidal emulsion particles can transport hydrophobic therapeutic agents through the aqueous environment of the gastrointestinal tract, ultimately the triglyceride must be digested and the therapeutic agent must be released in order to be absorbed through the intestinal mucosa.
  • the triglyceride carrier is emulsified by bile salts and hydrolyzed, primarily by pancreatic lipase. The rate and extent of lipolysis, however, are dependent upon several factors that are difficult to adequately control.
  • the amount and rate of bile salt secretion affect the lipolysis of the triglycerides, and the bile salt secretion can vary with stomach contents, with metabolic abnormalities, and with functional changes of the liver, bile ducts, gall bladder and intestine.
  • Lipase availability in patients with decreased pancreatic secretory function, such as cystic fibrosis or chronic pancreatitis may be undesirably low, resulting in a slow and incomplete triglyceride lipolysis.
  • the activity of lipase is pH dependent, with deactivation occurring at about pH 3, so that the lipolysis rate will vary with stomach contents, and may be insufficient in patients with gastric acid hyper-secretion.
  • surfactants commonly used in the preparation of pharmaceutical emulsions such as polyethoxylated castor oils
  • certain surfactant combinations when used in combination with digestible oils in emulsion preparations, can substantially decrease the lipolysis-inhibiting effect of some common pharmaceutical surfactants (see, U.S. Pat. No. 5,645,856), such formulations are still subject to the other disadvantages of pharmaceutical emulsions and triglyceride-based formulations.
  • microemulsions Like an emulsion, a microemulsion is a liquid dispersion of oil in water, stabilized by surfactants. The microemulsion particles are smaller than those of an emulsion, rendering the microemulsion essentially optically clear. Microemulsions, however, are thermodynamically stable, and are not subject to the particle agglomeration problems of conventional emulsions. It is generally believed that microemulsions are micelle-like particles, having an essentially micellar structure but containing a distinct oil phase in the micelle “core”. These micelle-like particles are often referred to as “swollen micelles”, a term which emphasizes their close relationship to true micellar particles.
  • microemulsions function quite differently in drug delivery systems.
  • the majority of hydrophobic therapeutic agents are lipophilic, and have greater solubility in triglycerides than in surfactants.
  • the hydrophobic therapeutic agent in a microemulsion-based delivery system is preferentially solvated in the triglyceride phase, which is in turn encapsulated in the swollen micelle.
  • the preferential partitioning in the triglyceride phase results in higher loading capacities than in comparable micelle-based systems, but at the cost of introducing into the delivery system the lipolysis-dependence and other disadvantages associated with the presence of triglycerides.
  • the larger size of microemulsion particles, relative to true micelles results in a slower rate of particle diffusion, and thus a slower rate of therapeutic agent absorption.
  • the present invention provides pharmaceutical compositions for improved delivery of hydrophobic therapeutic agents.
  • the present invention provides a triglyceride-free pharmaceutical composition including a hydrophobic therapeutic agent and a carrier.
  • the carrier includes a hydrophilic surfactant and a hydrophobic surfactant in amounts such that upon dilution with an aqueous solution such as simulated gastrointestinal fluids the carrier forms a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing the hydrophobic therapeutic agent.
  • the present invention provides a clear aqueous dispersion containing a hydrophilic surfactant, a hydrophobic surfactant and a hydrophobic therapeutic agent.
  • the dispersion is substantially free of triglycerides.
  • the present invention relates to a triglyceride-free pharmaceutical composition which includes a hydrophilic surfactant and a hydrophobic surfactant in amounts such that upon dilution with an aqueous solution a clear aqueous dispersion is formed, a first amount of a hydrophobic therapeutic agent solubilized in the clear aqueous dispersion, and a second amount of the hydrophobic therapeutic agent that remains non-solubilized but dispersed.
  • the present invention relates to methods of increasing the rate and/or extent of absorption of hydrophobic therapeutic agents by administering to a patient a pharmaceutical composition of the present invention.
  • FIG. 1 shows the enhanced bioabsorption of a hydrophobic therapeutic agent in the compositions of the present invention, relative to a commercial formulation.
  • the present invention overcomes the problems described above characteristic of conventional formulations such as micelle formulations, emulsions, and microemulsions, by providing unique triglyceride-free pharmaceutical compositions.
  • compositions including a combination of a hydrophilic surfactant and a hydrophobic surfactant can solubilize therapeutically effective amounts of hydrophobic therapeutic agents without recourse to the use of triglycerides, thereby avoiding the lipolysis dependence and other disadvantages of conventional formulations.
  • Use of these formulations results in an enhanced rate and/or extent of absorption of the hydrophobic therapeutic agent.
  • the present invention provides a pharmaceutical composition including a carrier and a hydrophobic therapeutic agent.
  • the carrier includes a hydrophilic surfactant and a hydrophobic surfactant in amounts such that upon dilution with an aqueous solution the carrier forms a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing the hydrophobic therapeutic agent.
  • the carrier is substantially free of triglycerides, thereby providing surprising and important advantages over conventional, triglyceride-containing formulations.
  • the carrier includes at least one hydrophilic surfactant and at least one hydrophobic surfactant.
  • hydrophilic and “hydrophobic” are relative terms.
  • a compound must necessarily include polar or charged hydrophilic moieties as well as non-polar hydrophobic (lipophilic) moieties; i.e., a surfactant compound must be amphiphilic.
  • An empirical parameter commonly used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value).
  • HLB hydrophilic-lipophilic balance
  • hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable.
  • hydrophobic surfactants are compounds having an HLB value less than about 10.
  • HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.
  • HLB values can differ by as much as about 8 HLB units, depending upon the empirical method chosen to determine the HLB value (Schott, J. Pharm. Sciences, 79(1), 87-88 (1990)).
  • PLURONIC® surfactants BASF Corp.
  • the HLB values may not accurately reflect the true physical chemical nature of the compounds.
  • the hydrophilic surfactant can be any hydrophilic surfactant suitable for use in pharmaceutical compositions.
  • Such surfactants can be anionic, cationic, zwitterionic or non-ionic, although non-ionic hydrophilic surfactants are presently preferred. As discussed above, these non-ionic hydrophilic surfactants will generally have HLB values greater than about 10. Mixtures of hydrophilic surfactants are also within the scope of the invention.
  • the hydrophobic surfactant can be any hydrophobic surfactant suitable for use in pharmaceutical compositions.
  • suitable hydrophobic surfactants will have an HLB value less than about 10. Mixtures of hydrophobic surfactants are also within the scope of the invention.
  • hydrophobic and hydrophilic surfactants should be made keeping in mind the particular hydrophobic therapeutic agent to be used in the composition, and the range of polarity appropriate for the chosen therapeutic agent, as discussed in more detail below. With these general principles in mind, a very broad range of surfactants is suitable for use in the present invention.
  • Such surfactants can be grouped into the following general chemical classes detailed in the Tables below.
  • the HLB values given in the Tables below generally represent the HLB value as reported by the manufacturer of the corresponding commercial product. In cases where more than one commercial product is listed, the HLB value in the Tables is the value as reported for one of the commercial products, a rough average of the reported values, or a value that, in the judgment of the present inventors, is more reliable. It should be emphasized that the invention is not limited to the surfactants in the following Tables, which show representative, but not exclusive, lists of available surfactants.
  • PEG polyethylene glycol
  • PEG-fatty acid esters have useful surfactant properties.
  • PEG-fatty acid monoesters esters of lauric acid, oleic acid, and stearic acid are most useful.
  • preferred hydrophilic surfactants include PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-10 oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20 laurate and PEG-20 oleate.
  • Polyethylene glycol fatty acid diesters are also suitable for use as surfactants in the compositions of the present invention.
  • preferred hydrophilic surfactants include PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate and PEG-32 dioleate.
  • Representative PEG-fatty acid diesters are shown in Table 2.
  • mixtures of surfactants are also useful in the present invention, including mixtures of two or more commercial surfactant products.
  • PEG-fatty acid esters are marketed commercially as mixtures or mono- and diesters.
  • Representative surfactant mixtures are shown in Table 3.
  • Suitable PEG glycerol fatty acid esters are shown in Table 4.
  • preferred hydrophilic surfactants are PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-20 glyceryl oleate, and PEG-30 glyceryl oleate.
  • a large number of surfactants of different degrees of hydrophobicity or hydrophilicity can be prepared by reaction of alcohols or polyalcohols with a variety of natural and/or hydrogenated oils.
  • the oils used are castor oil or hydrogenated castor oil, or an edible vegetable oil such as corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or almond oil.
  • Preferred alcohols include glycerol, propylene glycol, ethylene glycol, polyethylene glycol, sorbitol, and pentaerythritol.
  • preferred hydrophilic surfactants are PEG-35 castor oil (Incrocas-35), PEG-40 hydrogenated castor oil (Cremophor RH 40), PEG-25 trioleate (TAGAT® TO), PEG-60 corn glycerides (Crovol M70), PEG-60 almond oil (Crovol A70), PEG-40 palm kernel oil (Crovol PK70), PEG-50 castor oil (Emalex C-50), PEG-50 hydrogenated castor oil (Emalex HC-50), PEG-8 caprylic/capric glycerides (Labrasol), and PEG-6 caprylic/capric glycerides (Softigen 767).
  • Preferred hydrophobic surfactants in this class include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (Labrafil® M 2125 CS), PEG-6 almond oil (Labrafil® M 1966 CS), PEG-6 apricot kernel oil (Labrafil® M 1944 CS), PEG-6 olive oil (Labrafil® M 1980 CS), PEG-6 peanut oil (Labrafil® M 1969 CS), PEG-6 hydrogenated palm kernel oil (Labrafil® M 2130 BS), PEG-6 palm kernel oil (Labrafil® M 2130 CS), PEG-6 triolein (Labrafil® M 2735 CS), PEG-8 corn oil (Labrafil® WL 2609 BS), PEG-20 corn glycerides (Crovol M40), and PEG-20 almond glycerides (Crovol A40).
  • Polyglycerol esters of fatty acids are also suitable surfactants for the present invention.
  • preferred hydrophobic surfactants include polyglyceryl oleate (Plurol Oleique), polyglyceryl-2 dioleate (Nikkol DGDO), and polyglyceryl-10 trioleate.
  • Preferred hydrophilic surfactants include polyglyceryl-10 laurate (Nikkol Decaglyn 1-L), polyglyceryl-10 oleate (Nikkol Decaglyn 1-O), and polyglyceryl-10 mono, dioleate (Caprol® PEG 860).
  • Polyglyceryl polyricinoleates are also preferred hydrophilic and hydrophobic surfactants. Examples of suitable polyglyceryl esters are shown in Table 6. TABLE 6 Polyglycerized Fatty Acids COMPOUND COMMERCIAL PRODUCT (Supplier) HLB Polyglyceryl-2 stearate Nikkol DGMS (Nikko) 5-7 Polyglyceryl-2 oleate Nikkol DGMO (Nikko) 5-7 Polyglyceryl-2 Nikkol DGMIS (Nikko) 5-7 isostearate Polyglyceryl-3 oleate Caprol ® 3GO (ABITEC), Drewpol 6.5 3-1-O (Stepan) Polyglyceryl-4 oleate Nikkol Tetraglyn 1-O (Nikko) 5-7 Polyglyceryl-4 stearate Nikkol Tetraglyn 1-S (Nikko) 5-6 Polyglyceryl-6 oleate Drewpol 6-1-O (Stepan)
  • esters of propylene glycol and fatty acids are suitable surfactants for use in the present invention.
  • preferred hydrophobic surfactants include propylene glycol monolaurate (Lauroglycol FCC), propylene glycol ricinoleate (Propymuls), propylene glycol monooleate (Myverol P-O6), propylene glycol dicaprylate/dicaprate (Captex® 200), and propylene glycol dioctanoate (Captex® 800). Examples of surfactants of this class are given in Table 7.
  • mixtures of surfactants are also suitable for use in the present invention.
  • mixtures of propylene glycol fatty acid esters and glycerol fatty acid esters are suitable and are commercially available.
  • One preferred mixture is composed of the oleic acid esters of propylene glycol and glycerol (Arlacel 186). Examples of these surfactants are shown in Table 8. TABLE 8 Glycerol/Propylene Glycol Fatty Acid Esters COMPOUND COMMERCIAL PRODUCT (Supplier) HLB Oleic ATMOS 300, ARLACEL 186 (ICI) 3-4 Stearic ATMOS 150 3-4
  • a particularly important class of surfactants is the class of mono- and diglycerides. These surfactants are generally hydrophobic. Preferred hydrophobic surfactants in this class of compounds include glyceryl monooleate (Peceol), glyceryl ricinoleate, glyceryl laurate, glyceryl dilaurate (Capmul® GDL), glyceryl dioleate (Capmul® GDO), glyceryl mono/dioleate (Capmul® GMO-K), glyceryl caprylate/caprate (Capmul® MCM), caprylic acid mono/diglycerides (Imwitor® 988), and mono- and diacetylated monoglycerides (Myvacet® 9-45).
  • Peceol glyceryl monooleate
  • glyceryl ricinoleate glyceryl laurate
  • Capmul® GDL glyceryl dilaurate
  • Sterols and derivatives of sterols are suitable surfactants for use in the present invention. These surfactants can be hydrophilic or hydrophobic. Preferred derivatives include the polyethylene glycol derivatives. A preferred hydrophobic surfactant in this class is cholesterol. A preferred hydrophilic surfactant in this class is PEG-24 cholesterol ether (Solulan C-24). Examples of surfactants of this class are shown in Table 10.
  • PEG-sorbitan fatty acid esters are available and are suitable for use as surfactants in the present invention.
  • these surfactants are hydrophilic, although several hydrophobic surfactants of this class can be used.
  • preferred hydrophilic surfactants include PEG-20 sorbitan monolaurate (Tween-20), PEG-20 sorbitan monopalmitate (Tween-40), PEG-20 sorbitan monostearate (Tween-60), and PEG-20 sorbitan monooleate (Tween-80). Examples of these surfactants are shown in Table 11.
  • Ethers of polyethylene glycol and alkyl alcohols are suitable surfactants for use in the present invention.
  • Preferred hydrophobic ethers include PEG-3 oleyl ether (Volpo 3) and PEG-4 lauryl ether (Brij 30). Examples of these surfactants are shown in Table 12.
  • esters of sugars are suitable surfactants for use in the present invention.
  • Preferred hydrophilic surfactants in this class include sucrose monopalmitate and sucrose monolaurate. Examples of such surfactants are shown in Table 13. TABLE 13 Sugar Ester Surfactants COMPOUND COMMERCIAL PRODUCT (Supplier) HLB Sucrose distearate SUCRO ESTER 7 (Gattefosse), 3 Crodesta F-10 (Croda) Sucrose distearate/ SUCRO ESTER 11 (Gattefosse), 12 monostearate Crodesta F-110 (Croda) Sucrose dipalmitate 7.4 Sucrose monostearate Crodesta F-160 (Croda) 15 Sucrose monopalmitate SUCRO ESTER 15 (Gattefosse) >10 Sucrose monolaurate Saccharose monolaurate 15 1695 (Mitsubishi-Kasei)
  • hydrophilic PEG-alkyl phenol surfactants are available, and are suitable for use in the present invention. Examples of these surfactants are shown in Table 14. TABLE 14 Polyethylene Glycol Alkyl Phenol Surfactants COMMERCIAL COMPOUND PRODUCT (Supplier) HLB PEG-10-100 nonyl phenol Triton X series (Rohm & Haas), >10 Igepal CA series (GAF, USA), Antarox CA series (GAF, UK) PEG-15-100 octyl phenol ether Triton N-series (Rohm & Haas), >10 Igepal CO series (GAF, USA), Antarox CO series (GAF, UK)
  • the POE-POP block copolymers are a unique class of polymeric surfactants.
  • the unique structure of the surfactants, with hydrophilic POE and hydrophobic POP moieties in well-defined ratios and positions, provides a wide variety of surfactants suitable for use in the present invention.
  • These surfactants are available under various trade names, including Synperonic PE series (ICI); Pluronic® series (BASF), Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare, and Plurodac.
  • the generic term for these polymers is “poloxamer” (CAS 9003-11-6). These polymers have the formula:
  • Preferred hydrophilic surfactants of this class include Poloxamers 108, 188, 217, 238, 288, 338, and 407.
  • Preferred hydrophobic surfactants in this class include Poloxamers 124, 182, 183, 212, 331, and 335.
  • Sorbitan esters of fatty acids are suitable surfactants for use in the present invention.
  • preferred hydrophobic surfactants include sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span-80), sorbitan monostearate, and sorbitan tristearate. Examples of these surfactants are shown in Table 16.
  • esters of lower alcohols (C 2 to C 4 ) and fatty acids (C 8 to C 18 ) are suitable surfactants for use in the present invention.
  • preferred hydrophobic surfactants include ethyl oleate (Crodamol EO), isopropyl myristate (Crodamol IPM), and isopropyl palmitate (Crodamol IPP). Examples of these surfactants are shown in Table 17.
  • Ionic surfactants including cationic, anionic and zwitterionic surfactants, are suitable hydrophilic surfactants for use in the present invention.
  • Preferred anionic surfactants include fatty acid salts and bile salts.
  • preferred ionic surfactants include sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, and sodium taurocholate. Examples of such surfactants are shown in Table 18 below. For simplicity, typical counterions are shown in the entries in the Table. It will be appreciated by one skilled in the art, however, that any bioacceptable counterion may be used.
  • fatty acids are shown as sodium salts, other cation counterions can also be used, such as alkali metal cations or ammonium.
  • these ionic surfactants are generally available as pure compounds, rather than commercial (proprietary) mixtures. Because these compounds are readily available from a variety of commercial suppliers, such as Aldrich, Sigma, and the like, commercial sources are not generally listed in the Table.
  • Acyl lactylates lactylic esters of fatty acids calcium/sodium stearoyl-2-lactylate calcium/sodium stearoyl lactylate Alginate salts Propylene glycol alginate SULFATES AND SULFONATES Ethoxylated alkyl sulfates Alkyl benzene sulfones ⁇ -olefin sulfonates Acyl isethionates Acyl taurates Alkyl glyceryl ether sulfonates Octyl sulfosuccinate disodium Disodium undecylenamideo-MEA-sulfosuccinate CATIONIC Surfactants >10 Hexadecyl triammonium bromide Decyl trimethyl ammonium bromide Cetyl trimethyl ammonium bromide Dodecyl ammonium chloride Alkyl benzyldimethylammonium salts Diisobuty
  • hydrophilic and hydrophobic surfactants are present in the pharmaceutical compositions of the present invention in amounts such that upon dilution with an aqueous solution, the carrier forms a clear, aqueous dispersion of the hydrophilic and hydrophobic surfactants, containing the hydrophobic therapeutic agent.
  • the relative amounts of hydrophilic and hydrophobic surfactants are readily determined by observing the properties of the resultant dispersion; i.e., when the relative amounts of the hydrophobic and hydrophilic surfactants are within a suitable range, the resultant aqueous dispersion is optically clear.
  • the resulting dispersion is visibly “cloudy”, resembling a conventional emulsion or multiple phase system.
  • a visibly cloudy solution may be potentially useful for some applications, such a system would suffer from many of the same disadvantages as conventional prior art formulations, as described above.
  • a convenient method of determining the appropriate relative concentrations for any hydrophilic surfactant-hydrophobic surfactant pair is as follows. A convenient working amount of a hydrophilic surfactant is provided, and a known amount of a hydrophobic surfactant is added. The surfactants are stirred to form a homogeneous mixture, with the aid of gentle heating if desired. The resulting mixture is diluted with purified water to prepare an aqueous dispersion. Any dilution amount can be chosen, but convenient dilutions are those within the range expected in vivo, about a 10 to 250-fold dilution. The aqueous dispersion is then assessed qualitatively for optical clarity. The procedure can be repeated with incremental variations in the relative amount of hydrophobic surfactant added, to determine the maximum relative amount of hydrophobic surfactant that can be present for a given surfactant pair.
  • the optical clarity of the aqueous dispersion can be measured using standard quantitative techniques for turbidity assessment.
  • One convenient procedure to measure turbidity is to measure the amount of light of a given wavelength transmitted by the solution, using, for example, a UV-visible spectrophotometer. Using this measure, optical clarity corresponds to high transmittance, since cloudier solutions will scatter more of the incident radiation, resulting in lower transmittance measurements. If this procedure is used, care should be taken to insure that the surfactant mixture does not itself absorb light of the chosen wavelength, as any true absorbance necessarily reduces the amount of transmitted light and falsely increases the quantitative turbidity value.
  • suitable dispersions at a dilution of 10 ⁇ should have an apparent absorbance of less than about 0.3, preferably less than about 0.2, and more preferably less than about 0.1.
  • suitable dispersions should have an apparent absorbance of less than about 0.1, preferably less than about 0.05, and more preferably less than about 0.01.
  • a third method of determining optical clarity and carrier diffusivity through the aqueous boundary layer is to quantitatively measure the size of the particles of which the dispersion is composed. These measurements can be performed on commercially available particle size analyzers, such as, for example, a Nicomp particle size analyzer available from Particle Size Systems, Inc., of Santa Barbara, Calif. Using this measure, clear aqueous dispersions according to the present invention have average particle sizes much smaller than the wavelength of visible light, whereas dispersions containing excessive relative amounts of the hydrophobic surfactant have more complex particle size distributions, with much greater average particle sizes.
  • the average particle size be less than about 100 nm, preferably less than about 50 nm, more preferably less than about 30 nm, and still more preferably less than about 20 nm. It is also preferred that the particle size distribution be mono-modal. As is shown in more detail in the Examples herein, dispersions having an undesirably large relative amount of hydrophobic surfactant typically display bimodal particle size distributions, such distributions having a small particle size component, typically less than about 30 nm, and a large particle size component, typically on the order of 100 nm or more. It should be emphasized that these particle sizes are appropriate for the carrier particles in aqueous solution, in the absence of a hydrophobic therapeutic agent. It is expected that the presence of the hydrophobic therapeutic agent may result in an increase in the average particle size.
  • any or all of the available methods may be used to ensure that the resulting aqueous dispersions possess the requisite optical clarity.
  • the present inventors prefer to use the simple qualitative procedure; i.e., simple visible observation.
  • all three of the above measures are used to assess the dispersion clarity in the Examples herein.
  • any aqueous dispersion having the properties described above is within the scope of the present invention regardless of the specific relative amounts of hydrophobic and hydrophilic surfactants, it is expected that the amount of hydrophobic surfactant will generally be less than about 200% by weight, based on the amount of hydrophilic surfactant, and more specifically, in the range of about 1% to 200%. Further, based on observations reported in the Examples herein, it is expected that the amount of hydrophobic surfactant will generally be less than about 100%, and more specifically in the range of about 5% to about 100% by weight, or about 10% to about 100% by weight, based on the amount of hydrophilic surfactant.
  • cloudy solutions result when the amount of hydrophobic surfactant is greater than about 60% by weight, based on the amount of hydrophilic surfactant.
  • a preferred range for these surfactants is about 1% to about 60%, preferably about 5% to about 60%, and more preferably about 10% to about 60%. Addition of optional excipients as described below can further increase the maximum relative amount of hydrophobic surfactant that can be used.
  • hydrophobic and hydrophilic surfactants are also within the scope of the present invention. These considerations include the degree of bioacceptability of the surfactants, and the desired dosage of hydrophobic therapeutic agent to be provided. In some cases, the amount of hydrophobic surfactant actually used in a pharmaceutical composition according to the present invention will be less than the maximum that can be used, and it should be apparent that such compositions are also within the scope of the present invention.
  • Hydrophobic therapeutic agents suitable for use in the pharmaceutical compositions of the present invention are not particularly limited, as the carrier is surprisingly capable of solubilizing and delivering a wide variety of hydrophobic therapeutic agents.
  • Hydrophobic therapeutic agents are compounds with little or no water solubility.
  • Intrinsic water solubilities (i.e., water solubility of the unionized form) for hydrophobic therapeutic agents usable in the present invention are less than about 1% by weight, and typically less than about 0.1% or 0.01% by weight.
  • Such therapeutic agents can be any agents having therapeutic or other value when administered to an animal, particularly to a mammal, such as drugs, nutrients, and cosmetics (cosmeceuticals).
  • analgesics and anti-inflammatory agents such as aloxiprin, auranofin, azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, leflunomide, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, refocoxib, sulindac, tetrahydrocannabinol, tramadol and tromethamine;
  • anthelmintics such as albendazole, bephenium hydroxynaphthoate, cambendazole, dichlorophen, ivermectin, mebendazole, oxamniquine, oxfendazole, oxantel embonate, praziquantel, pyrantel embonate and thiabendazole;
  • anti-arrhythmic agents such as amiodarone HCl, disopyramide, flecainide acetate and quinidine sulfate;
  • anti-asthma agents such as zileuton, zafirlukast, terbutaline sulfate, montelukast, and albuterol;
  • anti-bacterial agents such as alatrofloxacin, azithromycin, baclofen, benethamine penicillin, cinoxacin, ciprofloxacin HCl, clarithromycin, clofazimine, cloxacillin, demeclocycline, dirithromycin, doxycycline, erythromycin, ethionamide, furazolidone, grepafloxacin, imipenem, levofloxacin, lorefloxacin, moxifloxacin HCl, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, rifampicin, rifabutine, rifapentine, sparfloxacin, spiramycin, sulphabenzamide, sulphadoxine, sulphamerazine, sulphacetamide, sulphadiazine, sulphafurazole, sulphamethoxazole
  • anti-viral agents such as abacavir, amprenavir, delavirdine, efavirenz, indivir, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, and stavueline;
  • anti-coagulants such as cilostazol, clopidrogel, dicoumarol, dipyridamole, nicoumalone, oprelvekin, phenindione, ticlidopine, and tirofibran;
  • anti-depressants such as amoxapine, bupropion, citalopram, clomipramine, fluexetine HCl, maprotiline HCl, mianserin HCl, nortriptyline HCl, paroxetine HCl, sertraline HCl, trazodone HCl, trimipramine maleate, and venlafaxine HCl;
  • anti-diabetics such as acetohexamide, chlorpropamide, glibenclamide, gliclazide, glipizide, glymepride, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone;
  • anti-epileptics such as beclamide, carbamazepine, clonazepam, ethotoin, felbamate, fosphenytoin sodium, lamotrigine, methoin, methsuximide, methylphenobarbitone, oxcarbazepine, paramethadione, phenacemide, phenobarbitone, phenytoin, phensuximide, primidone, sulthiame, tiagabine HCl, topiramate, valproic acid, and vigabatrin;
  • anti-fungal agents such as amphotericin, butenafine HCl, butoconazole nitrate, clotrimazole, econazole nitrate, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, miconazole, natamycin, nystatin, sulconazole nitrate, oxiconazole, terbinafine HCl, terconazole, tioconazole and undecenoic acid;
  • anti-gout agents such as allopurinol, probenecid and sulphin-pyrazone
  • anti-hypertensive agents such as amlodipine, benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HCl, diazoxide, doxazosin HCl, elanapril, eposartan losartan, mesylate, felodipine, fenolclopam, fosinopril, guanabenz acetate, irbesartan, isradipine, lisinopril, minoxidil, nicardipine HCl, nifedipine, nimodipine, nisolidipine, phenoxybenzamine HCl, prazosin HCl, quinapril, reserpine, terazosin HCl, telmisartan, and valsartan;
  • anti-malarials such as amodiaquine, chloroquine, chlorproguanil HCl, halofantrine HCl, mefloquine HCl, proguanil HCl, pyrimethamine and quinine sulfate;
  • anti-migraine agents such as dihydroergotamine mesylate, ergotamine tartrate, frovatriptan, methysergide maleate, naratriptan HCl, pizotifen maleate, rizatriptan benzoate, sumatriptan succinate, and zolmitriptan;
  • anti-muscarinic agents such as atropine, benzhexol HCl, biperiden, ethopropazine HCl, hyoscyamine, mepenzolate bromide, oxyphencylcimine HCl and tropicamide;
  • anti-neoplastic agents and immunosuppressants such as aminoglutethimide, amsacrine, azathioprine, bicalutamide, bisanthrene, busulphan, camptothecan, capecitabine, chlorambucil, cyclosporin, dacarbazine, ellipticine, estramustine, etoposide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, mofetil, mycophenolate, nilutamide, paclitaxel, procarbazine HCl, sirolimus, tacrolimus, tamoxifen citrate, teniposide, testolactone, topotecan HCl, and toremifene citrate;
  • immunosuppressants such as aminoglutethimide, amsacrine, azathioprine, bical
  • anti-protozoal agents such as atovaquone, benznidazole, clioquinol, decoquinate, diiodohydroxyquinoline, diloxanide furoate, dinitolmide, furzolidone, metronidazole, nimorazole, nitrofurazone, omidazole and tinidazole;
  • anti-thyroid agents such as carbimazole, paricalcitol, and propylthiouracil
  • anti-tussives such as benzonatate
  • anxiolytic, sedatives, hypnotics and neuroleptics such as alprazolam, amylobarbitone, barbitone, bentazepam, bromazepam, bromperidol, brotizolam, butobarbitone, carbromal, chlordiazepoxide, chlormethiazole, chlorpromazine, chlorprothiocene, clonazepam, clobazam, clotiazepam, clozapine, diazepam, droperidol, ethinamate, flunanisone, flunitrazepam, fluopromazine, flupenthixol decanoate, fluphenazine decanoate, flurazepam, gabapentin, haloperidol, lorazepam, lormetazepam, medazepam, meprobamate, mesoridiazine, methaqualone,
  • ⁇ -Blockers such as acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, pindolol and propranolol;
  • cardiac inotropic agents such as amrinone, digitoxin, digoxin, enoximone, lanatoside C and medigoxin;
  • corticosteroids such as beclomethasone, betamethasone, budesonide, cortisone acetate, desoxymethasone, dexamethasone, fludrocortisone acetate, flunisolide, flucortolone, fluticasone propionate, hydrocortisone, methylprednisolone, prednisolone, prednisone and triamcinolone;
  • diuretics such as acetazolamide, amiloride, bendrofluazide, bumetanide, chlorothiazide, chlorthalidone, ethacrynic acid, frusemide, metolazone, spironolactone and triamterene.
  • anti-parkinsonian agents such as bromocriptine mesylate, lysuride maleate, pramipexole, robinirole HCl, and tolcapone;
  • gastro-intestinal agents such as bisacodyl, cimetidine, cisapride, diphenoxylate HCl, domperidone, famotidine, lanosprazole, loperamide, mesalazine, nizatidine, omeprazole, ondansetron HCL, rabeprazole sodium, ranitidine HCl and sulphasalazine;
  • histamine H,-receptor antagonists such as acrivastine, astemizole, chlophenisamine, cinnarizine, citrizine, clemastine fumarate, cyclizine, cyproheptadine HCl, dexchlopheniramine, dimenhydrinate, fexofenadine, flunarizine HCl, loratadine, meclozine HCl, oxatomide, andnadine;
  • acrivastine astemizole
  • chlophenisamine such as acrivastine, astemizole, chlophenisamine, cinnarizine, citrizine, clemastine fumarate, cyclizine, cyproheptadine HCl, dexchlopheniramine, dimenhydrinate, fexofenadine, flunarizine HCl, loratadine, meclozine HCl,
  • keratolytics such as acutretin, calciprotiene, calcifediol, calcitriol, cholecalciferol, ergocalciferol, etretinate, retinoids, targretin, and tazarotene;
  • lipid regulating agents such as atorvastatin, bezafibrate, cerivistatin, clinofibrate, clofibrate, fenofibrate, fluvastatin, gemfibrozil, pravastatin, probucol, and simvastatin;
  • muscle relaxants such as dantrolene sodium and tizanidine HCl
  • nitrates and other anti-anginal agents such as amyl nitrate, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate and pentaerythritol tetranitrate;
  • nutritional agents such as calcitriol, carotenes, dihydrotachysterol, essential fatty acids, non-essential fatty acids, phytonodione, vitamin A, vitamin B 2 , vitamin D, vitamin E and vitamin K.
  • opioid analgesics such as codeine, dextropropyoxyphene, diamorphine, dihydrocodeine, fentanyl, meptazinol, methadone, morphine, nalbuphine and pentazocine;
  • sex hormones such as clomiphene citrate, cortisone acetate, danazol, dihydro epiandrosterone, ethinyloestradiol, finasteride, fludrocortisone, fluoxymisterone, medroxyprogesterone acetate, megesterol acetate, mestranol, methyltestosterone, norethisterone, norgestrel, oestradiol, conjugated estrogens, progesterone, rimexolone, stanozolol, stiboestrol, testosterone and tibolone;
  • sex hormones such as clomiphene citrate, cortisone acetate, danazol, dihydro epiandrosterone, ethinyloestradiol, finasteride, fludrocortisone, fluoxymisterone, medroxyprogesterone acetate, megesterol acetate, mestranol,
  • stimulants such as amphetamine, dexamphetamine, dexfenfluramine, fenfluramine and mazindol;
  • Preferred hydrophobic therapeutic agents include sildenafil citrate, amlodipine, tramadol, celecoxib, refocoxib, oxaprozin, nabumetone, ibuprofen, terbenafine, itraconazole, zileuton, zafirlukast, cisapride, fenofibrate, tizanidine, nizatidine, fexofenadine, loratadine, famotidine, paricalcitol, atovaquone, nabumetone, tetrahydrocannabinol, megesterol acetate, repaglinide, progesterone, rimexolone, cyclosporine, tacrolimus, sirolimus, teniposide, paclitaxel, pseudo-ephedrine, troglitazone, rosiglitazone, finasteride, vitamin A, vitamin
  • compositions of the present invention are merely illustrative. Indeed, a particular feature, and surprising advantage, of the compositions of the present invention is the ability of the present compositions to solubilize and deliver a broad range of hydrophobic therapeutic agents, regardless of functional class. Of course, mixtures of hydrophobic therapeutic agents may also be used where desired.
  • compositions of the present invention can optionally include additional compounds to enhance the solubility of the hydrophobic therapeutic agent in the carrier system.
  • additional compounds include:
  • alcohols and polyols such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives;
  • ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000 such as tetrahydrofurfuryl alcohol PEG ether (glycofurol, available commercially from BASF under the trade name Tetraglycol) or methoxy PEG (Union Carbide);
  • amides such as 2-pyrrolidone, 2-piperidone, ⁇ -caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, and polyvinylpyrrolidone;
  • esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ⁇ -caprolactone and isomers thereof, ⁇ -valerolactone and isomers thereof, ⁇ -butyrolactone and isomers thereof;
  • solubilizers such as dimethyl acetamide, dimethyl isosorbide (Arlasolve DMI (ICI)), N-methyl pyrrolidones (Pharmasolve (ISP)), monooctanoin, diethylene glycol monoethyl ether (available from Gattefosse under the trade name Transcutol), and water.
  • Preferred solubilizers include triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide.
  • Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.
  • the amount of solubilizer that can be included in compositions of the present invention is not particularly limited.
  • the amount of a given solubilizer is limited to a bioacceptable amount, which is readily determined by one of skill in the art.
  • the solubilizer can be in a concentration of 50%, 100%, 200%, or up to about 400% by weight, based on the amount of surfactant.
  • solubilizers may also be used, such as 25%, 10%, 5%, 1% or even less.
  • the solubilizer will be present in an amount of about 1% to about 100%, more typically about 5% to about 25% by weight.
  • additives conventionally used in pharmaceutical compositions can be included, and these additives are well known in the art.
  • additives include antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants odorants, opacifiers, suspending agents, binders, and mixtures thereof.
  • the amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired.
  • compositions of the present invention can be provided in the form of a solution preconcentrate; i.e., a composition as described above, and intended to be dispersed with water, either prior to administration, in the form of a drink, or dispersed in vivo.
  • the compositions can be provided in the form of a diluted preconcentrate (i.e., an aqueous dispersion), a semi-solid dispersion or a solid dispersion.
  • the compositions may be encapsulated in a hard or soft gelatin capsule, a starch capsule or an enteric coated capsule.
  • enteric coated capsule means a capsule coated with a coating resistant to acid; i.e., an acid resistant enteric coating.
  • solubilizers are typically used to enhance the solubility of a hydrophobic therapeutic agent, they may also render the compositions more suitable for encapsulation in hard or soft gelatin capsules.
  • a solubilizer such as those described above is particularly preferred in capsule dosage forms of the pharmaceutical compositions. If present, these solubilizers should be added in amounts sufficient to impart to the compositions the desired solubility enhancement or encapsulation properties.
  • compositions of the present invention can also be formulated for topical, transdermal, ocular, pulmonary, vaginal, rectal, transmucosal or parenteral administration, in the form of a triglyceride-free cream, lotion, ointment, suppository, gel or the like. If such a formulation is desired, other additives may be included, such as are well-known in the art, to impart the desired consistency and other properties to the formulation.
  • the compositions of the present invention can also be formulated as a spray or an aerosol.
  • the compositions may be formulated as a sprayable solution, and such formulation is particularly useful for spraying to coat a multiparticulate carrier, such as a bead.
  • multiparticulate carriers are well known in the art.
  • compositions of the present invention can be prepared by conventional methods well known to those skilled in the art. Of course, the specific method of preparation will depend upon the ultimate dosage form.
  • dosage forms substantially free of water i.e., when the composition is provided in a pre-concentrated form for later dispersion in an aqueous system, the composition is prepared by simple mixing of the components to form a pre-concentrate. The mixing process can be aided by gentle heating, if desired.
  • the pre-concentrate form is prepared, then the appropriate amount of purified water is added. Upon gentle mixing, a clear aqueous dispersion is formed. If any water-soluble additives are included, these may be added first as part of the pre-concentrate, or added later to the clear aqueous dispersion, as desired.
  • the present invention includes a multi-phase dispersion.
  • a pharmaceutical composition includes a carrier which forms a clear aqueous dispersion upon mixing with an aqueous solution, and an additional amount of non-solubilized hydrophobic therapeutic agent.
  • multi-phase as used herein to describe these compositions of the present invention means a composition which when mixed with an aqueous solution forms a clear aqueous phase and a particulate dispersion phase.
  • the carrier is as described above, and can include any of the surfactants, hydrophobic therapeutic agents, solubilizers and additives previously described. An additional amount of hydrophobic therapeutic agent is included in the composition.
  • the composition contains two phases: a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing a first, solubilized amount of the hydrophobic therapeutic agent, and a second, non-solubilized amount of the hydrophobic therapeutic agent dispersed therein.
  • the resultant multi-phase dispersion will not have the optical clarity of a dispersion in which the hydrophobic therapeutic agent is fully solubilized, but will appear to be cloudy, due to the presence of the non-solubilized phase.
  • a formulation may be useful, for example, when the desired dosage of a hydrophobic therapeutic agent exceeds that which can be solubilized in the carrier of the present invention.
  • the formulation may also contain additives, as described above.
  • a hydrophobic therapeutic agent may have a greater solubility in the pre-concentrate carrier than in the aqueous dispersion, so that meta-stable, supersaturated solutions having apparent optical clarity but containing a hydrophobic therapeutic agent in an amount in excess of its solubility in the aqueous dispersion can be formed.
  • Such super-saturated solutions whether characterized as clear aqueous dispersions (as initially formed) or as multi-phase solutions (as would be expected if the meta-stable state breaks down), are also within the scope of the present invention.
  • the multi-phase formulation can be prepared by the methods described above.
  • a pre-concentrate is prepared by simple mixing of the components, with the aid of gentle heating, if desired. It is convenient to consider the hydrophobic therapeutic agent as divided into two portions, a first solubilizable portion which will be solubilized by the carrier and contained within the clear aqueous dispersion upon dilution, and a second non-solubilizable portion which will remain non-solubilized. When the ultimate dosage form is non-aqueous, the first and second portions of the hydrophobic therapeutic agent are both included in the pre-concentrate mixture.
  • the composition can be prepared in the same manner, and upon dilution in an aqueous system, the composition will form the two phases as described above, with the second non-solubilizable portion of the hydrophobic therapeutic agent dispersed or suspended in the aqueous system, and the first solubilizable portion of the hydrophobic therapeutic agent solubilized in the mixed surfactant carrier.
  • the pre-concentrate can be prepared including only the first, solubilizable portion of the hydrophobic therapeutic agent.
  • This pre-concentrate can then be diluted in an aqueous system to form a clear aqueous dispersion, to which is then added the second, non-solubilizable portion of the hydrophobic therapeutic agent to form a multi-phase aqueous composition.
  • the amount of hydrophobic therapeutic agent included in the pharmaceutical compositions of the present invention can be any amount desired by the formulator, up to the maximum amount that can be solubilized or suspended in a given carrier system. In general, the amount of hydrophobic therapeutic agent will be about 0.1% to about 60% by weight, based on the total weight of the pharmaceutical composition. In another aspect of the invention, described below, excess hydrophobic therapeutic agent can also be added, in a multi-phase dispersion.
  • the present invention relates to methods of improving delivery of hydrophobic therapeutic agents in an animal by administering to the animal a dosage form of the pharmaceutical compositions described herein.
  • the animal is a mammal, and more preferably, a human.
  • the pharmaceutical compositions of the present invention when administered to an animal enable the hydrophobic therapeutic agent contained therein to be absorbed more rapidly than in conventional pharmaceutical compositions.
  • the invention relates to a method of increasing the rate of and/or extent of bioabsorption of a hydrophobic therapeutic agent by administering the hydrophobic therapeutic agent to an animal in the pharmaceutical compositions described herein.
  • compositions of the present invention have the following characteristics:
  • Rapid formation upon dilution with an aqueous solution, the carrier forms a clear dispersion very rapidly; i.e., the clear dispersion appears to form instantaneously.
  • Optical clarity the dispersions are essentially optically clear to the naked eye, and show no readily observable signs of heterogeneity, such as turbidity or cloudiness. More quantitatively, dispersions of the pharmaceutical compositions of the present invention show a mono-modal distribution of very small particles sizes, typically 20 nm or less in average diameter; absorbances of less than about 0.3, typically less than about 0.1, at 10 ⁇ dilution; and absorbances of less than about 0.1, typically less than about 0.01, at 100 ⁇ dilution, as described more fully in the Examples herein. In the multi-phase embodiment of the compositions described herein, it should be appreciated that the optical clarity of the aqueous carrier dispersion phase will be obscured by the dispersed particulate non-solubilized hydrophobic therapeutic agent.
  • the dispersions are surprisingly stable to dilution in aqueous solution, including aqueous solutions simulating physiological fluids such as enzyme-free simulated gastric fluid (SGF) and enzyme-free simulated intestinal fluid (SIF).
  • SGF enzyme-free simulated gastric fluid
  • SIF enzyme-free simulated intestinal fluid
  • the hydrophobic therapeutic agent remains solubilized for at least the period of time relevant for absorption.
  • Triglyceride-free It is a particular feature of the present invention that the pharmaceutical compositions are substantially triglyceride-free.
  • triglyceride as used herein means glycerol triesters of C 6 to about C 25 fatty acids.
  • the present compositions surprisingly solubilize hydrophobic therapeutic agents using combinations of substantially triglyceride-free surfactants.
  • substantially triglyceride-free means compositions which contain triglycerides, if at all, only as minor components or impurities in surfactant mixtures. It is well known in the art that commercially available surfactants often are complex mixtures of compounds. For example, one preferred surfactant is Capmul® GMO-K, a widely-used blend of glyceryl mono- and dioleates.
  • Capmul® GMO-K contains the following distribution of glyceryl esters, in percent by weight based on the total weight of glyceryl esters: Palmitic acid 3.3% Stearic acid 4.0% Oleic acid 81.0% Linoleic acid 9.7% Linolenic acid 0.3%
  • the surfactant mixture in the particular lot reported contains 0.10% water and 0.95% free, unesterified glycerol. These specific percentages are expected to vary, lot-by-lot, as well, and it is expected that commercial surfactant products will generally possess similar variability, regardless of the specific major component and the specific manufacturer.
  • the present invention does not include surfactants which contain triglycerides as an intended component. Indeed, such surfactants are not common, since triglycerides themselves have no surfactant properties. However, it should be appreciated that the present invention does not exclude the use of surfactant products which contain small amounts of triglycerides as impurities or as unreacted starting material.
  • substantially triglyceride-free should be understood as meaning free of added triglycerides, and containing less than 5%, preferably essentially 0%, triglyceride impurities.
  • each micelle is composed of molecules (or ions) of both the hydrophilic and hydrophobic surfactants.
  • the hydrophobic therapeutic agent may be distributed in any part of the micelle, such as near the outer, more hydrophilic region, near the inner, more hydrophobic region, or at various points in between.
  • micelles exist in dynamic equilibrium with their component molecules, and it is expected that this equilibrium will include dynamic redistribution of the hydrophobic therapeutic agent.
  • triglyceride-containing formulations suffer the disadvantage that bioabsorption of the hydrophobic therapeutic agents contained therein is dependent upon enzymatic degradation (lipolysis) of the triglyceride components.
  • the pharmaceutical compositions of the present invention are substantially free of triglycerides, and thus do not depend upon lipolysis to enable release of the hydrophobic therapeutic agent for bioabsorption.
  • the hydrophobic therapeutic agent is in a dynamic equilibrium between the free compound in solution and the solubilized compound, thus promoting rapid release.
  • compositions of the present invention present a number of significant and unexpected advantages, including:
  • Efficient transport The particle sizes in the aqueous dispersions of the present invention are much smaller, typically less than 20 nm, than the larger particles characteristic of vesicular, emulsion or microemulsion phases, and the particle size distribution is mono-modal and narrow. This reduced and more uniform size enables more efficient drug transport through the intestinal aqueous boundary layer, and through the absorptive brush border membrane. More efficient transport to absorptive sites leads to improved and more consistent absorption of hydrophobic therapeutic agents.
  • Non-dependence on lipolysis The lack of triglyceride components provides pharmaceutical compositions not dependent upon lipolysis, and upon the many poorly characterized factors which affect the rate and extent of lipolysis, for effective presentation of a hydrophobic therapeutic agent to an absorptive site. Such factors include the presence of composition components which may inhibit lipolysis; patient conditions which limit production of lipase, such as pancreatic lipase secretory diseases; and dependence of lipolysis on stomach pH, endogenous calcium concentration, and presence of co-lipase or other digestion enzymes.
  • compositions of the present invention can make use of hydrophilic surfactants which might otherwise be avoided or limited due to their potential lipolysis inhibiting effects.
  • Non-dependence on bile and meal fat contents Due to the higher solubilization potential over bile salt micelles, the present compositions are less dependent on endogenous bile and bile related patient disease states, and meal fat contents. These advantages overcome meal-dependent absorption problems caused by poor patient compliance with meal-dosage restrictions.
  • compositions of the present invention enable superior loading capacity over conventional micelle formulations.
  • particular combination of surfactants used can be optimized for a specific hydrophobic therapeutic agent to more closely match the polarity distribution of the therapeutic agent, resulting in still further enhanced solubilization.
  • Aqueous dispersions of the present invention are thermodynamically stable for the time period relevant for absorption, and can be more predictably reproduced, thereby limiting variability in bioavailability—a particularly important advantage for therapeutic agents with a narrow therapeutic index.
  • compositions of the present invention are designed with components that help to keep the hydrophobic therapeutic agent solubilized for transport to the absorption site, but readily available for absorption, thus providing a more efficient transport and release.
  • the present compositions are less prone to gastric emptying delays, resulting in faster absorption. Further, the particles in dispersions of the present invention are less prone to unwanted retention in the gastro-intestinal tract.
  • the pharmaceutical compositions of the present invention allow for faster transport of the hydrophobic therapeutic agent through the aqueous boundary layer.
  • a simple pre-concentrate of a hydrophobic surfactant and a hydrophilic surfactant is prepared as follows. Predetermined weighed amounts of hydrophilic and hydrophobic surfactants are stirred together to form a homogeneous mixture. For surfactant combinations that are poorly miscible, the mixture can be gently heated to aid in formation of the homogeneous mixture. A chosen hydrophobic therapeutic agent in a predetermined amount is added and stirred until solubilized. Optionally, solubilizers or additives are included by simple mixing.
  • a predetermined amount of purified water, buffer solution, or aqueous simulated physiological solution is added to the pre-concentrate, and the resultant mixture is stirred to form a clear, aqueous dispersion.
  • Surfactant mixtures giving clear, aqueous dispersions were prepared according to the method of Example 1. Seven hydrophilic surfactants and sixteen hydrophobic surfactants were used to produce approximately one hundred clear aqueous dispersions suitable for use in the present invention. For simplicity, no hydrophobic therapeutic agent was included in these compositions, since it is believed that the presence of the hydrophobic therapeutic agent does not substantially affect the clear, aqueous nature of composition. For the same reason, these compositions were free of additional solubilizers and other additives.
  • Each entry in the Table represents the approximate maximum number of grams of hydrophobic surfactant per 100 g of hydrophilic surfactant giving acceptable optical clarity.
  • the numbers in the Table are illustrative only, and it is expected that further optimization of the surfactant systems with solubilizers, co-surfactants, and other additives will give still higher numbers.
  • Example 2 The procedure of Example 2 was repeated for compositions containing PEG-40 hydrogenated castor oil (Cremophor RH 40) as the hydrophilic surfactant, with eight different hydrophobic surfactants, and four different solubilizers, to study the effect of solubilizer on the relative amounts of hydrophobic and hydrophilic surfactants giving clear aqueous dispersions.
  • the amount of solubilizer was held constant at 20% by weight, based on the total weight of the two surfactants.
  • Table 20 As in Example 2, the numbers in the Table represent the approximate maximum number of grams of hydrophobic surfactant per 100 g of hydrophilic surfactant giving a clear aqueous dispersion.
  • Example 3 was repeated, this time choosing a single hydrophobic surfactant (Arlacel 186) and three different hydrophilic surfactants, with addition of either ethanol or triacetin (20% by weight, based on the total weight of the two surfactants). The results are shown in Table 21. The corresponding entry from Table 19 (with no solubilizer present) is included in Table 21 for reference.
  • Example 3 The procedure of Example 3 was repeated, with the following differences.
  • a single hydrophilic surfactant (Cremophor RH-40) and hydrophobic surfactant (Arlacel 186) were chosen, to examine the effect of increased solubilizer concentration.
  • compositions were tested at a solubilizer concentration of 50% by weight, based on the total weight of the surfactant pair.
  • the numbers in Table 22 represent the maximum hydrophobic surfactant concentration giving a clear aqueous dispersion.
  • Example 5 was repeated, using the same surfactant pair, but with an 80% concentration of solubilizer, based on the total weight of the surfactants.
  • the 80% solubilizer was either PEG-400, or a mixture of PEG-400 and one of three alcohols or polyols.
  • the results are shown in Table 23, with the numbers in the Table having the same meaning as in the previous Examples. TABLE 23 Large Solubilizer Concentrations and Solubilizer Mixtures* 60% 60% 60% PEG-400 + PEG-400 + (no 80% PEG-400 + 20% Propylene 20% solubilizer) PEG-400 20% Glycerol Glycol Isopropanol 20 25 25 25 25 25 25
  • compositions of the present invention produce clear, aqueous dispersions, with no visible cloudiness.
  • the particle size distribution shows very small particles, with average diameters of from about 6 to about 15 nm.
  • the distribution is mono-modal, with a standard deviation of approximately 20%, indicating a highly uniform distribution of very small particles.
  • This particle size distribution is consistent with a solution of particles of micellar structure, although the invention is not limited by any particular theoretical framework.
  • compositions were prepared having hydrophobic surfactant concentrations higher than those suitable for forming clear aqueous dispersions. These compositions were prepared by weighing the components and mixing well, with gentle warming. The compositions were then diluted 10 ⁇ to form dispersions, and these dispersions were subjected to the particle size measurements as described in Example 7. The results are shown in Table 25. For direct comparison with the compositions of the present invention, Examples 7, 9, 10, 11 and 12 are shown next to the corresponding comparative compositions. TABLE 25 Optical Clarity and Particle Size Example Surfactant Particle Size (nm)** No.
  • compositions containing Tween 80 and Plurol Oleique CC497, Tween 80 and Peceol, and Tween 80 and Capmul MCM were prepared at a surfactant ratio of 67 g hydrophobic surfactant per 100 g hydrophilic surfactant. Particle sizes were not measured for these compositions, but each was observed to form a milky or hazy aqueous dispersion.
  • compositions having excessive amounts of hydrophobic surfactant form milky or hazy solutions, whereas those of the present invention form clear solutions.
  • the particle size distributions of the milky solutions are bimodal, in contrast to the mono-modal solutions of the corresponding clear solutions. These bimodal particle size distributions show a first mode having a small mean particle size of about 12 to about 27 nm, and a second mode having particle sizes of up to more than 200 nm.
  • compositions having excessive hydrophobic surfactant are heterogeneous (multi-phasic), non-clear dispersions, having a complex bimodal distribution of particles of two distinct size ranges.
  • compositions of the present invention are homogeneous (single phase), clear dispersion, having a mono-modal distribution of very small particle sizes.
  • compositions were prepared according to Example 1, and diluted to 10 ⁇ and 100 ⁇ solutions.
  • the specific compositions measured also include a solubilizer, to further illustrate preferred aspects of the invention.
  • compositions according to the present invention wherein either the hydrophilic surfactant (Examples 20 and 27) or the hydrophobic surfactant (Examples 41 and 42) itself is a mixture of surfactants.
  • a clear aqueous dispersion should have a very high transmittance, indicating little scattering of light by large particles. Absorbance and transmittance are related by the simple expression
  • suitable clear aqueous dispersions of the present invention should have an absorbance at 10 ⁇ dilution of less than about 0.3.
  • compositions observed to be milky or cloudy were characterized by absorption, as in Examples 13-42. Where available, results for comparable solutions from Examples 13-42 are reproduced for comparison. In such cases, where a given surfactant combination is presented in Examples 13-42 more than once (with different solubilizer concentrations), the composition having the lowest solubilizer concentration is chosen, to facilitate more direct comparison. The results are shown in Table 27. TABLE 27 Comparative Spectroscopic Characterization Example Absorbance (400.2 nm) No.
  • the solubility experiment of Examples 43-44 was performed on four standard aqueous solutions.
  • the first comparison solution was purified water with no additives.
  • a standard simulated intestinal fluid (SIF) was used, to simulate the in vivo conditions to be encountered by the hydrophobic therapeutic agent.
  • a third solution was prepared with simulated intestinal fluid, plus an additional aliquot of 20 mM sodium taurocholate (a bile salt); this solution is designated SIFB in Table 29.
  • a fourth solution was prepared with simulated intestinal fluid, 20 mM sodium taurocholate, and 5 mM lecithin; this solution is designated SIFBL.
  • the solubility of the polyfunctional hydrophobic therapeutic agent in the compositions of the present invention is far greater than its solubility in aqueous and gastrointestinal aqueous solutions.
  • the solubility of the lipophilic hydrophobic therapeutic agent in the compositions of the present invention is far greater than its solubility in aqueous and gastrointestinal aqueous solutions.
  • compositions according to the present invention were prepared, with a typical polyfunctional hydrophobic therapeutic agent, cyclosporin, as the therapeutic agent.
  • the compositions were prepared as described in Example 1, except that the ingredients were added in the order listed in Table 32.
  • the pre-concentrates were diluted 100 ⁇ with purified water, and a visual observation was made immediately after dilution. The solutions were then allowed to stand 6 hours to assess dilution stability, then the cyclosporin concentration in solution was measured, using a drug-specific HPLC assay. The results are shown in Table 32. TABLE 32 Dilution Stability of Polyfunctional Therapeutic Agents Cyclosporin Example Concen- No.
  • compositions according to the present invention were prepared, with a typical lipophilic hydrophobic therapeutic agent, progesterone, as the therapeutic agent.
  • the compositions were prepared and analyzed as in Examples 50-57, and the results are shown in Table 33. TABLE 33 Dilution Stability of Lipophilic Therapeutic Agents Proges- terone Example Concen- No.
  • a representative preconcentrate of the present invention containing a cyclosporin hydrophobic therapeutic agent was used.
  • the composition had the following formulation: Cyclosporine 0.140 g Cremophor RH-40 0.41 g Arlacel 186 0.29 g Sodium taurocholate 0.26 g Propylene glycol 0.46 g
  • the preconcentrate was diluted with an isotonic aqueous HEPES buffer rather than purified water.
  • the resultant solution was spiked with radioactive active and perfused through isolated ileal lumen segment of known length and diameter. Loss of radioactivity from the lumenal side and appearance of radioactivity in the mesenteric blood from the other side was monitored as an indicator of absorption.
  • Jugular vein cannulation the animal was anesthetized using 2% halothane in 98% oxygen via a halothane vaporizer (Vapomatic, A. M. Bickford, Inc., NY). An opening in the jugular vein was made with a 21 ga needle and a jugular cannula consisting of a 4 cm segment of silastic tubing connected to polyethylene tubing was inserted in the jugular vein and secured with cyanoacrylate glue.
  • Intestine cannulation after the animal was anesthetized, its body temperature was maintained at 37° C. using a heating pad. A vertical midline incision of approximately 3 cm was made through the skin to expose the small intestine. Approximately 6-10 cm segment of ileum was located. Using electro-cautery, a small incision was made at the ends of the segment and the lumenal contents were flushed with saline maintained at 37° C. Two 1.5 cm notched pieces of Teflon tubing were inserted into the intestinal lumen at each incision and tightened using 4-0 silk. A warm isotonic buffer was passed through the intestine using a 50-mL syringe. These Teflon cannula were used to perfuse the drug solution through the isolated intestinal segment using a syringe pump.
  • mesenteric vein cannulation the mesenteric vein draining blood from the resulting isolated mesenteric cascade venules was then cannulated using a 24 ga IV catheter and secured in place using 4-0 silk sutures. The cannula was then connected to a polyethylene tubing 25 cm long where the blood was collected in a vial kept under the animal level. Blood samples were collected continuously over 60 min. The infusion of blood via the jugular vein was initiated to replenish blood loss. The animal was then killed by a lethal injection of Phenobarbital after completion of the experiment.
  • FIG. 1 shows the accumulated radioactivity ( ⁇ Ci/cm 2 ⁇ Ci) in mesenteric blood as a function of time, over the course of 60 minutes, for the pharmaceutical compositions of the present invention (filled squares) and a commercial cyclosporin formulation (filled circles).
  • the bioabsorption of the hydrophobic therapeutic agent exceeds that of the commercial formulation at the earliest measurement point, and continues to increase relative to the commercial formulation over the course of the measurement interval.
  • the bioabsorption of the hydrophobic therapeutic agent from the compositions of the present invention exceeds that of the commercial formulation by nearly 100%.

Abstract

The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

Description

    FIELD OF THE INVENTION
  • The present invention relates to drug delivery systems, and in particular to pharmaceutical compositions for the improved delivery of hydrophobic compounds. [0001]
    • BACKGROUND
  • Hydrophobic therapeutic agents, i.e., therapeutic compounds having poor solubility in aqueous solution, present difficult problems in formulating such compounds for effective administration to patients. A well-designed formulation must, at a minimum, be capable of presenting a therapeutically effective amount of the hydrophobic compound to the desired absorption site, in an absorbable form. Even this minimal functionality is difficult to achieve when delivery of the hydrophobic therapeutic agent requires interaction with aqueous physiological environments, such as gastric fluids and intestinal fluids. Pharmaceutical compositions for delivery of such hydrophobic therapeutic agents must carry the hydrophobic compound through the aqueous environment, while maintaining the hydrophobic compound in an absorbable form, and avoiding the use of physiologically harmful solvents or excipients. [0002]
  • A number of approaches to formulating hydrophobic therapeutic agents for oral or parenteral delivery are known. One well-known approach uses surfactant micelles to solubilize and transport the therapeutic agent. Micelles are agglomerates of colloidal dimensions formed by amphiphilic compounds under certain conditions. Micelles, and pharmaceutical compositions containing micelles, have been extensively studied and are described in detail in the literature; see, e.g., Remington's Pharmaceutical Sciences, 17[0003] th ed. (1985), the disclosure of which is incorporated herein in its entirety. In aqueous solution, micelles can incorporate hydrophobic therapeutic agents in the hydrocarbon core of the micelle, or entangled at various positions within the micelle walls. Although micellar formulations can solubilize a variety of hydrophobic therapeutic agents, the loading capacity of conventional micelle formulations is limited by the solubility of the therapeutic agent in the micelle surfactant. For many hydrophobic therapeutic agents, such solubility is too low to offer formulations that can deliver therapeutically effective doses.
  • Another conventional approach takes advantage of the increased solubility of hydrophobic therapeutic agents in oils (triglycerides). Hydrophobic therapeutic agents, while poorly soluble in aqueous solution, could be sufficiently lipophilic that therapeutically effective concentrations of the therapeutic agents can be prepared in triglyceride-based solvents. Thus, one conventional approach is to solubilize a hydrophobic therapeutic agent in a bioacceptable triglyceride solvent, such as a digestible vegetable oil, and disperse this oil phase in an aqueous solution. The dispersion may be stabilized by emulsifying agents and provided in emulsion form. Alternatively, the therapeutic agent can be provided in a water-free formulation, with an aqueous dispersion being formed in the in vivo gastrointestinal environment. The properties of these oil-based formulations are determined by such factors as the size of the triglyceride/therapeutic agent colloidal particles and the presence or absence of surfactant additives. [0004]
  • In simplest form, a triglyceride-containing formulation suitable for delivering hydrophobic therapeutic agents through an aqueous environment is an oil-in-water emulsion. Such emulsions contain the hydrophobic therapeutic agent solubilized in an oil phase which is dispersed in an aqueous environment with the aid of a surfactant. The surfactant may be present in the oil-based formulation itself, or may be a compound provided in the gastrointestinal system, such as bile salts, which are known to be in vivo emulsifying agents. The colloidal oil particles sizes are relatively large, ranging from several hundred nanometers to several microns in diameter, in a broad particle size distribution. Since the particle sizes are on the order of or greater than the wavelength range of visible light, such emulsions, when prepared in an emulsion dosage form, are visibly “cloudy” or “milky” to the naked eye. [0005]
  • Although triglyceride-based pharmaceutical compositions are useful in solubilizing and delivering some hydrophobic therapeutic agents, such compositions are subject to a number of significant limitations and disadvantages. Emulsions are thermodynamically unstable, and colloidal emulsion particles will spontaneously agglomerate, eventually leading to complete phase separation. The tendency to agglomerate and phase separate presents problems of storage and handling, and increases the likelihood that pharmaceutical emulsions initially properly prepared will be in a less optimal, less effective, and poorly-characterized state upon ultimate administration to a patient. Uncharacterized degradation is particularly disadvantageous, since increased particle size slows the rate of transport of the colloidal particle and digestion of the oil component, and hence the rate and extent of absorption of the therapeutic agent. These problems lead to poorly-characterized and potentially harmful changes in the effective dosage received by the patient. Moreover, changes in colloidal emulsion particle size are also believed to render absorption more sensitive to and dependent upon conditions in the gastrointestinal tract, such as pH, enzyme activity, bile components, and stomach contents. Such uncertainty in the rate and extent of ultimate absorption of the therapeutic agent severely compromises the medical professional's ability to safely administer therapeutically effective dosages. [0006]
  • A further disadvantage of triglyceride-containing compositions is the dependence of therapeutic agent absorption on the rate and extent of lipolysis. Although colloidal emulsion particles can transport hydrophobic therapeutic agents through the aqueous environment of the gastrointestinal tract, ultimately the triglyceride must be digested and the therapeutic agent must be released in order to be absorbed through the intestinal mucosa. The triglyceride carrier is emulsified by bile salts and hydrolyzed, primarily by pancreatic lipase. The rate and extent of lipolysis, however, are dependent upon several factors that are difficult to adequately control. For example, the amount and rate of bile salt secretion affect the lipolysis of the triglycerides, and the bile salt secretion can vary with stomach contents, with metabolic abnormalities, and with functional changes of the liver, bile ducts, gall bladder and intestine. Lipase availability in patients with decreased pancreatic secretory function, such as cystic fibrosis or chronic pancreatitis, may be undesirably low, resulting in a slow and incomplete triglyceride lipolysis. The activity of lipase is pH dependent, with deactivation occurring at about pH 3, so that the lipolysis rate will vary with stomach contents, and may be insufficient in patients with gastric acid hyper-secretion. Moreover, certain surfactants commonly used in the preparation of pharmaceutical emulsions, such as polyethoxylated castor oils, may themselves act as inhibitors of lipolysis. Although recent work suggests that certain surfactant combinations, when used in combination with digestible oils in emulsion preparations, can substantially decrease the lipolysis-inhibiting effect of some common pharmaceutical surfactants (see, U.S. Pat. No. 5,645,856), such formulations are still subject to the other disadvantages of pharmaceutical emulsions and triglyceride-based formulations. [0007]
  • Yet another approach is based on formation of “microemulsions.” Like an emulsion, a microemulsion is a liquid dispersion of oil in water, stabilized by surfactants. The microemulsion particles are smaller than those of an emulsion, rendering the microemulsion essentially optically clear. Microemulsions, however, are thermodynamically stable, and are not subject to the particle agglomeration problems of conventional emulsions. It is generally believed that microemulsions are micelle-like particles, having an essentially micellar structure but containing a distinct oil phase in the micelle “core”. These micelle-like particles are often referred to as “swollen micelles”, a term which emphasizes their close relationship to true micellar particles. Despite their close relationship to micelles, microemulsions function quite differently in drug delivery systems. The majority of hydrophobic therapeutic agents are lipophilic, and have greater solubility in triglycerides than in surfactants. As a result, the hydrophobic therapeutic agent in a microemulsion-based delivery system is preferentially solvated in the triglyceride phase, which is in turn encapsulated in the swollen micelle. The preferential partitioning in the triglyceride phase results in higher loading capacities than in comparable micelle-based systems, but at the cost of introducing into the delivery system the lipolysis-dependence and other disadvantages associated with the presence of triglycerides. In addition, the larger size of microemulsion particles, relative to true micelles, results in a slower rate of particle diffusion, and thus a slower rate of therapeutic agent absorption. [0008]
  • Thus, there is a need for pharmaceutical compositions that overcome the limitations of conventional micelle formulations, but without suffering from the disadvantages of triglyceride-containing formulations. [0009]
    • SUMMARY OF THE INVENTION
  • It is therefore an object of the present invention to provide pharmaceutical compositions capable of solubilizing therapeutically effective amounts of hydrophobic therapeutic agents. [0010]
  • It is another object of the invention to provide pharmaceutical compositions that are homogeneous and thermodynamically stable. [0011]
  • It is yet another object of the invention to provide pharmaceutical compositions having a small and narrow particle size distribution. [0012]
  • It is still another object of the invention to provide pharmaceutical compositions of a hydrophobic therapeutic agent that are not dependent upon lipolysis for bioabsorption. [0013]
  • It is still another object of the invention to provide methods of treating a patient with a hydrophobic therapeutic agent. [0014]
  • It is still another object of the invention to provide less greasy pharmaceutical compositions for topical/transdermal delivery. [0015]
  • In accordance with these and other objects and features, the present invention provides pharmaceutical compositions for improved delivery of hydrophobic therapeutic agents. In one embodiment, the present invention provides a triglyceride-free pharmaceutical composition including a hydrophobic therapeutic agent and a carrier. The carrier includes a hydrophilic surfactant and a hydrophobic surfactant in amounts such that upon dilution with an aqueous solution such as simulated gastrointestinal fluids the carrier forms a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing the hydrophobic therapeutic agent. [0016]
  • In another embodiment, the present invention provides a clear aqueous dispersion containing a hydrophilic surfactant, a hydrophobic surfactant and a hydrophobic therapeutic agent. The dispersion is substantially free of triglycerides. [0017]
  • In another embodiment, the present invention relates to a triglyceride-free pharmaceutical composition which includes a hydrophilic surfactant and a hydrophobic surfactant in amounts such that upon dilution with an aqueous solution a clear aqueous dispersion is formed, a first amount of a hydrophobic therapeutic agent solubilized in the clear aqueous dispersion, and a second amount of the hydrophobic therapeutic agent that remains non-solubilized but dispersed. [0018]
  • In another embodiment, the present invention relates to methods of increasing the rate and/or extent of absorption of hydrophobic therapeutic agents by administering to a patient a pharmaceutical composition of the present invention. [0019]
  • These and other objects and features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.[0020]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • In order to illustrate the manner in which the above-recited and other advantages and objects of the invention are obtained, a more particular description of the invention briefly described above will be rendered by reference to the specific embodiments shown in the appended drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawing, in which: [0021]
  • FIG. 1 shows the enhanced bioabsorption of a hydrophobic therapeutic agent in the compositions of the present invention, relative to a commercial formulation. [0022]
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention overcomes the problems described above characteristic of conventional formulations such as micelle formulations, emulsions, and microemulsions, by providing unique triglyceride-free pharmaceutical compositions. Surprisingly, the present inventors have found that compositions including a combination of a hydrophilic surfactant and a hydrophobic surfactant can solubilize therapeutically effective amounts of hydrophobic therapeutic agents without recourse to the use of triglycerides, thereby avoiding the lipolysis dependence and other disadvantages of conventional formulations. Use of these formulations results in an enhanced rate and/or extent of absorption of the hydrophobic therapeutic agent. [0023]
  • A. Pharmaceutical Compositions [0024]
  • In one embodiment, the present invention provides a pharmaceutical composition including a carrier and a hydrophobic therapeutic agent. The carrier includes a hydrophilic surfactant and a hydrophobic surfactant in amounts such that upon dilution with an aqueous solution the carrier forms a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing the hydrophobic therapeutic agent. It is a particular feature of the present invention that the carrier is substantially free of triglycerides, thereby providing surprising and important advantages over conventional, triglyceride-containing formulations. [0025]
  • 1. Surfactants [0026]
  • The carrier includes at least one hydrophilic surfactant and at least one hydrophobic surfactant. As is well known in the art, the terms “hydrophilic” and “hydrophobic” are relative terms. To function as a surfactant, a compound must necessarily include polar or charged hydrophilic moieties as well as non-polar hydrophobic (lipophilic) moieties; i.e., a surfactant compound must be amphiphilic. An empirical parameter commonly used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value). Surfactants with lower HLB values are more hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions. [0027]
  • Using HLB values as a rough guide, hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, hydrophobic surfactants are compounds having an HLB value less than about 10. [0028]
  • It should be appreciated that the HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions. For many important surfactants, including several polyethoxylated surfactants, it has been reported that HLB values can differ by as much as about 8 HLB units, depending upon the empirical method chosen to determine the HLB value (Schott, [0029] J. Pharm. Sciences, 79(1), 87-88 (1990)). Likewise, for certain polypropylene oxide containing block copolymers (PLURONIC® surfactants, BASF Corp.), the HLB values may not accurately reflect the true physical chemical nature of the compounds. Finally, commercial surfactant products are generally not pure compounds, but are complex mixtures of compounds, and the HLB value reported for a particular compound may more accurately be characteristic of the commercial product of which the compound is a major component. Different commercial products having the same primary surfactant component can, and typically do, have different HLB values. In addition, a certain amount of lot-to-lot variability is expected even for a single commercial surfactant product. Keeping these inherent difficulties in mind, and using HLB values as a guide, one skilled in the art can readily identify surfactants having suitable hydrophilicity or hydrophobicity for use in the present invention, as described herein.
  • The hydrophilic surfactant can be any hydrophilic surfactant suitable for use in pharmaceutical compositions. Such surfactants can be anionic, cationic, zwitterionic or non-ionic, although non-ionic hydrophilic surfactants are presently preferred. As discussed above, these non-ionic hydrophilic surfactants will generally have HLB values greater than about 10. Mixtures of hydrophilic surfactants are also within the scope of the invention. [0030]
  • Similarly, the hydrophobic surfactant can be any hydrophobic surfactant suitable for use in pharmaceutical compositions. In general, suitable hydrophobic surfactants will have an HLB value less than about 10. Mixtures of hydrophobic surfactants are also within the scope of the invention. [0031]
  • The choice of specific hydrophobic and hydrophilic surfactants should be made keeping in mind the particular hydrophobic therapeutic agent to be used in the composition, and the range of polarity appropriate for the chosen therapeutic agent, as discussed in more detail below. With these general principles in mind, a very broad range of surfactants is suitable for use in the present invention. Such surfactants can be grouped into the following general chemical classes detailed in the Tables below. The HLB values given in the Tables below generally represent the HLB value as reported by the manufacturer of the corresponding commercial product. In cases where more than one commercial product is listed, the HLB value in the Tables is the value as reported for one of the commercial products, a rough average of the reported values, or a value that, in the judgment of the present inventors, is more reliable. It should be emphasized that the invention is not limited to the surfactants in the following Tables, which show representative, but not exclusive, lists of available surfactants. [0032]
  • 1.1. Polyethoxylated Fatty Acids [0033]
  • Although polyethylene glycol (PEG) itself does not function as a surfactant, a variety of PEG-fatty acid esters have useful surfactant properties. Among the PEG-fatty acid monoesters, esters of lauric acid, oleic acid, and stearic acid are most useful. Among the surfactants of Table 1, preferred hydrophilic surfactants include PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-10 oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20 laurate and PEG-20 oleate. Examples of polyethoxylated fatty acid monoester surfactants commercially available are shown in Table 1. [0034]
    TABLE 1
    PEG-Fatty Acid Monoester Surfactants
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    PEG 4-100 monolaurate Crodet L series (Croda) >9
    PEG 4-100 monooleate Crodet O series (Croda) >8
    PEG 4-100 monostearate Crodet S series (Croda), Myrj Series >6
    (Atlas/ICI)
    PEG 400 distearate Cithrol 4DS series (Croda) >10
    PEG 100,200,300 Cithrol ML series (Croda) >10
    monolaurate
    PEG 100,200,300 Cithrol MO series (Croda) >10
    monooleate
    PEG 400 dioleate Cithrol 4DO series (Croda) >10
    PEG 400-1000 Cithrol MS series (Croda) >10
    monostearate
    PEG-1 stearate Nikkol MYS-1EX (Nikko), Coster 2
    K1 (Condea)
    PEG-2 stearate Nikkol MYS-2 (Nikko) 4
    PEG-2 oleate Nikkol MYO-2 (Nikko) 4.5
    PEG-4 laurate Mapeg ® 200 ML (PPG), Kessco ® 9.3
    PEG 200ML (Stepan), LIPOPEG 2L
    (LIPO Chem.)
    PEG-4 oleate Mapeg ® 200 MO (PPG), Kessco ® 8.3
    PEG200 MO (Stepan),
    PEG-4 stearate Kessco ® PEG 200 MS (Stepan), 6.5
    Hodag 20 S (Calgene), Nikkol
    MYS-4 (Nikko)
    PEG-5 stearate Nikkol TMGS-5 (Nikko) 9.5
    PEG-5 oleate Nikkol TMGO-5 (Nikko) 9.5
    PEG-6 oleate Algon OL 60 (Auschem SpA),
    Kessco ® PEG 300 MO (Stepan), 8.5
    Nikkol MYO-6 (Nikko), Emulgante A6
    (Condea)
    PEG-7 oleate Algon OL 70 (Auschem SpA) 10.4
    PEG-6 laurate Kessco ® PEG300 ML (Stepan) 11.4
    PEG-7 laurate Lauridac 7 (Condea) 13
    PEG-6 stearate Kessco ® PEG300 MS (Stepan) 9.7
    PEG-8 laurate Mapeg ® 400 ML (PPG), LIPOPEG 13
    4DL(Lipo Chem.)
    PEG-8 oleate Mapeg ® 400 MO (PPG), Emulgante 12
    A8 (Condea)
    PEG-8 stearate Mapeg ® 400 MS (PPG), Myrj 45 12
    PEG-9 oleate Emulgante A9 (Condea) >10
    PEG-9 stearate Cremophor S9 (BASF) >10
    PEG-10 laurate Nikkol MYL-10 (Nikko), Lauridac 10 13
    (Croda)
    PEG-10 oleate Nikkol MYG-10 (Nikko) 11
    PEG-10 stearate Nikkol MYS-10 (Nikko), Coster K100 11
    (Condea)
    PEG-12 laurate Kessco ® PEG 600ML (Stepan) 15
    PEG-12 oleate Kessco ® PEG 600MO (Stepan) 14
    PEG-12 ricinoleate (CAS #9004-97-1) >10
    PEG-12 stearate Mapeg ® 600 MS (PPG), Kessco ® 14
    PEG 600MS (Stepan)
    PEG-15 stearate Nikkol TMGS-15 (Nikko), Koster K15 14
    (Condea)
    PEG-15 oleate Nikkol TMGO-15 (Nikko) 15
    PEG-20 laurate Kessco ® PEG 1000 ML (Stepan) 17
    PEG-20 oleate Kessco ® PEG 1000 MO (Stepan) 15
    PEG-20 stearate Mapeg ® 1000 MS (PPG), Kessco ® 16
    PEG 1000 MS (Stepan), Myrj 49
    PEG-25 stearate Nikkol MYS-25 (Nikko) 15
    PEG-32 laurate Kessco ® PEG 1540 ML (Stepan) 16
    PEG-32 oleate Kessco ® PEG 1540 MO (Stepan) 17
    PEG-32 stearate Kessco ® PEG 1540 MS (Stepan) 17
    PEG-30 stearate Myrj 51 >10
    PEG-40 laurate Crodet L40 (Croda) 17.9
    PEG-40 oleate Crodet O40 (Croda) 17.4
    PEG-40 stearate Myrj 52, Emerest ® 2715 (Henkel), >10
    Nikkol MYS-40 (Nikko)
    PEG-45 stearate Nikkol MYS-45 (Nikko) 18
    PEG-50 stearate Myrj 53 >10
    PEG-55 stearate Nikkol MYS-55 (Nikko) 18
    PEG-100 oleate Crodet O-100 (Croda) 18.8
    PEG-100 stearate Myrj 59, Arlacel 165 (ICI) 19
    PEG-200 oleate Albunol 200 MO (Taiwan Surf.) >10
    PEG-400 oleate LACTOMUL (Henkel), Albunol 400 >10
    MO (Taiwan Surf.)
    PEG-600 oleate Albunol 600 MO (Taiwan Surf.) >10
  • 1.2 PEG-Fatty Acid Diesters [0035]
  • Polyethylene glycol fatty acid diesters are also suitable for use as surfactants in the compositions of the present invention. Among the surfactants in Table 2, preferred hydrophilic surfactants include PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate and PEG-32 dioleate. Representative PEG-fatty acid diesters are shown in Table 2. [0036]
    TABLE 2
    PEG-Fatty Acid Diester Surfactants
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    PEG-4 dilaurate Mapeg ® 200 DL (PPG), Kessco ® PEG 7
    200 DL (Stepan), LIPOPEG 2-DL
    (Lipo Chem.)
    PEG-4 dioleate Mapeg ® 200 DO (PPG), 6
    PEG-4 distearate Kessco ® 200 DS (Stepan— 5
    PEG-6 dilaurate Kessco ® PEG 300 DL (Stepan) 9.8
    PEG-6 dioleate Kessco ® PEG 300 DO (Stepan) 7.2
    PEG-6 distearate Kessco ® PEG 300 DS (Stepan) 6.5
    PEG-8 dilaurate Mapeg ® 400 DL (PPG), Kessco ® PEG 11
    400 DL (Stepan), LIPOPEG 4 DL
    (Lipo Chem.)
    PEG-8 dioleate Mapeg ® 400 DO (PPG), Kessco ® PEG 8.8
    400 DO (Stepan), LIPOPEG 4 DO
    (Lipo Chem.)
    PEG-8 distearate Mapeg ® 400 DS (PPG), CDS 400 (Nikkol) 11
    PEG-10 dipalmitate Polyaldo 2PKFG >10
    PEG-12 dilaurate Kessco ® PEG 600 DL (Stepan) 11.7
    PEG-12 distearate Kessco ® PEG 600 DS (Stepan) 10.7
    PEG-12 dioleate Mapeg ® 600 DO (PPG), Kessco ® 600 10
    DO(Stepan)
    PEG-20 dilaurate Kessco ® PEG 1000 DL (Stepan) 15
    PEG-20 dioleate Kessco ® PEG 1000 DO (Stepan) 13
    PEG-20 distearate Kessco ® PEG 1000 DS (Stepan) 12
    PEG-32 dilaurate Kessco ® PEG 1540 DL (Stepan) 16
    PEG-32 dioleate Kessco ® PEG 1540 DO (Stepan) 15
    PEG-32 distearate Kessco ® PEG 1540 DS (Stepan) 15
    PEG-400 dioleate Cithrol 4DO series (Croda) >10
    PEG-400 distearate Cithrol 4DS series (Croda) >10
  • 1.3 PEG-Fatty Acid Mono- and Di-ester Mixtures [0037]
  • In general, mixtures of surfactants are also useful in the present invention, including mixtures of two or more commercial surfactant products. Several PEG-fatty acid esters are marketed commercially as mixtures or mono- and diesters. Representative surfactant mixtures are shown in Table 3. [0038]
    TABLE 3
    PEG-Fatty Acid Mono- and Diester Mixtures
    COMMERCIAL
    COMPOUND PRODUCT (Supplier) HLB
    PEG 4-150 mono, dilaurate Kessco ® PEG 200-6000 mono,
    dilaurate (Stepan)
    PEG 4-150 mono, dioleate Kessco ® PEG 200-6000 mono,
    dioleate (Stepan)
    PEG 4-150 mono, distearate Kessco ® 200-6000 mono,
    distearate (Stepan)
  • 1.4 Polyethylene Glycol Glycerol Fatty Acid Esters [0039]
  • Suitable PEG glycerol fatty acid esters are shown in Table 4. Among the surfactants in the Table, preferred hydrophilic surfactants are PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-20 glyceryl oleate, and PEG-30 glyceryl oleate. [0040]
    TABLE 4
    PEG Glycerol Fatty Acid Esters
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    PEG-20 glyceryl laurate Tagat ® L (Goldschmidt) 16
    PEG-30 glyceryl laurate Tagat ® L2 (Goldschmidt) 16
    PEG-15 glyceryl laurate Glycerox L series (Croda) 15
    PEG-40 glyceryl laurate Glycerox L series (Croda) 15
    PEG-20 glyceryl stearate Capmul ® EMG (ABITEC), 13
    Aldo ® MS-20 KFG (Lonza)
    PEG-20 glyceryl oleate Tagat ® O (Goldschmidt) >10  
    PEG-30 glyceryl oleate Tagat ® O2 (Goldschmidt) >10  
  • 1.5. Alcohol-Oil Transesterification Products [0041]
  • A large number of surfactants of different degrees of hydrophobicity or hydrophilicity can be prepared by reaction of alcohols or polyalcohols with a variety of natural and/or hydrogenated oils. Most commonly, the oils used are castor oil or hydrogenated castor oil, or an edible vegetable oil such as corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or almond oil. Preferred alcohols include glycerol, propylene glycol, ethylene glycol, polyethylene glycol, sorbitol, and pentaerythritol. Among these alcohol-oil transesterified surfactants, preferred hydrophilic surfactants are PEG-35 castor oil (Incrocas-35), PEG-40 hydrogenated castor oil (Cremophor RH 40), PEG-25 trioleate (TAGAT® TO), PEG-60 corn glycerides (Crovol M70), PEG-60 almond oil (Crovol A70), PEG-40 palm kernel oil (Crovol PK70), PEG-50 castor oil (Emalex C-50), PEG-50 hydrogenated castor oil (Emalex HC-50), PEG-8 caprylic/capric glycerides (Labrasol), and PEG-6 caprylic/capric glycerides (Softigen 767). Preferred hydrophobic surfactants in this class include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (Labrafil® M 2125 CS), PEG-6 almond oil (Labrafil® M 1966 CS), PEG-6 apricot kernel oil (Labrafil® M 1944 CS), PEG-6 olive oil (Labrafil® M 1980 CS), PEG-6 peanut oil (Labrafil® M 1969 CS), PEG-6 hydrogenated palm kernel oil (Labrafil® M 2130 BS), PEG-6 palm kernel oil (Labrafil® M 2130 CS), PEG-6 triolein (Labrafil® M 2735 CS), PEG-8 corn oil (Labrafil® WL 2609 BS), PEG-20 corn glycerides (Crovol M40), and PEG-20 almond glycerides (Crovol A40). The latter two surfactants are reported to have HLB values of 10, which is generally considered to be the approximate border line between hydrophilic and hydrophobic surfactants. For purposes of the present invention, these two surfactants are considered to be hydrophobic. Representative surfactants of this class suitable for use in the present invention are shown in Table 5. [0042]
    TABLE 5
    Transesterification Products of Oils and Alcohols
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    PEG-3 castor oil Nikkol CO-3 (Nikko) 3
    PEG-5, 9, and 16 ACCONON CA series (ABITEC) 6-7
    castor oil
    PEG-20 castor oil Emalex C-20 (Nihon Emulsion), Nikkol 11
    CO-20 TX (Nikko)
    PEG-23 castor oil Emulgante EL23 >10
    PEG-30 castor oil Emalex C-30 (Nihon Emulsion), 11
    Alkamuls ® EL 620 (Rhone-Poulenc),
    Incrocas 30 (Croda)
    PEG-35 castor oil Cremophor EL and EL-P (BASF),
    Emulphor EL, Incrocas-35 (Croda),
    Emulgin RO 35 (Henkel)
    PEG-38 castor oil Emulgante EL 65 (Condea)
    PEG-40 castor oil Emalex C-40 (Nihon Emulsion), 13
    Alkamuls ® EL 719 (Rhone-Poulenc)
    PEG-50 castor oil Emalex C-50 (Nihon Emulsion) 14
    PEG-56 castor oil Eumulgin ® PRT 56 (Pulcra SA) >10
    PEG-60 castor oil Nikkol CO-60TX (Nikko) 14
    PEG-100 castor oil Thomley >10
    PEG-200 castor oil Eumulgin ® PRT 200 (Pulcra SA) >10
    PEG-5 hydrogenated Nikkol HCO-5 (Nikko) 6
    castor oil
    PEG-7 hydrogenated Simusol ® 989 (Seppic), Cremophor 6
    castor oil WO7 (BASF)
    PEG-10 hydrogenated Nikkol HCO-10 (Nikko) 6.5
    castor oil
    PEG-20 hydrogenated Nikkol HCO-20 (Nikko) 11
    castor oil
    PEG-25 hydrogenated Simulsol ® 1292 (Seppic), Cerex ELS 11
    castor oil 250 (Auschem SpA)
    PEG-30 hydrogenated Nikkol HCO-30 (Nikko) 11
    castor oil
    PEG-40 hydrogenated Cremophor RH 40 (BASF), Croduret 13
    castor oil (Croda), Emulgin HRE 40 (Henkel)
    PEG-45 hydrogenated Cerex ELS 450 (Auschem Spa) 14
    castor oil
    PEG-50 hydrogenated Emalex HC-50 (Nihon Emulsion) 14
    castor oil
    PEG-60 hydrogenated Nikkol HCO-60 (Nikko); Cremophor 15
    castor oil RH 60 (BASF)
    PEG-80 hydrogenated Nikkol HCO-80 (Nikko) 15
    castor oil
    PEG-100 hydro- Nikkol HCO-100 (Nikko) 17
    genated castor oil
    PEG-6 corn oil Labrafil ® M 2125 CS (Gattefosse) 4
    PEG-6 almond oil Labrafil ® M 1966 CS (Gattefosse) 4
    PEG-6 apricot Labrafil ® M 1944 CS (Gattefosse) 4
    kernel oil
    PEG-6 olive oil Labrafil ® M 1980 CS (Gattefosse) 4
    PEG-6 peanut oil Labrafil ® M 1969 CS (Gattefosse) 4
    PEG-6 hydrogenated Labrafil ® M 2130 BS (Gattefosse) 4
    palm kernel oil
    PEG-6 palm kernel oil Labrafil ® M 2130 CS (Gattefosse) 4
    PEG-6 triolein Labrafil ® M 2735 CS (Gattefosse) 4
    PEG-8 corn oil Labrafil ® WL 2609 BS (Gattefosse) 6-7
    PEG-20 corn Crovol M40 (Croda) 10
    glycerides
    PEG-20 almond Crovol A40 (Croda) 10
    glycerides
    PEG-25 trioleate TAGAT ® TO (Goldschmidt) 11
    PEG-40 palm Crovol PK-70 >10
    kernel oil
    PEG-60 corn Crovol M70(Croda) 15
    glycerides
    PEG-60 almond Crovol A70 (Croda) 15
    glycerides
    PEG-4 caprylic/capric Labrafac ® Hydro (Gattefosse), 4-5
    triglyceride
    PEG-8 caprylic/capric Labrasol (Gattefosse),Labrafac CM 10 >10
    glycerides (Gattefosse)
    PEG-6 caprylic/capric SOFTIGEN ® 767 (Hüls), Glycerox 19
    glycerides 767 (Croda)
    Lauroyl macrogol-32 GELUCIRE 44/14 (Gattefosse) 14
    glyceride
    Stearoyl macrogol GELUCIRE 50/13 (Gattefosse) 13
    glyceride
    Mono, di, tri, tetra SorbitoGlyceride (Gattefosse) <10
    esters of vegetable
    oils and sorbitol
    Pentaerythrityl Crodamol PTIS (Croda) <10
    tetraisostearate
    Pentaerythrityl Albunol DS (Taiwan Surf.) <10
    distearate
    Pentaerythrityl Liponate PO-4 (Lipo Chem.) <10
    tetraoleate
    Pentaerythrityl Liponate PS-4 (Lipo Chem.) <10
    tetrastearate
    Pentaerythrityl Liponate PE-810 (Lipo Chem.), <10
    tetracaprylate/ Crodamol PTC (Croda)
    tetracaprate
    Pentaerythrityl Nikkol Pentarate 408 (Nikko)
    tetraoctanoate
  • 1.6. Polyglycerized Fatty Acids [0043]
  • Polyglycerol esters of fatty acids are also suitable surfactants for the present invention. Among the polyglyceryl fatty acid esters, preferred hydrophobic surfactants include polyglyceryl oleate (Plurol Oleique), polyglyceryl-2 dioleate (Nikkol DGDO), and polyglyceryl-10 trioleate. Preferred hydrophilic surfactants include polyglyceryl-10 laurate (Nikkol Decaglyn 1-L), polyglyceryl-10 oleate (Nikkol Decaglyn 1-O), and polyglyceryl-10 mono, dioleate (Caprol® PEG 860). Polyglyceryl polyricinoleates (Polymuls) are also preferred hydrophilic and hydrophobic surfactants. Examples of suitable polyglyceryl esters are shown in Table 6. [0044]
    TABLE 6
    Polyglycerized Fatty Acids
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Polyglyceryl-2 stearate Nikkol DGMS (Nikko) 5-7
    Polyglyceryl-2 oleate Nikkol DGMO (Nikko) 5-7
    Polyglyceryl-2 Nikkol DGMIS (Nikko) 5-7
    isostearate
    Polyglyceryl-3 oleate Caprol ® 3GO (ABITEC), Drewpol 6.5
    3-1-O (Stepan)
    Polyglyceryl-4 oleate Nikkol Tetraglyn 1-O (Nikko) 5-7
    Polyglyceryl-4 stearate Nikkol Tetraglyn 1-S (Nikko) 5-6
    Polyglyceryl-6 oleate Drewpol 6-1-O (Stepan), Nikkol 9
    Hexaglyn 1-O (Nikko)
    Polyglyceryl-10 Nikkol Decaglyn 1-L (Nikko) 15
    laurate
    Polyglyceryl-10 oleate Nikkol Decaglyn 1-O (Nikko) 14
    Polyglyceryl-10 Nikkol Decaglyn 1-S (Nikko) 12
    stearate
    Polyglyceryl-6 Nikkol Hexaglyn PR-15 (Nikko) >8
    ricinoleate
    Polyglyceryl-10 Nikkol Decaglyn 1-LN (Nikko) 12
    linoleate
    Polyglyceryl-6 Nikkol Hexaglyn 5-O (Nikko) <10
    pentaoleate
    Polyglyceryl-3 dioleate Cremophor GO32 (BASF) <10
    Polyglyceryl-3 Cremophor GS32 (BASF) <10
    distearate
    Polyglyceryl-4 Nikkol Tetraglyn 5-O (Nikko) <10
    pentaoleate
    Polyglyceryl-6 dioleate Caprol ® 6G20 (ABITEC); Hodag 8.5
    PGO-62 (Calgene), PLUROL
    OLEIQUE CC 497 (Gattefosse)
    Polyglyceryl-2 dioleate Nikkol DGDO (Nikko) 7
    Polyglyceryl-10 Nikkol Decaglyn 3-O (Nikko) 7
    trioleate
    Polyglyceryl-10 Nikkol Decaglyn 5-O (Nikko) 3.5
    pentaoleate
    Polyglyceryl-10 Nikkol Decaglyn 7-O (Nikko) 3
    septaoleate
    Polyglyceryl-10 Caprol ® 10G4O (ABITEC); 6.2
    tetraoleate Hodag PGO-62 (CALGENE), Drewpol
    10-4-O (Stepan)
    Polyglyceryl-10
    decaisostearate Nikkol Decaglyn 10-IS (Nikko) <10
    Polyglyceryl-101 Drewpol 10-10-O (Stepan), Caprol 3.5
    decaoleate 10G10O (ABITEC), Nikkol Decaglyn
    10-O
    Polyglyceryl-10 mono, Caprol ® PGE 860 (ABITEC) 11
    dioleate
    Polyglyceryl Polymuls (Henkel)  3-20
    polyricinoleate
  • 1.7. Propylene Glycol Fatty Acid Esters [0045]
  • Esters of propylene glycol and fatty acids are suitable surfactants for use in the present invention. In this surfactant class, preferred hydrophobic surfactants include propylene glycol monolaurate (Lauroglycol FCC), propylene glycol ricinoleate (Propymuls), propylene glycol monooleate (Myverol P-O6), propylene glycol dicaprylate/dicaprate (Captex® 200), and propylene glycol dioctanoate (Captex® 800). Examples of surfactants of this class are given in Table 7. [0046]
    TABLE 7
    Propylene Glycol Fatty Acid Esters
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Propylene glycol Capryol 90 (Gattefosse), Nikkol Sefsol 218 <10
    monocaprylate (Nikko)
    Propylene glycol Lauroglycol 90 (Gattefosse), Lauroglycol <10
    monolaurate FCC (Gattefosse)
    Propylene glycol Lutrol OP2000 (BASF) <10
    oleate
    Propylene glycol Mirpyl <10
    myristate
    Propylene glycol ADM PGME-03 (ADM), LIPO PGMS (Lipo 3-4
    monostearate Chem.), Aldo ® PGHMS (Lonza)
    Propylene glycol <10
    hydroxy stearate
    Propylene glycol PROPYMULS (Henkel) <10
    ricinoleate
    Propylene glycol <10
    isostearate
    Propylene glycol Myverol P-O6 (Eastman) <10
    monooleate
    Propylene glycol Captex ® 200 (ABITEC), Miglyol ® 840 >6 
    dicaprylate/dicaprate (Hüls), Neobee ® M-20 (Stepan)
    Propylene glycol Captex ® 800 (ABITEC) >6 
    dioctanoate
    Propylene glycol LABRAFAC PG (Gattefosse) >6 
    caprylate/caprate
    Propylene glycol >6 
    dilaurate
    Propylene glycol Kessco ® PGDS (Stepan) >6 
    distearate
    Propylene glycol Nikkol Sefsol 228 (Nikko) >6 
    dicaprylate
    Propylene glycol Nikkol PDD (Nikko) >6 
    dicaprate
  • 1.8. Mixtures of Propylene Glycol Esters-Glycerol Esters [0047]
  • In general, mixtures of surfactants are also suitable for use in the present invention. In particular, mixtures of propylene glycol fatty acid esters and glycerol fatty acid esters are suitable and are commercially available. One preferred mixture is composed of the oleic acid esters of propylene glycol and glycerol (Arlacel 186). Examples of these surfactants are shown in Table 8. [0048]
    TABLE 8
    Glycerol/Propylene Glycol Fatty Acid Esters
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Oleic ATMOS 300, ARLACEL 186 (ICI) 3-4
    Stearic ATMOS 150 3-4
  • 1.9. Mono- and Diglycerides [0049]
  • A particularly important class of surfactants is the class of mono- and diglycerides. These surfactants are generally hydrophobic. Preferred hydrophobic surfactants in this class of compounds include glyceryl monooleate (Peceol), glyceryl ricinoleate, glyceryl laurate, glyceryl dilaurate (Capmul® GDL), glyceryl dioleate (Capmul® GDO), glyceryl mono/dioleate (Capmul® GMO-K), glyceryl caprylate/caprate (Capmul® MCM), caprylic acid mono/diglycerides (Imwitor® 988), and mono- and diacetylated monoglycerides (Myvacet® 9-45). Examples of these surfactants are given in Table 9. [0050]
    TABLE 9
    Mono- and Diglyceride Surfactants
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Monopalmitolein (Larodan) <10
    (C16:1)
    Monoelaidin (Larodan) <10
    (C18:1)
    Monocaproin (C6) (Larodan) <10
    Monocaprylin (Larodan) <10
    Monocaprin (Larodan) <10
    Monolaurin (Larodan) <10
    Glyceryl Nikkol MGM (Nikko) 3-4
    monomyristate (C14)
    Glyceryl monooleate PECEOL (Gattefosse), Hodag GMO-D, 3-4
    (C18:1) Nikkol MGO (Nikko)
    Glyceryl monooleate RYLO series (Danisco), DIMODAN 3-4
    series (Danisco), EMULDAN
    (Danisco), ALDO ® MO FG (Lonza),
    Kessco GMO (Stepan),
    MONOMULS ® series (Henkel),
    TEGIN O, DREWMULSE GMO
    (Stepan), Atlas G-695 (ICI), GMOrphic
    80 (Eastman), ADM DMG-40, 70,
    and 100 (ADM), Myverol (Eastman)
    Glycerol monooleate/ OLICINE (Gattefosse) 3-4
    linoleate
    Glycerol Maisine (Gattefosse), MYVEROL 3-4
    monolinoleate 18-92, Myverol 18-06 (Eastman)
    Glyceryl ricinoleate Softigen ® 701 (Hüls), HODAG 6
    GMR-D (Calgene), ALDO ®
    MR (Lonza)
    Glyceryl monolaurate ALDO ® MLD (Lonza), Hodag GML 6.8
    (Calgene)
    Glycerol Emalex GMS-P (Nihon) 4
    monopalmitate
    Glycerol monostearate Capmul ® GMS (ABITEC), Myvaplex 5-9
    (Eastman), IMWITOR ® 191 (Hüls),
    CUTINA GMS, Aldo ® MS (Lonza),
    Nikkol MGS series (Nikko)
    Glyceryl mono-, Capmul ® GMO-K (ABITEC) <10
    dioleate
    Glyceiyl CUTINA MD-A, ESTAGEL-G18 <10
    palmitic/stearic
    Glyceryl acetate Lamegin ® EE (Grünau GmbH) <10
    Glyceryl laurate Imwitor ® 312 (Hüls), 4
    Monomuls ® 90-45 (Grünau GmbH),
    Aldo ® MLD (Lonza)
    Glyceryl citrate/ Imwitor ® 375 (Hüls) <10
    lactate/oleate/
    linoleate
    Glyceryl caprylate Imwitor ® 308 (Hüls), Capmul ® 5-6
    MCMC8 (ABITEC)
    Glyceryl caprylate/ Capmul ® MCM (ABITEC) 5-6
    caprate
    Caprylic acid mono, Imwitor ® 988 (Hüls) 5-6
    diglycerides
    Caprylic/capric Imwitor ® 742 (Hüls) <10
    glycerides
    Mono-and diacetylated Myvacet ® 9-45, Myvacet ® 9-40, 3.8-4  
    monoglycerides Myvacet ® 9-08 (Eastman),
    Lamegin ® (Grünau)
    Glyceryl monostearate Aldo ® MS, Arlacel 129 (ICI), LIPO 4.4
    GMS (Lipo Chem.), Imwitor ® 191
    (Hüls), Myvaplex (Eastman)
    Lactic acid esters of LAMEGIN GLP (Henkel) <10
    mono,diglycerides
    Dicaproin (C6) (Larodan) <10
    Dicaprin (C10) (Larodan) <10
    Dioctanoin (C8) (Larodan) <10
    Dimyristin (C14) (Larodan) <10
    Dipalmitin (C16) (Larodan) <10
    Distearin (Larodan) <10
    Glyceryl dilaurate Capmul ® GDL (ABITEC) 3-4
    (C12)
    Glyceryl dioleate Capmul ® GDO (ABITEC) 3-4
    Glycerol esters GELUCIRE 39/01 (Gattefosse), 1
    of fatty acids GELUCIRE 43/01 (Gattefosse)
    GELUCIRE 37/06 (Gattefosse) 6
    Dipalmitolein (C16:1) (Larodan) <10
    1,2 and 1,3-diolein (Larodan) <10
    (C18:1)
    Dielaidin (C18:1) (Larodan) <10
    Dilinolein (C18:2) (Larodan) <10
  • 1.10. Sterol and Sterol Derivatives [0051]
  • Sterols and derivatives of sterols are suitable surfactants for use in the present invention. These surfactants can be hydrophilic or hydrophobic. Preferred derivatives include the polyethylene glycol derivatives. A preferred hydrophobic surfactant in this class is cholesterol. A preferred hydrophilic surfactant in this class is PEG-24 cholesterol ether (Solulan C-24). Examples of surfactants of this class are shown in Table 10. [0052]
    TABLE 10
    Sterol and Sterol Derivative Surfactants
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Cholesterol, sitosterol, <10
    lanosterol
    PEG-24 cholesterol ether Solulan C-24 (Amerchol) >10
    PEG-30 cholesterol Nikkol DHC (Nikko) >10
    Phytosterol GENEROL series (Henkel) <10
    PEG-25 phyto sterol Nikkol BPSH-25 (Nikko) >10
    PEG-5 soya sterol Nikkol BPS-5 (Nikko) <10
    PEG-10 soya sterol Nikkol BPS-10 (Nikko) <10
    PEG-20 soya sterol Nikkol BPS-20 (Nikko) <10
    PEG-30 soya sterol Nikkol BPS-30 (Nikko) >10
  • 1.11. Polyethylene Glycol Sorbitan Fatty Acid Esters [0053]
  • A variety of PEG-sorbitan fatty acid esters are available and are suitable for use as surfactants in the present invention. In general, these surfactants are hydrophilic, although several hydrophobic surfactants of this class can be used. Among the PEG-sorbitan fatty acid esters, preferred hydrophilic surfactants include PEG-20 sorbitan monolaurate (Tween-20), PEG-20 sorbitan monopalmitate (Tween-40), PEG-20 sorbitan monostearate (Tween-60), and PEG-20 sorbitan monooleate (Tween-80). Examples of these surfactants are shown in Table 11. [0054]
    TABLE 11
    PEG-Sorbitan Fatty Acid Esters
    COMMERCIAL
    COMPOUND PRODUCT (Supplier) HLB
    PEG-10 sorbitan laurate Liposorb L-10 (Lipo Chem.) >10
    PEG-20 sorbitan monolaurate Tween-20 (Atlas/ICI), Crillet 1 17
    (Croda), DACOL MLS 20
    (Condea)
    PEG-4 sorbitan monolaurate Tween-21 (Atlas/ICI), Crillet 11 13
    (Croda)
    PEG-80 sorbitan monolaurate Hodag PSML-80 (Calgene); >10
    T-Maz 28
    PEG-6 sorbitan monolaurate Nikkol GL-1 (Nikko) 16
    PEG-20 sorbitan monopalmitate Tween-40 (Atlas/ICI), Crillet 2 16
    (Croda)
    PEG-20 sorbitan monostearate Tween-60 (Atlas/ICI), Crillet 3 15
    (Croda)
    PEG-4 sorbitan monostearate Tween-61 (Atlas/ICI), Crillet 31 9.6
    (Croda)
    PEG-8 sorbitan monostearate DACOL MSS (Condea) >10
    PEG-6 sorbitan monostearate Nikkol TS106 (Nikko) 11
    PEG-20 sorbitan tristearate Tween-65 (Atlas/ICI), Crillet 35 11
    (Croda)
    PEG-6 sorbitan tetrastearate Nikkol GS-6 (Nikko) 3
    PEG-60 sorbitan tetrastearate Nikkol GS-460 (Nikko) 13
    PEG-5 sorbitan monooleate Tween-81 (Atlas/ICI), Crillet 41 10
    (Croda)
    PEG-6 sorbitan monooleate Nikkol TO-106 (Nikko) 10
    PEG-20 sorbitan monooleate Tween-80 (Atlas/ICI), Crillet 4 15
    (Croda)
    PEG-40 sorbitan oleate Emalex ET 8040 18
    (Nihon Emulsion)
    PEG-20 sorbitan trioleate Tween-85 (Atlas/ICI), Crillet 45 11
    (Croda)
    PEG-6 sorbitan tetraoleate Nikkol GO-4 (Nikko) 8.5
    PEG-30 sorbitan tetraoleate Nikkol GO-430 (Nikko) 12
    PEG-40 sorbitan tetraoleate Nikkol GO-440 (Nikko) 13
    PEG-20 sorbitan Tween-120 (Atlas/ICI), Crillet 6 >10
    monoisostearate (Croda)
    PEG sorbitol hexaoleate Atlas G-1086 (ICI) 10
    PEG-6 sorbitol hexastearate Nikkol GS-6 (Nikko) 3
  • 1.12. Polyethylene Glycol Alkyl Ethers [0055]
  • Ethers of polyethylene glycol and alkyl alcohols are suitable surfactants for use in the present invention. Preferred hydrophobic ethers include PEG-3 oleyl ether (Volpo 3) and PEG-4 lauryl ether (Brij 30). Examples of these surfactants are shown in Table 12. [0056]
    TABLE 12
    Polyethylene Glycol Alkyl Ethers
    COMMERCIAL
    COMPOUND PRODUCT (Supplier) HLB
    PEG-2 oleyl ether,oleth-2 Brij 92/93 (Atlas/ICI) 4.9
    PEG-3 oleyl ether,oleth-3 Volpo 3 (Croda) <10
    PEG-5 oleyl ether,oleth-5 Volpo 5 (Croda) <10
    PEG-10 oleyl ether,oleth-10 Volpo 10 (Croda), Brij 96/97 12
    (Atlas/ICI)
    PEG-20 oleyl ether,oleth-20 Volpo 20 (Croda), Brij 98/99 15
    (Atlas/ICI)
    PEG-4 lauryl ether, laureth-4 Brij 30 (Atlas/ICI) 9.7
    PEG-9 lauryl ether >10
    PEG-23 lauryl ether, laureth-23 Brij 35 (Atlas/ICI) 17
    PEG-2 cetyl ether Brij 52 (ICI) 5.3
    PEG-10 cetyl ether Brij 56 (ICI) 13
    PEG-20 cetyl ether Brij 58 (ICI) 16
    PEG-2 stearyl ether Brij 72 (ICI) 4.9
    PEG-10 stearyl ether Brij 76 (ICI) 12
    PEG-20 stearyl ether Brij 78 (ICI) 15
    PEG-100 stearyl ether Brij 700 (ICI) >10
  • 1.13. Sugar Esters [0057]
  • Esters of sugars are suitable surfactants for use in the present invention. Preferred hydrophilic surfactants in this class include sucrose monopalmitate and sucrose monolaurate. Examples of such surfactants are shown in Table 13. [0058]
    TABLE 13
    Sugar Ester Surfactants
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Sucrose distearate SUCRO ESTER 7 (Gattefosse), 3
    Crodesta F-10 (Croda)
    Sucrose distearate/ SUCRO ESTER 11 (Gattefosse), 12
    monostearate Crodesta F-110 (Croda)
    Sucrose dipalmitate 7.4
    Sucrose monostearate Crodesta F-160 (Croda) 15
    Sucrose monopalmitate SUCRO ESTER 15 (Gattefosse) >10
    Sucrose monolaurate Saccharose monolaurate 15
    1695 (Mitsubishi-Kasei)
  • 1.14. Polyethylene Glycol Alkyl Phenols [0059]
  • Several hydrophilic PEG-alkyl phenol surfactants are available, and are suitable for use in the present invention. Examples of these surfactants are shown in Table 14. [0060]
    TABLE 14
    Polyethylene Glycol Alkyl Phenol Surfactants
    COMMERCIAL
    COMPOUND PRODUCT (Supplier) HLB
    PEG-10-100 nonyl phenol Triton X series (Rohm & Haas), >10
    Igepal CA series (GAF, USA),
    Antarox CA series (GAF, UK)
    PEG-15-100 octyl phenol ether Triton N-series (Rohm & Haas), >10
    Igepal CO series (GAF, USA),
    Antarox CO series (GAF, UK)
  • 1.15. Polyoxyethylene-Polyoxypropylene Block Copolymers [0061]
  • The POE-POP block copolymers are a unique class of polymeric surfactants. The unique structure of the surfactants, with hydrophilic POE and hydrophobic POP moieties in well-defined ratios and positions, provides a wide variety of surfactants suitable for use in the present invention. These surfactants are available under various trade names, including Synperonic PE series (ICI); Pluronic® series (BASF), Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare, and Plurodac. The generic term for these polymers is “poloxamer” (CAS 9003-11-6). These polymers have the formula: [0062]
  • HO(C2H4O)a(C3H6O)b(C2H4O)nH
  • where “a” and “b” denote the number of polyoxyethylene and polyoxypropylene units, respectively. [0063]
  • Preferred hydrophilic surfactants of this class include Poloxamers 108, 188, 217, 238, 288, 338, and 407. Preferred hydrophobic surfactants in this class include Poloxamers 124, 182, 183, 212, 331, and 335. [0064]
  • Examples of suitable surfactants of this class are shown in Table 15. Since the compounds are widely available, commercial sources are not listed in the Table. The compounds are listed by generic name, with the corresponding “a” and “b” values. [0065]
    TABLE 15
    POE-POP Block Copolymers
    a, b values in
    COMPOUND HO(C2H4O)a(C3H6O)b(C2H4O)aH HLB
    Poloxamer 105 a = 11 b = 16 8
    Poloxamer 108 a = 46 b = 16 >10
    Poloxamer 122 a = 5 b = 21 3
    Poloxamer 123 a = 7 b = 21 7
    Poloxamer 124 a = 11 b = 21 >7
    Poloxamer 181 a = 3 b = 30
    Poloxamer 182 a = 8 b = 30 2
    Poloxamer 183 a = 10 b = 30
    Poloxamer 184 a = 13 b = 30
    Poloxamer 185 a = 19 b = 30
    Poloxamer 188 a = 75 b = 30 29
    Poloxamer 212 a = 8 b = 35
    Poloxamer 215 a = 24 b = 35
    Poloxamer 217 a = 52 b = 35
    Poloxamer 231 a = 16 b = 39
    Poloxamer 234 a = 22 b = 39
    Poloxamer 235 a = 27 b = 39
    Poloxamer 237 a = 62 b = 39 24
    Poloxamer 238 a = 97 b = 39
    Poloxamer 282 a = 10 b = 47
    Poloxamer 284 a = 21 b = 47
    Poloxamer 288 a = 122 b = 47 >10
    Poloxamer 331 a = 7 b = 54 0.5
    Poloxamer 333 a = 20 b = 54
    Poloxamer 334 a = 31 b = 54
    Poloxamer 335 a = 38 b = 54
    Poloxamer 338 a = 128 b = 54
    Poloxamer 401 a = 6 b = 67
    Poloxamer 402 a = 13 b = 67
    Poloxamer 403 a = 21 b = 67
    Poloxamer 407 a = 98 b = 67
  • 1.16. Sorbitan Fatty Acid Esters [0066]
  • Sorbitan esters of fatty acids are suitable surfactants for use in the present invention. Among these esters, preferred hydrophobic surfactants include sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span-80), sorbitan monostearate, and sorbitan tristearate. Examples of these surfactants are shown in Table 16. [0067]
    TABLE 16
    Sorbitan Fatty Acid Ester Surfactants
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Sorbitan monolaurate Span-20 (Atlas/ICI), Crill 1 (Croda), 8.6
    Arlacel 20 (ICI)
    Sorbitan monopalmitate Span-40 (Atlas/ICI), Crill 2 (Croda), 6.7
    Nikkol SP-10 (Nikko)
    Sorbitan monooleate Span-80 (Atlas/ICI), Crill 4 (Croda), 4.3
    Crill 50 (Croda)
    Sorbitan monostearate Span-60 (Atlas/ICI), Crill 3 (Croda), 4.7
    Nikkol SS-10 (Nikko)
    Sorbitan trioleate Span-85 (Atlas/ICI), Crill 45 (Croda), 4.3
    Nikkol SO-30 (Nikko)
    Sorbitan sesquioleate Arlacel-C (ICI), Crill 43 (Croda), 3.7
    Nikkol SO-15 (Nikko)
    Sorbitan tristearate Span-65 (Atlas/ICI) Crill 35 (Croda), 2.1
    Nikkol SS-30 (Nikko)
    Sorbitan monoisostearate Crill 6 (Croda), Nikkol SI-10 (Nikko) 4.7
    Sorbitan sesquistearate Nikkol SS-15 (Nikko) 4.2
  • 1.17. Lower Alcohol Fatty Acid Esters [0068]
  • Esters of lower alcohols (C[0069] 2 to C4) and fatty acids (C8 to C18) are suitable surfactants for use in the present invention. Among these esters, preferred hydrophobic surfactants include ethyl oleate (Crodamol EO), isopropyl myristate (Crodamol IPM), and isopropyl palmitate (Crodamol IPP). Examples of these surfactants are shown in Table 17.
    TABLE 17
    Lower Alcohol Fatty Acid Ester Surfactants
    COMPOUND COMMERCIAL PRODUCT (Supplier) HLB
    Ethyl oleate Crodamol EO (Croda), Nikkol EOO (Nikko) <10
    Isopropyl myristate Crodamol IPM (Croda) <10
    Isopropyl palmitate Crodamol IPP (Croda) <10
    Ethyl linoleate Nikkol VF-E (Nikko) <10
    Isopropyl linoleate Nikkol VF-IP (Nikko) <10
  • 1.18. Ionic Surfactants [0070]
  • Ionic surfactants, including cationic, anionic and zwitterionic surfactants, are suitable hydrophilic surfactants for use in the present invention. Preferred anionic surfactants include fatty acid salts and bile salts. Specifically, preferred ionic surfactants include sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, and sodium taurocholate. Examples of such surfactants are shown in Table 18 below. For simplicity, typical counterions are shown in the entries in the Table. It will be appreciated by one skilled in the art, however, that any bioacceptable counterion may be used. For example, although the fatty acids are shown as sodium salts, other cation counterions can also be used, such as alkali metal cations or ammonium. Unlike typical non-ionic surfactants, these ionic surfactants are generally available as pure compounds, rather than commercial (proprietary) mixtures. Because these compounds are readily available from a variety of commercial suppliers, such as Aldrich, Sigma, and the like, commercial sources are not generally listed in the Table. [0071]
    TABLE 18
    Ionic Surfactants
    COMPOUND HLB
    FATTY ACID SALTS >10
    Sodium caproate
    Sodium caprylate
    Sodium caprate
    Sodium laurate
    Sodium myristate
    Sodium myristolate
    Sodium palmitate
    Sodium palmitoleate
    Sodium oleate 18
    Sodium ricinoleate
    Sodium linoleate
    Sodium linolenate
    Sodium stearate
    Sodium lauryl sulfate (dodecyl) 40
    Sodium tetradecyl sulfate
    Sodium lauryl sarcosinate
    Sodium dioctyl sulfosuccinate [sodium docusate (Cytec)]
    BILE SALTS >10
    Sodium cholate
    Sodium taurocholate
    Sodium glycocholate
    Sodium deoxycholate
    Sodium taurodeoxycholate
    Sodium glycodeoxycholate
    Sodium ursodeoxycholate
    Sodium chenodeoxycholate
    Sodium taurochenodeoxycholate
    Sodium glyco cheno deoxycholate
    Sodium cholylsarcosinate
    Sodium N-methyl taurocholate
    PHOSPHOLIPIDS
    Egg/Soy lecithin [Epikuron ™ (Lucas Meyer), Ovothin ™
    (Lucas Meyer)]
    Lyso egg/soy lecithin
    Hydroxylated lecithin
    Lysophosphatidylcholine
    Cardiolipin
    Sphingomyelin
    Phosphatidylcholine
    Phosphatidyl ethanolamine
    Phosphatidic acid
    Phosphatidyl glycerol
    Phosphatidyl serine
    PHOSPHORIC ACID ESTERS
    Diethanolammonium polyoxyethylene-10 oleyl ether phosphate
    Esterification products of fatty alcohols or fatty alcohol
    ethoxylates with phosphoric acid or anhydride
    CARBOXYLATES
    Ether carboxylates (by oxidation of terminal OH group of
    fatty alcohol ethoxylates)
    Succinylated monoglycerides [LAMEGIN ZE (Henkel)]
    Sodium stearyl fumarate
    Stearoyl propylene glycol hydrogen succinate
    Mono/diacetylated tartaric acid esters of mono- and diglycerides
    Citric acid esters of mono-, diglycerides
    Glyceryl-lacto esters of fatty acids (CFR ref. 172.852)
    Acyl lactylates:
    lactylic esters of fatty acids
    calcium/sodium stearoyl-2-lactylate
    calcium/sodium stearoyl lactylate
    Alginate salts
    Propylene glycol alginate
    SULFATES AND SULFONATES
    Ethoxylated alkyl sulfates
    Alkyl benzene sulfones
    α-olefin sulfonates
    Acyl isethionates
    Acyl taurates
    Alkyl glyceryl ether sulfonates
    Octyl sulfosuccinate disodium
    Disodium undecylenamideo-MEA-sulfosuccinate
    CATIONIC Surfactants >10
    Hexadecyl triammonium bromide
    Decyl trimethyl ammonium bromide
    Cetyl trimethyl ammonium bromide
    Dodecyl ammonium chloride
    Alkyl benzyldimethylammonium salts
    Diisobutyl phenoxyethoxydimethyl benzylammonium salts
    Alkylpyridinium salts
    Betaines (trialkylglycine):
    Lauryl betaine (N-lauryl,N,N-dimethylglycine)
    Ethoxylated amines:
    Polyoxyethylene-15 coconut amine
  • 1.19 Surfactant Concentrations [0072]
  • The hydrophilic and hydrophobic surfactants are present in the pharmaceutical compositions of the present invention in amounts such that upon dilution with an aqueous solution, the carrier forms a clear, aqueous dispersion of the hydrophilic and hydrophobic surfactants, containing the hydrophobic therapeutic agent. The relative amounts of hydrophilic and hydrophobic surfactants are readily determined by observing the properties of the resultant dispersion; i.e., when the relative amounts of the hydrophobic and hydrophilic surfactants are within a suitable range, the resultant aqueous dispersion is optically clear. When the relative amount of hydrophobic surfactant is too great, the resulting dispersion is visibly “cloudy”, resembling a conventional emulsion or multiple phase system. Although a visibly cloudy solution may be potentially useful for some applications, such a system would suffer from many of the same disadvantages as conventional prior art formulations, as described above. [0073]
  • A convenient method of determining the appropriate relative concentrations for any hydrophilic surfactant-hydrophobic surfactant pair is as follows. A convenient working amount of a hydrophilic surfactant is provided, and a known amount of a hydrophobic surfactant is added. The surfactants are stirred to form a homogeneous mixture, with the aid of gentle heating if desired. The resulting mixture is diluted with purified water to prepare an aqueous dispersion. Any dilution amount can be chosen, but convenient dilutions are those within the range expected in vivo, about a 10 to 250-fold dilution. The aqueous dispersion is then assessed qualitatively for optical clarity. The procedure can be repeated with incremental variations in the relative amount of hydrophobic surfactant added, to determine the maximum relative amount of hydrophobic surfactant that can be present for a given surfactant pair. [0074]
  • Alternatively, the optical clarity of the aqueous dispersion can be measured using standard quantitative techniques for turbidity assessment. One convenient procedure to measure turbidity is to measure the amount of light of a given wavelength transmitted by the solution, using, for example, a UV-visible spectrophotometer. Using this measure, optical clarity corresponds to high transmittance, since cloudier solutions will scatter more of the incident radiation, resulting in lower transmittance measurements. If this procedure is used, care should be taken to insure that the surfactant mixture does not itself absorb light of the chosen wavelength, as any true absorbance necessarily reduces the amount of transmitted light and falsely increases the quantitative turbidity value. In the absence of chromophores at the chosen wavelength, suitable dispersions at a dilution of 10× should have an apparent absorbance of less than about 0.3, preferably less than about 0.2, and more preferably less than about 0.1. At a dilution of 100×, suitable dispersions should have an apparent absorbance of less than about 0.1, preferably less than about 0.05, and more preferably less than about 0.01. [0075]
  • A third method of determining optical clarity and carrier diffusivity through the aqueous boundary layer is to quantitatively measure the size of the particles of which the dispersion is composed. These measurements can be performed on commercially available particle size analyzers, such as, for example, a Nicomp particle size analyzer available from Particle Size Systems, Inc., of Santa Barbara, Calif. Using this measure, clear aqueous dispersions according to the present invention have average particle sizes much smaller than the wavelength of visible light, whereas dispersions containing excessive relative amounts of the hydrophobic surfactant have more complex particle size distributions, with much greater average particle sizes. It is desirable that the average particle size be less than about 100 nm, preferably less than about 50 nm, more preferably less than about 30 nm, and still more preferably less than about 20 nm. It is also preferred that the particle size distribution be mono-modal. As is shown in more detail in the Examples herein, dispersions having an undesirably large relative amount of hydrophobic surfactant typically display bimodal particle size distributions, such distributions having a small particle size component, typically less than about 30 nm, and a large particle size component, typically on the order of 100 nm or more. It should be emphasized that these particle sizes are appropriate for the carrier particles in aqueous solution, in the absence of a hydrophobic therapeutic agent. It is expected that the presence of the hydrophobic therapeutic agent may result in an increase in the average particle size. [0076]
  • Other methods of determining optical clarity or particle size can be used as desired. Such methods are well know to those skilled in the art. [0077]
  • It should be emphasized that any or all of the available methods may be used to ensure that the resulting aqueous dispersions possess the requisite optical clarity. For convenience, however, the present inventors prefer to use the simple qualitative procedure; i.e., simple visible observation. However, in order to more fully illustrate the practice of the present invention, all three of the above measures are used to assess the dispersion clarity in the Examples herein. [0078]
  • Although it should be understood that any aqueous dispersion having the properties described above is within the scope of the present invention regardless of the specific relative amounts of hydrophobic and hydrophilic surfactants, it is expected that the amount of hydrophobic surfactant will generally be less than about 200% by weight, based on the amount of hydrophilic surfactant, and more specifically, in the range of about 1% to 200%. Further, based on observations reported in the Examples herein, it is expected that the amount of hydrophobic surfactant will generally be less than about 100%, and more specifically in the range of about 5% to about 100% by weight, or about 10% to about 100% by weight, based on the amount of hydrophilic surfactant. For some particular surfactant combinations, cloudy solutions result when the amount of hydrophobic surfactant is greater than about 60% by weight, based on the amount of hydrophilic surfactant. A preferred range for these surfactants is about 1% to about 60%, preferably about 5% to about 60%, and more preferably about 10% to about 60%. Addition of optional excipients as described below can further increase the maximum relative amount of hydrophobic surfactant that can be used. [0079]
  • Other considerations well known to those skilled in the art will further inform the choice of specific proportions of hydrophobic and hydrophilic surfactants. These considerations include the degree of bioacceptability of the surfactants, and the desired dosage of hydrophobic therapeutic agent to be provided. In some cases, the amount of hydrophobic surfactant actually used in a pharmaceutical composition according to the present invention will be less than the maximum that can be used, and it should be apparent that such compositions are also within the scope of the present invention. [0080]
  • 2. Hydrophobic Therapeutic Agents [0081]
  • Hydrophobic therapeutic agents suitable for use in the pharmaceutical compositions of the present invention are not particularly limited, as the carrier is surprisingly capable of solubilizing and delivering a wide variety of hydrophobic therapeutic agents. Hydrophobic therapeutic agents are compounds with little or no water solubility. Intrinsic water solubilities (i.e., water solubility of the unionized form) for hydrophobic therapeutic agents usable in the present invention are less than about 1% by weight, and typically less than about 0.1% or 0.01% by weight. Such therapeutic agents can be any agents having therapeutic or other value when administered to an animal, particularly to a mammal, such as drugs, nutrients, and cosmetics (cosmeceuticals). It should be understood that while the invention is described with particular reference to its value in the form of aqueous dispersions, the invention is not so limited. Thus, hydrophobic drugs, nutrients or cosmetics which derive their therapeutic or other value from, for example, topical or transdermal administration, are still considered to be suitable for use in the present invention. [0082]
  • Specific non-limiting examples of hydrophobic therapeutic agents that can be used in the pharmaceutical compositions of the present invention include the following representative compounds, as well as their pharmaceutically acceptable salts, isomers, esters, ethers and other derivatives: [0083]
  • analgesics and anti-inflammatory agents, such as aloxiprin, auranofin, azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, leflunomide, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, refocoxib, sulindac, tetrahydrocannabinol, tramadol and tromethamine; [0084]
  • anthelmintics, such as albendazole, bephenium hydroxynaphthoate, cambendazole, dichlorophen, ivermectin, mebendazole, oxamniquine, oxfendazole, oxantel embonate, praziquantel, pyrantel embonate and thiabendazole; [0085]
  • anti-arrhythmic agents, such as amiodarone HCl, disopyramide, flecainide acetate and quinidine sulfate; [0086]
  • anti-asthma agents, such as zileuton, zafirlukast, terbutaline sulfate, montelukast, and albuterol; [0087]
  • anti-bacterial agents, such as alatrofloxacin, azithromycin, baclofen, benethamine penicillin, cinoxacin, ciprofloxacin HCl, clarithromycin, clofazimine, cloxacillin, demeclocycline, dirithromycin, doxycycline, erythromycin, ethionamide, furazolidone, grepafloxacin, imipenem, levofloxacin, lorefloxacin, moxifloxacin HCl, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, rifampicin, rifabutine, rifapentine, sparfloxacin, spiramycin, sulphabenzamide, sulphadoxine, sulphamerazine, sulphacetamide, sulphadiazine, sulphafurazole, sulphamethoxazole, sulphapyridine, tetracycline, trimethoprim, trovafloxacin, and vancomycin; [0088]
  • anti-viral agents, such as abacavir, amprenavir, delavirdine, efavirenz, indivir, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, and stavueline; [0089]
  • anti-coagulants, such as cilostazol, clopidrogel, dicoumarol, dipyridamole, nicoumalone, oprelvekin, phenindione, ticlidopine, and tirofibran; [0090]
  • anti-depressants, such as amoxapine, bupropion, citalopram, clomipramine, fluexetine HCl, maprotiline HCl, mianserin HCl, nortriptyline HCl, paroxetine HCl, sertraline HCl, trazodone HCl, trimipramine maleate, and venlafaxine HCl; [0091]
  • anti-diabetics, such as acetohexamide, chlorpropamide, glibenclamide, gliclazide, glipizide, glymepride, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone; [0092]
  • anti-epileptics, such as beclamide, carbamazepine, clonazepam, ethotoin, felbamate, fosphenytoin sodium, lamotrigine, methoin, methsuximide, methylphenobarbitone, oxcarbazepine, paramethadione, phenacemide, phenobarbitone, phenytoin, phensuximide, primidone, sulthiame, tiagabine HCl, topiramate, valproic acid, and vigabatrin; [0093]
  • anti-fungal agents, such as amphotericin, butenafine HCl, butoconazole nitrate, clotrimazole, econazole nitrate, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, miconazole, natamycin, nystatin, sulconazole nitrate, oxiconazole, terbinafine HCl, terconazole, tioconazole and undecenoic acid; [0094]
  • anti-gout agents, such as allopurinol, probenecid and sulphin-pyrazone; [0095]
  • anti-hypertensive agents, such as amlodipine, benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HCl, diazoxide, doxazosin HCl, elanapril, eposartan losartan, mesylate, felodipine, fenolclopam, fosinopril, guanabenz acetate, irbesartan, isradipine, lisinopril, minoxidil, nicardipine HCl, nifedipine, nimodipine, nisolidipine, phenoxybenzamine HCl, prazosin HCl, quinapril, reserpine, terazosin HCl, telmisartan, and valsartan; [0096]
  • anti-malarials, such as amodiaquine, chloroquine, chlorproguanil HCl, halofantrine HCl, mefloquine HCl, proguanil HCl, pyrimethamine and quinine sulfate; [0097]
  • anti-migraine agents, such as dihydroergotamine mesylate, ergotamine tartrate, frovatriptan, methysergide maleate, naratriptan HCl, pizotifen maleate, rizatriptan benzoate, sumatriptan succinate, and zolmitriptan; [0098]
  • anti-muscarinic agents, such as atropine, benzhexol HCl, biperiden, ethopropazine HCl, hyoscyamine, mepenzolate bromide, oxyphencylcimine HCl and tropicamide; [0099]
  • anti-neoplastic agents and immunosuppressants, such as aminoglutethimide, amsacrine, azathioprine, bicalutamide, bisanthrene, busulphan, camptothecan, capecitabine, chlorambucil, cyclosporin, dacarbazine, ellipticine, estramustine, etoposide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, mofetil, mycophenolate, nilutamide, paclitaxel, procarbazine HCl, sirolimus, tacrolimus, tamoxifen citrate, teniposide, testolactone, topotecan HCl, and toremifene citrate; [0100]
  • anti-protozoal agents, such as atovaquone, benznidazole, clioquinol, decoquinate, diiodohydroxyquinoline, diloxanide furoate, dinitolmide, furzolidone, metronidazole, nimorazole, nitrofurazone, omidazole and tinidazole; [0101]
  • anti-thyroid agents, such as carbimazole, paricalcitol, and propylthiouracil; [0102]
  • anti-tussives, such as benzonatate; [0103]
  • anxiolytic, sedatives, hypnotics and neuroleptics, such as alprazolam, amylobarbitone, barbitone, bentazepam, bromazepam, bromperidol, brotizolam, butobarbitone, carbromal, chlordiazepoxide, chlormethiazole, chlorpromazine, chlorprothiocene, clonazepam, clobazam, clotiazepam, clozapine, diazepam, droperidol, ethinamate, flunanisone, flunitrazepam, fluopromazine, flupenthixol decanoate, fluphenazine decanoate, flurazepam, gabapentin, haloperidol, lorazepam, lormetazepam, medazepam, meprobamate, mesoridiazine, methaqualone, methyl phenidate, midazolam, molindone, nitrazepam, olanzapine, oxazepam, pentobarbitone, perphenazine pimozide, prochlorperazine, pseudo-ephedrine, quetiapine, risperodone, sertindole, sulpiride, temazepam, thioridazine, triazolam, zolpidem, and zopiclone; [0104]
  • β-Blockers, such as acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, pindolol and propranolol; [0105]
  • cardiac inotropic agents, such as amrinone, digitoxin, digoxin, enoximone, lanatoside C and medigoxin; [0106]
  • corticosteroids, such as beclomethasone, betamethasone, budesonide, cortisone acetate, desoxymethasone, dexamethasone, fludrocortisone acetate, flunisolide, flucortolone, fluticasone propionate, hydrocortisone, methylprednisolone, prednisolone, prednisone and triamcinolone; [0107]
  • diuretics, such as acetazolamide, amiloride, bendrofluazide, bumetanide, chlorothiazide, chlorthalidone, ethacrynic acid, frusemide, metolazone, spironolactone and triamterene. [0108]
  • anti-parkinsonian agents, such as bromocriptine mesylate, lysuride maleate, pramipexole, robinirole HCl, and tolcapone; [0109]
  • gastro-intestinal agents, such as bisacodyl, cimetidine, cisapride, diphenoxylate HCl, domperidone, famotidine, lanosprazole, loperamide, mesalazine, nizatidine, omeprazole, ondansetron HCL, rabeprazole sodium, ranitidine HCl and sulphasalazine; [0110]
  • histamine H,-receptor antagonists, such as acrivastine, astemizole, chlophenisamine, cinnarizine, citrizine, clemastine fumarate, cyclizine, cyproheptadine HCl, dexchlopheniramine, dimenhydrinate, fexofenadine, flunarizine HCl, loratadine, meclozine HCl, oxatomide, and terenadine; [0111]
  • keratolytics, such as acutretin, calciprotiene, calcifediol, calcitriol, cholecalciferol, ergocalciferol, etretinate, retinoids, targretin, and tazarotene; [0112]
  • lipid regulating agents, such as atorvastatin, bezafibrate, cerivistatin, clinofibrate, clofibrate, fenofibrate, fluvastatin, gemfibrozil, pravastatin, probucol, and simvastatin; [0113]
  • muscle relaxants, such as dantrolene sodium and tizanidine HCl; [0114]
  • nitrates and other anti-anginal agents, such as amyl nitrate, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate and pentaerythritol tetranitrate; [0115]
  • nutritional agents, such as calcitriol, carotenes, dihydrotachysterol, essential fatty acids, non-essential fatty acids, phytonodione, vitamin A, vitamin B[0116] 2, vitamin D, vitamin E and vitamin K.
  • opioid analgesics, such as codeine, dextropropyoxyphene, diamorphine, dihydrocodeine, fentanyl, meptazinol, methadone, morphine, nalbuphine and pentazocine; [0117]
  • sex hormones, such as clomiphene citrate, cortisone acetate, danazol, dihydro epiandrosterone, ethinyloestradiol, finasteride, fludrocortisone, fluoxymisterone, medroxyprogesterone acetate, megesterol acetate, mestranol, methyltestosterone, norethisterone, norgestrel, oestradiol, conjugated estrogens, progesterone, rimexolone, stanozolol, stiboestrol, testosterone and tibolone; [0118]
  • stimulants, such as amphetamine, dexamphetamine, dexfenfluramine, fenfluramine and mazindol; [0119]
  • and others, such as becaplermin, donepezil HCl, L-thryroxine, methoxsalen, nerteporfin, physostigmine, pyridostigmine, raloxifene HCl, sibutramine HCl, sildenafil citrate, tacrine, tamsulosin HCl, and tolterodine. [0120]
  • Preferred hydrophobic therapeutic agents include sildenafil citrate, amlodipine, tramadol, celecoxib, refocoxib, oxaprozin, nabumetone, ibuprofen, terbenafine, itraconazole, zileuton, zafirlukast, cisapride, fenofibrate, tizanidine, nizatidine, fexofenadine, loratadine, famotidine, paricalcitol, atovaquone, nabumetone, tetrahydrocannabinol, megesterol acetate, repaglinide, progesterone, rimexolone, cyclosporine, tacrolimus, sirolimus, teniposide, paclitaxel, pseudo-ephedrine, troglitazone, rosiglitazone, finasteride, vitamin A, vitamin D, vitamin E, and pharmaceutically acceptable salts, isomers and derivatives thereof. Particularly preferred hydrophobic therapeutic agents are progesterone and cyclosporin. [0121]
  • It should be appreciated that this listing of hydrophobic therapeutic agents and their therapeutic classes is merely illustrative. Indeed, a particular feature, and surprising advantage, of the compositions of the present invention is the ability of the present compositions to solubilize and deliver a broad range of hydrophobic therapeutic agents, regardless of functional class. Of course, mixtures of hydrophobic therapeutic agents may also be used where desired. [0122]
  • 3. Solubilizers [0123]
  • If desired, the pharmaceutical compositions of the present invention can optionally include additional compounds to enhance the solubility of the hydrophobic therapeutic agent in the carrier system. Examples of such compounds, referred to as “solubilizers”, include: [0124]
  • alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; [0125]
  • ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol, available commercially from BASF under the trade name Tetraglycol) or methoxy PEG (Union Carbide); [0126]
  • amides, such as 2-pyrrolidone, 2-piperidone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, and polyvinylpyrrolidone; [0127]
  • esters, such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof; [0128]
  • and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide (Arlasolve DMI (ICI)), N-methyl pyrrolidones (Pharmasolve (ISP)), monooctanoin, diethylene glycol monoethyl ether (available from Gattefosse under the trade name Transcutol), and water. [0129]
  • Mixtures of solubilizers are also within the scope of the invention. Except as indicated, these compounds are readily available from standard commercial sources. [0130]
  • Preferred solubilizers include triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol. [0131]
  • The amount of solubilizer that can be included in compositions of the present invention is not particularly limited. Of course, when such compositions are ultimately administered to a patient, the amount of a given solubilizer is limited to a bioacceptable amount, which is readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in access of bioacceptable amounts in order to maximize the concentration of hydrophobic therapeutic agent, with excess solubilizer removed prior to providing the composition to a patient using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a concentration of 50%, 100%, 200%, or up to about 400% by weight, based on the amount of surfactant. If desired, very small amounts of solubilizers may also be used, such as 25%, 10%, 5%, 1% or even less. Typically, the solubilizer will be present in an amount of about 1% to about 100%, more typically about 5% to about 25% by weight. [0132]
  • 4. Other Additives [0133]
  • Other additives conventionally used in pharmaceutical compositions can be included, and these additives are well known in the art. Such additives include antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants odorants, opacifiers, suspending agents, binders, and mixtures thereof. The amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired. [0134]
  • 5. Dosage Forms [0135]
  • The pharmaceutical compositions of the present invention can be provided in the form of a solution preconcentrate; i.e., a composition as described above, and intended to be dispersed with water, either prior to administration, in the form of a drink, or dispersed in vivo. Alternatively, the compositions can be provided in the form of a diluted preconcentrate (i.e., an aqueous dispersion), a semi-solid dispersion or a solid dispersion. If desired, the compositions may be encapsulated in a hard or soft gelatin capsule, a starch capsule or an enteric coated capsule. The term “enteric coated capsule” as used herein means a capsule coated with a coating resistant to acid; i.e., an acid resistant enteric coating. Although solubilizers are typically used to enhance the solubility of a hydrophobic therapeutic agent, they may also render the compositions more suitable for encapsulation in hard or soft gelatin capsules. Thus, the use of a solubilizer such as those described above is particularly preferred in capsule dosage forms of the pharmaceutical compositions. If present, these solubilizers should be added in amounts sufficient to impart to the compositions the desired solubility enhancement or encapsulation properties. [0136]
  • Although formulations specifically suited to oral administration are presently preferred, the compositions of the present invention can also be formulated for topical, transdermal, ocular, pulmonary, vaginal, rectal, transmucosal or parenteral administration, in the form of a triglyceride-free cream, lotion, ointment, suppository, gel or the like. If such a formulation is desired, other additives may be included, such as are well-known in the art, to impart the desired consistency and other properties to the formulation. The compositions of the present invention can also be formulated as a spray or an aerosol. In particular, the compositions may be formulated as a sprayable solution, and such formulation is particularly useful for spraying to coat a multiparticulate carrier, such as a bead. Such multiparticulate carriers are well known in the art. [0137]
  • 6. Preparation of Pharmaceutical Compositions [0138]
  • The pharmaceutical compositions of the present invention can be prepared by conventional methods well known to those skilled in the art. Of course, the specific method of preparation will depend upon the ultimate dosage form. For dosage forms substantially free of water, i.e., when the composition is provided in a pre-concentrated form for later dispersion in an aqueous system, the composition is prepared by simple mixing of the components to form a pre-concentrate. The mixing process can be aided by gentle heating, if desired. For compositions in the form of an aqueous dispersion, the pre-concentrate form is prepared, then the appropriate amount of purified water is added. Upon gentle mixing, a clear aqueous dispersion is formed. If any water-soluble additives are included, these may be added first as part of the pre-concentrate, or added later to the clear aqueous dispersion, as desired. [0139]
  • In another embodiment, the present invention includes a multi-phase dispersion. In this embodiment, a pharmaceutical composition includes a carrier which forms a clear aqueous dispersion upon mixing with an aqueous solution, and an additional amount of non-solubilized hydrophobic therapeutic agent. Thus, the term “multi-phase” as used herein to describe these compositions of the present invention means a composition which when mixed with an aqueous solution forms a clear aqueous phase and a particulate dispersion phase. The carrier is as described above, and can include any of the surfactants, hydrophobic therapeutic agents, solubilizers and additives previously described. An additional amount of hydrophobic therapeutic agent is included in the composition. This additional amount is not solubilized by the carrier, and upon mixing with an aqueous system is present as a separate dispersion phase. The additional amount is optionally a milled, micronized, or precipitated form. Thus, upon dilution, the composition contains two phases: a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing a first, solubilized amount of the hydrophobic therapeutic agent, and a second, non-solubilized amount of the hydrophobic therapeutic agent dispersed therein. It should be emphasized that the resultant multi-phase dispersion will not have the optical clarity of a dispersion in which the hydrophobic therapeutic agent is fully solubilized, but will appear to be cloudy, due to the presence of the non-solubilized phase. Such a formulation may be useful, for example, when the desired dosage of a hydrophobic therapeutic agent exceeds that which can be solubilized in the carrier of the present invention. The formulation may also contain additives, as described above. [0140]
  • One skilled in the art will appreciate that a hydrophobic therapeutic agent may have a greater solubility in the pre-concentrate carrier than in the aqueous dispersion, so that meta-stable, supersaturated solutions having apparent optical clarity but containing a hydrophobic therapeutic agent in an amount in excess of its solubility in the aqueous dispersion can be formed. Such super-saturated solutions, whether characterized as clear aqueous dispersions (as initially formed) or as multi-phase solutions (as would be expected if the meta-stable state breaks down), are also within the scope of the present invention. [0141]
  • The multi-phase formulation can be prepared by the methods described above. A pre-concentrate is prepared by simple mixing of the components, with the aid of gentle heating, if desired. It is convenient to consider the hydrophobic therapeutic agent as divided into two portions, a first solubilizable portion which will be solubilized by the carrier and contained within the clear aqueous dispersion upon dilution, and a second non-solubilizable portion which will remain non-solubilized. When the ultimate dosage form is non-aqueous, the first and second portions of the hydrophobic therapeutic agent are both included in the pre-concentrate mixture. When the ultimate dosage form is aqueous, the composition can be prepared in the same manner, and upon dilution in an aqueous system, the composition will form the two phases as described above, with the second non-solubilizable portion of the hydrophobic therapeutic agent dispersed or suspended in the aqueous system, and the first solubilizable portion of the hydrophobic therapeutic agent solubilized in the mixed surfactant carrier. Alternatively, when the ultimate dosage form is aqueous, the pre-concentrate can be prepared including only the first, solubilizable portion of the hydrophobic therapeutic agent. This pre-concentrate can then be diluted in an aqueous system to form a clear aqueous dispersion, to which is then added the second, non-solubilizable portion of the hydrophobic therapeutic agent to form a multi-phase aqueous composition. [0142]
  • The amount of hydrophobic therapeutic agent included in the pharmaceutical compositions of the present invention can be any amount desired by the formulator, up to the maximum amount that can be solubilized or suspended in a given carrier system. In general, the amount of hydrophobic therapeutic agent will be about 0.1% to about 60% by weight, based on the total weight of the pharmaceutical composition. In another aspect of the invention, described below, excess hydrophobic therapeutic agent can also be added, in a multi-phase dispersion. [0143]
  • B. Methods of Improved Delivery [0144]
  • In another aspect, the present invention relates to methods of improving delivery of hydrophobic therapeutic agents in an animal by administering to the animal a dosage form of the pharmaceutical compositions described herein. Preferably the animal is a mammal, and more preferably, a human. It has been found that the pharmaceutical compositions of the present invention when administered to an animal enable the hydrophobic therapeutic agent contained therein to be absorbed more rapidly than in conventional pharmaceutical compositions. Thus, in this aspect the invention relates to a method of increasing the rate of and/or extent of bioabsorption of a hydrophobic therapeutic agent by administering the hydrophobic therapeutic agent to an animal in the pharmaceutical compositions described herein. [0145]
  • C. Characteristics of the Pharmaceutical Compositions [0146]
  • The dispersions formed upon dilution of the pharmaceutical compositions of the present invention have the following characteristics: [0147]
  • Rapid formation: upon dilution with an aqueous solution, the carrier forms a clear dispersion very rapidly; i.e., the clear dispersion appears to form instantaneously. [0148]
  • Optical clarity: the dispersions are essentially optically clear to the naked eye, and show no readily observable signs of heterogeneity, such as turbidity or cloudiness. More quantitatively, dispersions of the pharmaceutical compositions of the present invention show a mono-modal distribution of very small particles sizes, typically 20 nm or less in average diameter; absorbances of less than about 0.3, typically less than about 0.1, at 10× dilution; and absorbances of less than about 0.1, typically less than about 0.01, at 100× dilution, as described more fully in the Examples herein. In the multi-phase embodiment of the compositions described herein, it should be appreciated that the optical clarity of the aqueous carrier dispersion phase will be obscured by the dispersed particulate non-solubilized hydrophobic therapeutic agent. [0149]
  • Robustness to dilution: the dispersions are surprisingly stable to dilution in aqueous solution, including aqueous solutions simulating physiological fluids such as enzyme-free simulated gastric fluid (SGF) and enzyme-free simulated intestinal fluid (SIF). The hydrophobic therapeutic agent remains solubilized for at least the period of time relevant for absorption. [0150]
  • Triglyceride-free: It is a particular feature of the present invention that the pharmaceutical compositions are substantially triglyceride-free. The term “triglyceride” as used herein means glycerol triesters of C[0151] 6 to about C25 fatty acids. Unlike conventional compositions such as oil-based solutions, emulsions, and microemulsions, which rely on the solubilizing power of triglycerides, the present compositions surprisingly solubilize hydrophobic therapeutic agents using combinations of substantially triglyceride-free surfactants.
  • As used herein, the term “substantially triglyceride-free” means compositions which contain triglycerides, if at all, only as minor components or impurities in surfactant mixtures. It is well known in the art that commercially available surfactants often are complex mixtures of compounds. For example, one preferred surfactant is Capmul® GMO-K, a widely-used blend of glyceryl mono- and dioleates. Due to difficulties in separating complex product mixtures, however, a typical lot of Capmul® GMO-K, as reported by the manufacturer's certificate of analysis, contains the following distribution of glyceryl esters, in percent by weight based on the total weight of glyceryl esters: [0152]
    Palmitic acid 3.3%
    Stearic acid 4.0%
    Oleic acid 81.0% 
    Linoleic acid 9.7%
    Linolenic acid 0.3%
  • In addition, the surfactant mixture in the particular lot reported contains 0.10% water and 0.95% free, unesterified glycerol. These specific percentages are expected to vary, lot-by-lot, as well, and it is expected that commercial surfactant products will generally possess similar variability, regardless of the specific major component and the specific manufacturer. Thus, the present invention does not include surfactants which contain triglycerides as an intended component. Indeed, such surfactants are not common, since triglycerides themselves have no surfactant properties. However, it should be appreciated that the present invention does not exclude the use of surfactant products which contain small amounts of triglycerides as impurities or as unreacted starting material. It is expected that commercial mixtures suitable for use in the present invention may contain as much as 5% triglycerides by weight as unintended components. Thus, “substantially triglyceride-free” should be understood as meaning free of added triglycerides, and containing less than 5%, preferably essentially 0%, triglyceride impurities. [0153]
  • Without wishing to be bound by theory, it is believed that the observed properties of the clear, aqueous dispersions formed by the compositions of the present invention are consistent with, and best explained by, the formation of mixed micelles of the hydrophobic and hydrophilic surfactants, with the hydrophobic therapeutic agent solubilized by the micelles. It should be emphasized that these dispersions are characterized by the properties described herein, regardless of the precise microscopic physical form of the dispersed particles. Nevertheless, in order to more fully explain the invention, and to illustrate its unexpected and important advantages, the following discussion is offered in terms consistent with the theoretical principles believed to be correct. [0154]
  • It is believed that the hydrophobic and hydrophilic surfactants form mixed micelles in aqueous solution. In this model, each micelle is composed of molecules (or ions) of both the hydrophilic and hydrophobic surfactants. Depending upon the detailed three-dimensional structure of the hydrophobic therapeutic agent, its distribution of polar moieties, if any, its polarizability in local regions, and other molecule-specific and complex factors, the hydrophobic therapeutic agent may be distributed in any part of the micelle, such as near the outer, more hydrophilic region, near the inner, more hydrophobic region, or at various points in between. Further, it is known that micelles exist in dynamic equilibrium with their component molecules, and it is expected that this equilibrium will include dynamic redistribution of the hydrophobic therapeutic agent. [0155]
  • As discussed above, triglyceride-containing formulations suffer the disadvantage that bioabsorption of the hydrophobic therapeutic agents contained therein is dependent upon enzymatic degradation (lipolysis) of the triglyceride components. The pharmaceutical compositions of the present invention, however, are substantially free of triglycerides, and thus do not depend upon lipolysis to enable release of the hydrophobic therapeutic agent for bioabsorption. The hydrophobic therapeutic agent is in a dynamic equilibrium between the free compound in solution and the solubilized compound, thus promoting rapid release. [0156]
  • The unique pharmaceutical compositions of the present invention present a number of significant and unexpected advantages, including: [0157]
  • Efficient transport: The particle sizes in the aqueous dispersions of the present invention are much smaller, typically less than 20 nm, than the larger particles characteristic of vesicular, emulsion or microemulsion phases, and the particle size distribution is mono-modal and narrow. This reduced and more uniform size enables more efficient drug transport through the intestinal aqueous boundary layer, and through the absorptive brush border membrane. More efficient transport to absorptive sites leads to improved and more consistent absorption of hydrophobic therapeutic agents. [0158]
  • Non-dependence on lipolysis: The lack of triglyceride components provides pharmaceutical compositions not dependent upon lipolysis, and upon the many poorly characterized factors which affect the rate and extent of lipolysis, for effective presentation of a hydrophobic therapeutic agent to an absorptive site. Such factors include the presence of composition components which may inhibit lipolysis; patient conditions which limit production of lipase, such as pancreatic lipase secretory diseases; and dependence of lipolysis on stomach pH, endogenous calcium concentration, and presence of co-lipase or other digestion enzymes. The lack of lipolysis dependence further provides transport which does not suffer from any lag time between administration and absorption caused by the lipolysis process, enabling a more rapid onset of therapeutic action and better bioperformance characteristics. In addition, pharmaceutical compositions of the present invention can make use of hydrophilic surfactants which might otherwise be avoided or limited due to their potential lipolysis inhibiting effects. [0159]
  • Non-dependence on bile and meal fat contents: Due to the higher solubilization potential over bile salt micelles, the present compositions are less dependent on endogenous bile and bile related patient disease states, and meal fat contents. These advantages overcome meal-dependent absorption problems caused by poor patient compliance with meal-dosage restrictions. [0160]
  • Superior solubilization: The surfactant combinations used in compositions of the present invention enable superior loading capacity over conventional micelle formulations. In addition, the particular combination of surfactants used can be optimized for a specific hydrophobic therapeutic agent to more closely match the polarity distribution of the therapeutic agent, resulting in still further enhanced solubilization. [0161]
  • Faster dissolution and release: Due to the robustness of compositions of the present invention to dilution, the hydrophobic therapeutic agents remain solubilized and thus do not suffer problems of precipitation of the therapeutic agent in the time frame relevant for absorption. In addition, the therapeutic agent is presented in small particle carriers, and is not limited in dilution rate by entrapment in emulsion carriers. These factors avoid liabilities associated with the poor partitioning of lipid solubilized drug in to the aqueous phase, such as large emulsion droplet surface area, and high interfacial transfer resistance, and enable rapid completion of the critical partitioning step. [0162]
  • Consistent performance: Aqueous dispersions of the present invention are thermodynamically stable for the time period relevant for absorption, and can be more predictably reproduced, thereby limiting variability in bioavailability—a particularly important advantage for therapeutic agents with a narrow therapeutic index. [0163]
  • Efficient release: The compositions of the present invention are designed with components that help to keep the hydrophobic therapeutic agent solubilized for transport to the absorption site, but readily available for absorption, thus providing a more efficient transport and release. [0164]
  • Less prone to gastric emptying delays: Unlike triglyceride-containing formulations, the present compositions are less prone to gastric emptying delays, resulting in faster absorption. Further, the particles in dispersions of the present invention are less prone to unwanted retention in the gastro-intestinal tract. [0165]
  • Small size: Because of the small particle size in aqueous dispersion, the pharmaceutical compositions of the present invention allow for faster transport of the hydrophobic therapeutic agent through the aqueous boundary layer. [0166]
  • These and other advantages of the present invention, as well as aspects of preferred embodiments, are illustrated more fully in the Examples which follow. [0167]
    • EXAMPLES Example 1
  • Preparation of Compositions [0168]
  • A simple pre-concentrate of a hydrophobic surfactant and a hydrophilic surfactant is prepared as follows. Predetermined weighed amounts of hydrophilic and hydrophobic surfactants are stirred together to form a homogeneous mixture. For surfactant combinations that are poorly miscible, the mixture can be gently heated to aid in formation of the homogeneous mixture. A chosen hydrophobic therapeutic agent in a predetermined amount is added and stirred until solubilized. Optionally, solubilizers or additives are included by simple mixing. [0169]
  • To form an aqueous dispersion of the pre-concentrate, a predetermined amount of purified water, buffer solution, or aqueous simulated physiological solution, is added to the pre-concentrate, and the resultant mixture is stirred to form a clear, aqueous dispersion. [0170]
    • Example 2
  • Surfactant Combinations Giving Clear Aqueous Dispersions [0171]
  • Surfactant mixtures giving clear, aqueous dispersions were prepared according to the method of Example 1. Seven hydrophilic surfactants and sixteen hydrophobic surfactants were used to produce approximately one hundred clear aqueous dispersions suitable for use in the present invention. For simplicity, no hydrophobic therapeutic agent was included in these compositions, since it is believed that the presence of the hydrophobic therapeutic agent does not substantially affect the clear, aqueous nature of composition. For the same reason, these compositions were free of additional solubilizers and other additives. [0172]
  • Multiple solutions were prepared for each surfactant combination, to determine the approximate maximum amount of hydrophobic therapeutic agent giving a clear aqueous dispersion with a given amount of hydrophilic therapeutic agent. Thus, for each gram of the hydrophilic surfactant, a predetermined amount of hydrophobic agent was used to prepare a 10× aqueous dispersion. If the dispersion appeared to be optically clear, a new dispersion was prepared according to Example 1, using a larger amount of hydrophobic surfactant. Similarly, if the dispersion appeared to be cloudy, a new dispersion was prepared using a smaller amount of hydrophobic surfactant. The results are shown in Table 19. [0173]
    TABLE 19
    Surfactant Combinations Giving Clear Dispersions
    Hydrophilic Surfactant
    PEG-35 PEG-40H PEG-60 PEG-8 PEG-25
    Castor Oil Castor Oil Polysorbate Polysorbate Corn Oil Capric/ Glyceryl
    Hydrophobic (Incrocas (Cremophor -20 80 (Crovol M- Caprylic trioleate
    Surfactant 35) RH-40) (Tween 20) (Tween 80) 70) (Labrasol) (Tagat TO)
    Glyceryl/Propylene 20 20 20 8 15 25 10
    Glycol Oleate
    (Arlacel 186)
    Glyceryl Oleate 15 40 10 12 10 35 10
    (Peceol)
    Acetylated 80 80 20 15 10 10 10
    Monoglycerides
    (Myvacet 9-45)
    PEG-6 Corn Oil 50 95 10 10 20 10 10
    (Labrafil M2125CS)
    Sorbitan Monooleate 25 65 5 5 20 15 10
    (Span 80)
    Sorbitan Monolaurate 30 20 20 10 15 30 10
    (Arlacel 20)
    Polyglyceryl oleate 10 5 35 10 10 35 10
    (Plurol Oleique CC497)
    Propylene Glycol Laurate 10 55 35 20 15 35 10
    (Lauroglycol FCC)
    Glyceryl Caprylate/ 10 50 20 25 25 20 10
    Caprate (Capmul MCM)
    PEG-20 Corn Oil 35 40 40 25 30 90 10
    (Crovol M-40)
    PEG-20 Almond Oil 30 35 40 25 30 90 10
    (Crovol A-40)
    Mono/diglycerides of 50 50 60 25 25 30 10
    Caprylic Acid (Imwitor
    988)
    PEG-4-lauryl ether 40 45 95 70 * 90 10
    (Brij 30)
    PEG-3-oleyl ether 20 30 25 20 20 25 10
    (Volpo 3)
    Glyceryl mono/dioleate * 10 * * 10 25 10
    (Capmul GMO-K)
    Ethyl Oleate 40 60 10 10 60 10 10
    (Crodamol EO)
  • Each entry in the Table represents the approximate maximum number of grams of hydrophobic surfactant per 100 g of hydrophilic surfactant giving acceptable optical clarity. The numbers in the Table are illustrative only, and it is expected that further optimization of the surfactant systems with solubilizers, co-surfactants, and other additives will give still higher numbers. [0174]
    • Example 3
  • Compositions Containing Solubilizers [0175]
  • The procedure of Example 2 was repeated for compositions containing PEG-40 hydrogenated castor oil (Cremophor RH 40) as the hydrophilic surfactant, with eight different hydrophobic surfactants, and four different solubilizers, to study the effect of solubilizer on the relative amounts of hydrophobic and hydrophilic surfactants giving clear aqueous dispersions. In each case, the amount of solubilizer was held constant at 20% by weight, based on the total weight of the two surfactants. The results are shown in Table 20. As in Example 2, the numbers in the Table represent the approximate maximum number of grams of hydrophobic surfactant per 100 g of hydrophilic surfactant giving a clear aqueous dispersion. For convenience, the corresponding entries from Table 19 (with no solubilizer present) are reproduced in Table 20 in the column labeled “none.” [0176]
    TABLE 20
    Effect of Solubilizer on Hydrophobic Surfactant Amounts
    Hydrophilic Surfactant
    (Cremophor RH40) + 20% Solubilizer
    PEG- Glyco-
    Hydrophobic Surfactant (None) Triacetin Ethanol 400 furol
    Glyceryl/Propylene 20 28 25 25 25
    Glycol Oleate (Arlacel
    186)
    Glyceryl Oleate 40 40 42 40 44
    (Peceol)
    Sorbitan Monooleate 65 40 40 25 30
    (Span 80)
    Sorbitan Monolaurate 20 65 * * 65
    (Span 20)
    PEG-6 Corn Oil 95 95 * 95 *
    (Labrafil M2125CS)
    Acetylated 80 80 80 80 80
    Monoglyceride
    (Myvacet 9-45)
    Ethyl Oleate 60 60 60 * 60
    (Crodamol EO)
    Mono/diglycerides of 50 80 * * 75
    Caprylic Acid (Imwitor
    988)
  • As is clear from the data in the Table, the effect of added solubilizer on the relative amount of hydrophobic surfactant that can be used varies considerably. For some surfactant combinations, the added solubilizer has a dramatic effect on the amount of hydrophobic surfactant (e.g., [0177] Span 20, Imwitor 988). In other systems, the effect is moderate (Arlacel 186, Peceol) or negligible (Crodamol EO, Myvacet 9-45). In the one case of Span 80, the presence of the solubilizer actually decreases the amount of hydrophobic surfactant that can be used.
    • Example 4
  • Compositions Containing Solubilizers [0178]
  • Example 3 was repeated, this time choosing a single hydrophobic surfactant (Arlacel 186) and three different hydrophilic surfactants, with addition of either ethanol or triacetin (20% by weight, based on the total weight of the two surfactants). The results are shown in Table 21. The corresponding entry from Table 19 (with no solubilizer present) is included in Table 21 for reference. [0179]
    TABLE 21
    Effect of Solubilizer on Hydrophobic Surfactant Amounts
    Hydrophobic Surfactant (Arlacel 186) +
    Hydrophilic 20% Solubilizer
    Surfactant (None) Ethanol Triacetin
    PEG-60 Corn Oil 15 20 20
    (Crovol M-70)
    PEG-35 Castor Oil 20 25 25
    (Incrocas 35)
    Polysorbate 20 20 25 25
    (Tween 20)
  • In each case, a moderate increase (20%) in the relative amount of hydrophobic surfactant was observed. [0180]
    • Example 5
  • Effect of Solubilizer Concentration [0181]
  • The procedure of Example 3 was repeated, with the following differences. A single hydrophilic surfactant (Cremophor RH-40) and hydrophobic surfactant (Arlacel 186) were chosen, to examine the effect of increased solubilizer concentration. For each of the four solubilizers tested at 20% concentrations in Example 3 (Table 20) plus an additional solubilizer (propylene glycol), compositions were tested at a solubilizer concentration of 50% by weight, based on the total weight of the surfactant pair. As in each of the previous examples, the numbers in Table 22 represent the maximum hydrophobic surfactant concentration giving a clear aqueous dispersion. Note that the “0” column in Table 22 reproduces the numbers shown in Table 19 (no solubilizer), and the “20%” column reproduces the numbers in Table 20, with the value for propylene glycol also supplied. [0182]
    TABLE 22
    Effect of Solubilizer Concentration on Hydrophobic
    Surfactant Amounts*
    Weight Percent of Solubilizer
    Solubilizer
    0 20 50
    PEG-400 20 25 25
    Propylene Glycol 20 28 30
    Triacetin 20 28 25
    Ethanol 20 25 30
    Glycofurol 20 25 30
  • As the Table shows, increasing the amount of solubilizer has a small to moderate effect on the amount of hydrophobic surfactant that can be present in a clear aqueous dispersion. It should be appreciated that the data equivalently show that very large amounts of solubilizer can be used, without detrimental effect on the ability of the surfactant system to form a clear, aqueous dispersion. [0183]
    • Example 6
  • Effect of High Solubilizer Concentration and Solubilizer Mixtures [0184]
  • Example 5 was repeated, using the same surfactant pair, but with an 80% concentration of solubilizer, based on the total weight of the surfactants. The 80% solubilizer was either PEG-400, or a mixture of PEG-400 and one of three alcohols or polyols. The results are shown in Table 23, with the numbers in the Table having the same meaning as in the previous Examples. [0185]
    TABLE 23
    Large Solubilizer Concentrations and Solubilizer Mixtures*
    60% 60%
    60% PEG-400 + PEG-400 +
    (no 80% PEG-400 + 20% Propylene 20%
    solubilizer) PEG-400 20% Glycerol Glycol Isopropanol
    20 25 25 25 25
  • It is clear from the data in the Table that very high concentrations of solubilizers, as well as mixtures of solubilizers, can be used effectively in the clear aqueous dispersions of the present invention. [0186]
    • Examples 7-12
  • Average Particle Size [0187]
  • In order to more quantitatively characterize the clear aqueous dispersions of the present invention, particle sizes were measured for several compositions of the present invention. For simplicity, the measurement were made for the dispersed carrier, in the absence of a hydrophobic therapeutic agent. In this Example, formulations were prepared as in Example 1, and diluted to form 10× or 100× aqueous dispersions. Each of the resulting dispersions was observed to be optically clear to the naked eye. Average particle sizes were measured with a Nicomp Particle Size Analyzer (Particle Size Systems, Inc., Santa Barbara, Calif.). The results of these measurements are shown in Table 24. [0188]
    TABLE 24
    Average Particle Size
    Ex- Particle
    am- Sur- Size
    ple factant Dilu- Observa- (nm) ±
    No. Formula Ratio* tion tion S.D.**
    7 Tween 80 520 mg 9.6 100X very clear  6.5 ± 1.1
    Lauroglycol 50 mg solution
    FCC
    8 Tween 80 500 mg 15  10X very clear  8.1 ± 1.6
    Capmul 73 mg solution
    MCM
    9 Cremophor 530 mg 28 100X clear 12.4 ± 3.0
    RH-40 150 mg solution
    Peceol
    10 Cremophor 500 mg 2.0 100X clear 14.7 ± 3.0
    RH-40 10 mg solution
    Plurol
    Oleique
    CC497
    11 Cremophor 550 mg 36 100X clear 14.3 ± 2.5
    RH-40 200 mg solution
    Lauroglycol
    FCC
    12 Cremophor 500 mg 40 100X clear 12.6 ± 2.9
    RH-40 200 mg solution
    Capmul
    MCM
  • As the data show, the compositions of the present invention produce clear, aqueous dispersions, with no visible cloudiness. The particle size distribution shows very small particles, with average diameters of from about 6 to about 15 nm. The distribution is mono-modal, with a standard deviation of approximately 20%, indicating a highly uniform distribution of very small particles. This particle size distribution is consistent with a solution of particles of micellar structure, although the invention is not limited by any particular theoretical framework. [0189]
    • Comparative Examples C1-C5
  • Optical Clarity and Particle Sizes of Compositions Not Forming Clear Aqueous Dispersions [0190]
  • For comparison to the clear aqueous dispersions of the present invention, several compositions were prepared having hydrophobic surfactant concentrations higher than those suitable for forming clear aqueous dispersions. These compositions were prepared by weighing the components and mixing well, with gentle warming. The compositions were then diluted 10× to form dispersions, and these dispersions were subjected to the particle size measurements as described in Example 7. The results are shown in Table 25. For direct comparison with the compositions of the present invention, Examples 7, 9, 10, 11 and 12 are shown next to the corresponding comparative compositions. [0191]
    TABLE 25
    Optical Clarity and Particle Size
    Example Surfactant Particle Size (nm)**
    No. Surfactants Ratio* Observation Mean 1 Mean 2
    C1 Tween 80 67 milky 26.6 209
    Lauroglycol solution
    FCC
    7 Tween 80 9.6 very clear 6.5 —
    Lauroglycol solution
    FCC
    C2 Cremophor 67 milky 25 116
    RH-40 solution
    Peceol
    9 Cremophor 28 clear 8.1 —
    RH-40 solution
    Peceol
    C3 Cremophor 67 milky 16.5 102
    RH-40 solution
    Plurol
    Oleique
    CC497
    10 Cremophor 2.0 clear 12.4 —
    RH-40 solution
    Plurol
    Oleique
    CC497
    C4 Cremophor 69 hazy 17.1 45.3
    RH-40 solution
    Lauroglycol
    FCC
    11 Cremophor 36 clear 14.3
    RH-40 solution
    Lauroglycol
    FCC
    C5 Cremophor 67 milky 11.6 176
    RH-40 solution
    Capmul
    MCM
    12 Cremophor 40 clear 12.6 —
    RH-40 solution
    Capmul
    MCM
  • In addition to the compositions shown in the Table, compositions containing Tween 80 and Plurol Oleique CC497, Tween 80 and Peceol, and Tween 80 and Capmul MCM were prepared at a surfactant ratio of 67 g hydrophobic surfactant per 100 g hydrophilic surfactant. Particle sizes were not measured for these compositions, but each was observed to form a milky or hazy aqueous dispersion. [0192]
  • As the data show, compositions having excessive amounts of hydrophobic surfactant form milky or hazy solutions, whereas those of the present invention form clear solutions. In addition, the particle size distributions of the milky solutions are bimodal, in contrast to the mono-modal solutions of the corresponding clear solutions. These bimodal particle size distributions show a first mode having a small mean particle size of about 12 to about 27 nm, and a second mode having particle sizes of up to more than 200 nm. Thus, compositions having excessive hydrophobic surfactant are heterogeneous (multi-phasic), non-clear dispersions, having a complex bimodal distribution of particles of two distinct size ranges. In contrast, compositions of the present invention are homogeneous (single phase), clear dispersion, having a mono-modal distribution of very small particle sizes. [0193]
    • Examples 13-42
  • Spectroscopic Characterization of Optical Clarity [0194]
  • The optical clarity of aqueous dispersions of the present invention was measured spectroscopically. Compositions were prepared according to Example 1, and diluted to 10× and 100× solutions. The specific compositions measured also include a solubilizer, to further illustrate preferred aspects of the invention. In addition, several of the compositions illustrate compositions according to the present invention wherein either the hydrophilic surfactant (Examples 20 and 27) or the hydrophobic surfactant (Examples 41 and 42) itself is a mixture of surfactants. [0195]
  • The absorbance of each solution was measured at 400.2 nm, using a purified water standard, and the results are shown in Table 26. [0196]
    TABLE 26
    Spectroscopic Characterization of Optical Clarity
    Example Absorbance (400.2 nm)
    No. Formulation 10X 100X
    13 Cremophor RH-40 430 mg 0.407 0.099
    Myvacet 9-45 310 mg
    Ethyl Alcohol 210 mg
    14 Cremophor RH-40 610 mg 0.299 0.055
    Peceol 160 mg
    Ethyl Alcohol 200 mg
    15 Cremophor RH-40 540 mg 0.655 0.076
    Span 80 260 mg
    Triacetin 220 mg
    16 Incrocas 35 470 mg 0.158 0.038
    Myvacet 9-45 250 mg
    Ethyl Alcohol 220 mg
    17 Incrocas 35 510 mg 0.064 0.009
    Imwitor 988 220 mg
    Triacetin 200 mg
    18 Tween 20 570 mg 0.031 0.003
    Lauroglycol FCC 140 mg
    Glycofurol 220 mg
    19 Crovol M70 610 mg 0.049 0.006
    Crovol M40 120 mg
    Ethyl Alcohol 200 mg
    20 Cremophor RH-40 250 mg 0.028 0.008
    Labrasol 250 mg
    Capmul GMO-K 110 mg
    Triacetin 100 mg
    21 Cremophor RH-40 220 mg 0.114 0.018
    Lauroglycol FCC 200 mg
    Ethyl Alcohol 75 mg
    22 Tween 80 170 mg 0.050 0.008
    Capmul MCM 30 mg
    Ethyl Alcohol 38 mg
    23 Cremophor RH-40 550 mg 0.029 0.006
    Capmul MCM 80 mg
    Ethyl Alcohol 53 mg
    24 Cremophor RH-40 230 mg 0.187 0.020
    Peceol 70 mg
    Ethyl Alcohol 54 mg
    25 Cremophor RH-40 500 mg 0.028 0.005
    Plurol Oleique 10 mg
    CC497 11 mg
    Ethyl Alcohol
    26 Tween 80 180 mg 0.036 0.003
    Lauroglycol FCC 20 mg
    Ethyl Alcohol 37 mg
    27 Tween 80 420 mg 0.036 0.009
    Labrasol 330 mg
    Arlacel 186 54 mg
    Ethyl Alcohol 140 mg
    28 Tagat O2 500 mg 0.077 0.005
    PGMG-03 50 mg
    Ethyl Alcohol 100 mg
    29 Incrocas 35 250 mg 0.053 0.005
    Gelucire 44/14 150 mg
    Triacetin 94 mg
    30 Cremophor RH-40 270 mg 0.232 0.047
    Labrafil 170 mg
    Ethyl Alcohol 100 mg
    31 Crovol M-70 380 mg 0.064 0.011
    Labrafil 50 mg
    Triacetin 100 mg
    32 Cremophor RH-40 300 mg 0.163 0.034
    Peceol 110 mg
    Triacetin 110 mg
    33 Tween 20 340 mg 0.038 0.005
    Lauroglycol FCC 110 mg
    Glycofurol 100 mg
    34 Incrocas-35 310 mg 0.101 0.020
    Labrafil 110 mg
    Ethyl Alcohol 100 mg
    35 Cremophor RH-40 300 mg 0.908 0.114
    Span 80 130 mg
    Triacetin 100 mg
    36 Cremophor RH-40 510 mg 0.039 0.008
    Arlacel 186 58 mg
    Propylene Glycol 55 mg
    37 Cremophor RH-40 510 mg 0.440 0.100
    Peceol 140 mg
    Propylene Glycol 58 mg
    38 Cremophor RH-40 500 mg 0.411 0.107
    Labrafil M2125CS 400 mg
    Propylene Glycol 88 mg
    39 Cremophor RH-40 550 mg 0.715 0.106
    Span 80 220 mg
    Propylene Glycol 78 mg
    40 Cremophor RH-40 500 mg 0.547 0.147
    Crodamol 280 mg
    Propylene Glycol 100 mg
    41 Cremophor RH-40 550 mg 0.419 0.055
    Labrafil M2125CS 340 mg
    Span 80 200 mg
    Ethyl Alcohol 110 mg
    42 Cremophor RH-40 500 mg 0.293 0.260
    Labrafil M2125CS 270 mg
    Crovol M-40 280 mg
    Ethyl Alcohol 100 mg
  • Ideally, a clear aqueous dispersion should have a very high transmittance, indicating little scattering of light by large particles. Absorbance and transmittance are related by the simple expression [0197]
  • A=−log T
  • where A is absorbance, and T is the transmittance expressed as a decimal. Thus, preferred solutions of the present invention will have small absorbances. As noted above, in the absence of true absorption (due to chromophores in solution), suitable clear aqueous dispersions of the present invention should have an absorbance at 10× dilution of less than about 0.3. [0198]
  • The data in Table 26 show 30 solutions, 22 of which have absorbances less than about 0.3 at 10× dilution. Of these solutions, 3 have absorbances between 0.2 and 0.3, 5 have absorbances between 0.1 and 0.2, and 14 have absorbances less than 0.1. Thus, for the majority of the solutions, absorbance provides an adequate measure of optical clarity. [0199]
  • Solutions having absorbances greater than 0.3 may still be suitable for use in the present invention, as these are observed to have acceptable optical clarity by visual examination. For these relatively high absorbance solutions, this simple spectroscopic measure of optical clarity is inadequate, and other methods are more well-suited to assessing optical clarity, such as visual observation and particle size. As an example, Example 37, which shows an absorbance of 0.440, has a surfactant ratio of 27, well below the value of 40 shown in Table 19, and is observed to be a clear solution. This same composition, without the additional solubilizer, is shown in Example 9 at a surfactant ratio of 28 to have a mono-modal, narrow particle size distribution, at an average particle size of 12.4 nm. It should be appreciated that direct particle size measurement and absorbance measurement are different ways of assessing optical clarity, and provide alternative criteria for quantifying clarity. However, it is believed that the simple, qualitative visual observation of optical clarity is a sufficient measure of suitable clarity for use in the present invention, particularly so since compositions outside the scope of the invention show marked and unmistakable cloudiness without recourse to quantitative measurement (See, e.g., Comparative Example 1). [0200]
    • Comparative Examples C6-C12
  • Spectroscopic Characterization of Compositions Not Forming Clear Aqueous Dispersions [0201]
  • For comparison to the clear aqueous dispersions of the present invention, compositions observed to be milky or cloudy were characterized by absorption, as in Examples 13-42. Where available, results for comparable solutions from Examples 13-42 are reproduced for comparison. In such cases, where a given surfactant combination is presented in Examples 13-42 more than once (with different solubilizer concentrations), the composition having the lowest solubilizer concentration is chosen, to facilitate more direct comparison. The results are shown in Table 27. [0202]
    TABLE 27
    Comparative Spectroscopic Characterization
    Example Absorbance (400.2 nm)
    No. Formulation 10X 100X
    C6 Tween 80 100 mg 2.938 2.827
    Lauroglycol FCC 67 mg
    26 Tween 80 180 mg 0.036 0.003
    Lauroglycol FCC 20 mg
    Ethyl Alcohol 37 mg
    C7 Tween 80 100 mg 0.980 0.932
    Capmul MCM 67 mg
    22 Tween 80 170 mg 0.050 0.008
    Capmul MCM 30 mg
    Ethyl Alcohol 38 mg
    C8 Cremophor RH-40 100 mg 2.886 1.595
    Plurol Oleique CC497 67 mg
    25 Cremophor RH-40 500 mg 0.028 0.005
    Plurol Oleique CC497 10 mg
    Ethyl Alcohol 11 mg
    C9 Cremophor RH-40 100 mg 2.892 1.507
    Peceol 67 mg
    24 Cremophor RH-40 230 mg 0.187 0.020
    Peceol 70 mg
    Ethyl Alcohol 54 mg
    C10 Cremophor RH-40 100 mg 1.721 0.491
    Capmul MCM 67 mg
    23 Cremophor RH-40 550 mg 0.029 0.006
    Capmul MCM 80 mg
    Ethyl Alcohol 53 mg
    C11 Tween 80 100 mg 1.585 1.357
    Plurol Oleique CC497 67 mg
    C12 Tween 80 100 mg 2.849 2.721
    Peceol 67 mg
  • The data in the Table demonstrate that the clear aqueous dispersions of the present invention show very different absorptive behavior from compositions having excessive hydrophobic surfactant concentrations, having apparent absorbances (through scattering losses) lower by at least a factor of ten, and in some cases by a factor of more than one hundred. [0203]
    • Examples 43 and 44
  • Solubility of a Polyfunctional Hydrophobic Therapeutic Agent [0204]
  • The enhanced solubility of a typical polyfunctional hydrophobic therapeutic agent, cyclosporin, in the pharmaceutical compositions of the present invention was measured using a conventional “shake flask” method. Compositions were prepared and diluted to 10× and 100× as in Example 1, without including the therapeutic agent. The solutions were then provided with an excess of cyclosporin, and agitated to allow the cyclosporin to achieve an equilibrium partitioning between the solubilized phase and the non-solubilized dispersion phase. Concentration of the solubilized cyclosporin was then determined using standard HPLC techniques, optimized for the quantitative detection of cyclosporin. The results are shown in Table 28. [0205]
    TABLE 28
    Solubility of Cyclosporin in Clear Aqueous Dispersions
    Ex-
    ample Solubility (μg/mL)
    No. Carrier Composition 10X Dilution 100X Dilution
    43 Cremophor RH-40 430 mg 13,205 1,008
    Myvacet 9-45 321 mg
    Ethyl Alcohol 210 mg
    44 Cremophor RH-40 540 mg 11,945 1,127
    Span 80 260 mg
    Triacetin 220 mg
  • This Example demonstrates the dramatically enhanced solubility of a hydrophobic therapeutic agent in the pharmaceutical compositions of the present invention. [0206]
    • Comparative Examples C13-C16
  • Solubility of a Polyfunctional Hydrophobic Therapeutic Agent [0207]
  • For comparison, the solubility experiment of Examples 43-44 was performed on four standard aqueous solutions. The first comparison solution was purified water with no additives. Next, a standard simulated intestinal fluid (SIF) was used, to simulate the in vivo conditions to be encountered by the hydrophobic therapeutic agent. A third solution was prepared with simulated intestinal fluid, plus an additional aliquot of 20 mM sodium taurocholate (a bile salt); this solution is designated SIFB in Table 29. Finally, a fourth solution was prepared with simulated intestinal fluid, 20 mM sodium taurocholate, and 5 mM lecithin; this solution is designated SIFBL. The 20 mM bile salt and 5 mM lecithin concentrations are believed to be representative of the average concentration of these compounds encountered in the gastrointestinal tract. As in the previous Examples, these comparison solutions were equilibrated with cyclosporin using the shake flask method, and analyzed by HPLC. The results of these measurements are presented in Table 29. [0208]
    TABLE 29
    Solubility of Cyclosporin in Aqueous Solutions
    Example No. Solution Solubility (μg/mL)
    C13 Water 6
    C14 SIF 6
    C15 SIFB 49
    C16 SIFBL 414
    43-44 (average at 10X) present invention 12,575
  • As the Table indicates, the solubility of the polyfunctional hydrophobic therapeutic agent in the compositions of the present invention is far greater than its solubility in aqueous and gastrointestinal aqueous solutions. [0209]
    • Examples 45-49
  • Solubility of a Lipophilic Hydrophobic Therapeutic Agent [0210]
  • The enhanced solubility of a typical lipophilic hydrophobic therapeutic agent, progesterone, in the pharmaceutical compositions of the present invention was measured as described in Examples 43-44. The results are shown in Table 30. [0211]
    TABLE 30
    Solubility of Progesterone in Clear Aqueous Dispersions
    Ex-
    ample Solubility (μg/mL)
    No. Carrier Composition 10X Dilution 100X Dilution
    45 Cremophor RH-40 1000 mg 1100 200
    Arlacel 186 120 mg
    Propylene Glycol 110 mg
    46 Cremophor RH-40 1000 mg 1240 140
    Peceol 240 mg
    Propylene Glycol 120 mg
    47 Cremophor RH-40 1000 mg 1760 190
    Labrafil M2125CS 800 mg
    Propylene Glycol 180 mg
    48 Cremophor RH-40 1000 mg 1360 160
    Span 80 350 mg
    Propylene Glycol 140 mg
    49 Cremophor RH-40 1000 mg 1720 190
    Crodamol EO 600 mg
    Propylene Glycol 160 mg
  • This Example demonstrates the dramatically enhanced solubility of a hydrophobic therapeutic agent in the pharmaceutical compositions of the present invention. [0212]
    • Comparative Examples C17-C20
  • Solubility of a Lipophilic Hydrophobic Therapeutic Agent [0213]
  • For comparison, the solubility experiment of Comparative Examples C13-C16 was repeated, using progesterone instead of cyclosporin. The results of these measurements are presented in Table 31. [0214]
    TABLE 31
    Solubility of Progesterone in Aqueous Solutions
    Example No. Solution Solubility (μg/mL)
    C17 Water   6
    C18 SIF  7-10
    C19 SIFB 32-40
    C20 SIFBL  80
    45-49 (average at 10X) present invention 1436
  • As the Table indicates, the solubility of the lipophilic hydrophobic therapeutic agent in the compositions of the present invention is far greater than its solubility in aqueous and gastrointestinal aqueous solutions. [0215]
    • Examples 50-57
  • Aqueous Dilution Stability of Compositions Containing a Polyfunctional Hydrophobic Therapeutic Agent [0216]
  • Compositions according to the present invention were prepared, with a typical polyfunctional hydrophobic therapeutic agent, cyclosporin, as the therapeutic agent. The compositions were prepared as described in Example 1, except that the ingredients were added in the order listed in Table 32. The pre-concentrates were diluted 100× with purified water, and a visual observation was made immediately after dilution. The solutions were then allowed to stand 6 hours to assess dilution stability, then the cyclosporin concentration in solution was measured, using a drug-specific HPLC assay. The results are shown in Table 32. [0217]
    TABLE 32
    Dilution Stability of Polyfunctional Therapeutic Agents
    Cyclosporin
    Example Concen-
    No. Composition Observation tration*
    50 Cremophor RH-40 430 mg clear solution 121
    Myvacet 9-45 310 mg
    Ethyl Alcohol 210 mg
    Cyclosporin  99 mg
    51 Cremophor RH-40 610 mg clear solution 99 
    Peceol 160 mg
    Ethyl Alcohol 200 mg
    Cyclosporin 100 mg
    52 Cremophor RH-40 540 mg clear solution 114
    Span 80 260 mg
    Triacetin 220 mg
    Cyclosporin  97 mg
    53 Incrocas 35 470 mg clear solution 96 
    Myvacet 9-45 250 mg
    Ethyl Alcohol 220 mg
    Cyclosporin 100 mg
    54 Cremophor RH-40 660 mg clear solution 105
    Arlacel 186 120 mg
    Propylene Glycol 100 mg
    Ethanol 100 mg
    Cyclosporin 100 mg
    55 Cremophor RH-40 550 mg clear solution 102
    Arlacel 186 120 mg
    Propylene Glycol 450 mg
    Cyclosporin 100 mg
    56 Cremophor RH-40 580 mg clear solution 108
    Arlacel 186 120 mg
    Propylene Glycol 100 mg
    Ethanol 100 mg
    Cyclosporin 100 mg
    57 Gelucire 44/14 120 mg clear solution 108
    Incrocas 35 200 mg (at 37° C.)
    Glycofurol 100 mg
    Cyclosporin 100 mg
  • [0218]
  • The data in the Table indicate that large amounts of a polyfunctional hydrophobic therapeutic agent can be solubilized in the compositions of the present invention to produce clear, aqueous dispersions. These dispersions show no instability effects, such as hydrophobic therapeutic agent precipitation or particle agglomeration, upon standing. [0219]
    • Examples 58-74
  • Aqueous Dilution Stability of Compositions Containing a Lipophilic Hydrophobic Therapeutic Agent [0220]
  • Compositions according to the present invention were prepared, with a typical lipophilic hydrophobic therapeutic agent, progesterone, as the therapeutic agent. The compositions were prepared and analyzed as in Examples 50-57, and the results are shown in Table 33. [0221]
    TABLE 33
    Dilution Stability of Lipophilic Therapeutic Agents
    Proges-
    terone
    Example Concen-
    No. Composition Observation tration*
    58 Cremophor RH-40 1000 mg very clear 99.1
    Arlacel 186 120 mg solution
    Propylene Glycol 110 mg
    Progesterone 48 mg
    59 Cremophor RH-40 1000 mg very clear 99.3
    Peceol 240 mg solution
    Propylene Glycol 120 mg
    Progesterone 48 mg
    60 Cremophor RH-40 1000 mg very clear 100.2
    Labrafil 800 mg solution
    Propylene Glycol 180 mg
    Progesterone 45 mg
    61 Cremophor RH-40 1000 mg very clear 97.2
    Span 80 350 mg solution
    Propylene Glycol 140 mg
    Progesterone 50 mg
    62 Cremophor RH-40 1000 mg very clear 98.4
    Crodamol EO 600 mg solution
    Propylene Glycol 160 mg
    Progesterone 48 mg
    63 Cremophor RH-40 540 mg clear solution 104.4
    Labrafil M2125CS 350 mg
    Ethyl Alcohol 200 mg
    Progesterone 42 mg
    64 Cremophor RH-40 570 mg very slight tang 106.1
    Ethyl Oleate 260 mg blue color
    Ethyl Alcohol 200 mg solution
    Progesterone 42 mg
    65 Cremophor RH-40 600 mg very slight tang 104.6
    Peceol 210 mg blue color
    Triacetin 210 mg solution
    Progesterone 42 mg
    66 Cremophor RH-40 600 mg very clear 97.7
    Capmul MCM 200 mg solution
    Triacetin 200 mg
    Progesterone 44 mg
    67 Cremophor RH-40 590 mg clear solution 102.3
    Span 80 270 mg
    Triacetin 210 mg
    Progesterone 41 mg
    68 Crovol M-70 760 mg very clear 104.6
    Labrafil M2125CS 100 mg solution
    Triacetin 200 mg
    Progesterone 43 mg
    69 Tween 20 610 mg very slight tang 98.0
    Imwitor 988 300 mg blue color
    Triacetin 200 mg solution
    Progesterone 45 mg
    70 Tween 20 670 mg very clear 96.3
    Lauroglycol FCC 170 mg solution
    Glycofurol 200 mg
    Progesterone 43 mg
    71 Incrocas 35 620 mg very clear 99.5
    Labrafil M2125CS 220 mg solution
    Ethyl Alcohol 200 mg
    Progesterone 43 mg
    72 Incrocas 35 660 mg very clear 105.9
    Span 20 160 mg solution
    Ethyl Alcohol 210 mg
    Progesterone 41 mg
    73 Cremophor RH-40 980 mg very clear 103.7
    Arlacel 186 130 mg supernatant
    Propylene Glycol 110 mg
    Progesterone 110 mg
    74 Cremophor RH-40 520 mg very clear 103.1
    Labrafil 400 mg supernatant
    Propylene Glycol 110 mg
    Progesterone 100 mg
  • The data in the Table indicate that a lipophilic hydrophobic therapeutic agent can be solubilized in the compositions of the present invention to produce clear, aqueous dispersions. These dispersions show no instability effects, such as hydrophobic therapeutic agent precipitation or particle agglomeration, upon standing. [0222]
    • Example 75
  • Enhancement of Bioabsorption [0223]
  • Studies were performed to establish that the clear aqueous dispersions of the present invention facilitate an increased rate of bioabsorption of the hydrophobic therapeutic agent contained therein. The studies used a rat model with perfused intestinal loop along with cannulation of the mesenteric vein. This unique methodology enabled assessment of the “true” absorption potential free of any systemic metabolic interference. [0224]
  • A representative preconcentrate of the present invention containing a cyclosporin hydrophobic therapeutic agent was used. The composition had the following formulation: [0225]
    Cyclosporine 0.140 g
    Cremophor RH-40 0.41 g
    Arlacel 186 0.29 g
    Sodium taurocholate 0.26 g
    Propylene glycol 0.46 g
  • For this experiment, the preconcentrate was diluted with an isotonic aqueous HEPES buffer rather than purified water. The resultant solution was spiked with radioactive active and perfused through isolated ileal lumen segment of known length and diameter. Loss of radioactivity from the lumenal side and appearance of radioactivity in the mesenteric blood from the other side was monitored as an indicator of absorption. [0226]
    • Experimental Details
  • Young adult (275-300 g) male Sprague Dawley rats were used. The procedures were consistent with those reported by Winne et al., “In vivo studies of mucosal-serosal transfer in rat jejunum”, Naunyn-Schmeideberg's Arch. Pharmacol., 329, 70 (1985). [0227]
  • Jugular vein cannulation: the animal was anesthetized using 2% halothane in 98% oxygen via a halothane vaporizer (Vapomatic, A. M. Bickford, Inc., NY). An opening in the jugular vein was made with a 21 ga needle and a jugular cannula consisting of a 4 cm segment of silastic tubing connected to polyethylene tubing was inserted in the jugular vein and secured with cyanoacrylate glue. For the donor rat, approximately 20 mL of blood was freshly collected in the presence of heparin (1,000 units) and the collected blood was infused at a rate of 0.2 mL/min through the jugular vein in the experimental rat to replenish blood sampling. [0228]
  • Intestine cannulation: after the animal was anesthetized, its body temperature was maintained at 37° C. using a heating pad. A vertical midline incision of approximately 3 cm was made through the skin to expose the small intestine. Approximately 6-10 cm segment of ileum was located. Using electro-cautery, a small incision was made at the ends of the segment and the lumenal contents were flushed with saline maintained at 37° C. Two 1.5 cm notched pieces of Teflon tubing were inserted into the intestinal lumen at each incision and tightened using 4-0 silk. A warm isotonic buffer was passed through the intestine using a 50-mL syringe. These Teflon cannula were used to perfuse the drug solution through the isolated intestinal segment using a syringe pump. [0229]
  • Mesenteric vein cannulation: the mesenteric vein draining blood from the resulting isolated mesenteric cascade venules was then cannulated using a 24 ga IV catheter and secured in place using 4-0 silk sutures. The cannula was then connected to a polyethylene tubing 25 cm long where the blood was collected in a vial kept under the animal level. Blood samples were collected continuously over 60 min. The infusion of blood via the jugular vein was initiated to replenish blood loss. The animal was then killed by a lethal injection of Phenobarbital after completion of the experiment. [0230]
  • The experiment was performed twice using the compositions of the present invention as the drug carrier, and twice using a commercial cyclosporin microemulsion formulation for comparison (NeOral®). For each formulation, the results of the two trials were averaged. The results are presented graphically in FIG. 1. [0231]
  • FIG. 1 shows the accumulated radioactivity (μCi/cm[0232] 2μCi) in mesenteric blood as a function of time, over the course of 60 minutes, for the pharmaceutical compositions of the present invention (filled squares) and a commercial cyclosporin formulation (filled circles). As the Figure shows, the bioabsorption of the hydrophobic therapeutic agent exceeds that of the commercial formulation at the earliest measurement point, and continues to increase relative to the commercial formulation over the course of the measurement interval. At the final measurement point (60 min), the bioabsorption of the hydrophobic therapeutic agent from the compositions of the present invention exceeds that of the commercial formulation by nearly 100%.
  • The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.[0233]

Claims (140)

What is claimed and desired to be secured by United States Letters Patent is:
1. A pharmaceutical composition comprising:
(a) a hydrophobic therapeutic agent; and
(b) a carrier,
 said carrier comprising:
(i) at least one hydrophilic surfactant; and
(ii) at least one hydrophobic surfactant,
 said hydrophilic and hydrophobic surfactants being present in amounts such that upon mixing with an aqueous solution the carrier forms a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing the hydrophobic therapeutic agent,
said composition being substantially free of triglycerides.
2. The pharmaceutical composition of claim 1, wherein the hydrophobic surfactant is present in an amount of less than about 200% by weight, relative to the amount of the hydrophilic surfactant.
3. The pharmaceutical composition of claim 2, wherein the hydrophobic surfactant is present in an amount of less than about 100% by weight, relative to the amount of the hydrophilic surfactant.
4. The pharmaceutical composition of claim 3, wherein the hydrophobic surfactant is present in an amount of less than about 60% by weight, relative to the amount of the hydrophilic surfactant.
5. The pharmaceutical composition of claim 1, wherein the hydrophilic surfactant comprises at least one non-ionic hydrophilic surfactant having an HLB value greater than or equal to about 10.
6. The pharmaceutical composition of claim 1, wherein the hydrophilic surfactant comprises at least one ionic surfactant.
7. The pharmaceutical composition of claim 5, which further comprises at least one ionic surfactant.
8. The pharmaceutical composition of claim 5, wherein the non-ionic surfactant is selected from the group consisting of alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyethylene alkyl ethers; polyoxyethylene alkylphenols; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; sugar esters, sugar ethers; sucroglycerides; and mixtures thereof.
9. The pharmaceutical composition of claim 5, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
10. The pharmaceutical composition of claim 9, wherein the glyceride is a monoglyceride, diglyceride, triglyceride, or a mixture thereof.
11. The pharmaceutical composition of claim 9, wherein the reaction mixture comprises the transesterification products of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
12. The pharmaceutical composition of claim 9, wherein the polyol is glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol or a mixture thereof.
13. The pharmaceutical composition of claim 5, wherein the hydrophilic surfactant is PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, a poloxamer, or a mixture thereof.
14. The pharmaceutical composition of claim 5, wherein the hydrophilic surfactant is PEG-20 laurate, PEG-20 oleate, PEG-35 castor oil, PEG-40 palm kernel oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, polyglyceryl-10 laurate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, PEG-30 cholesterol, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, PEG-24 cholesterol, sucrose monostearate, sucrose monolaurate, a poloxamer, or a mixture thereof.
15. The pharmaceutical composition of claim 5, wherein the hydrophilic surfactant is PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, a poloxamer, or a mixture thereof.
16. The pharmaceutical composition of claim 6, wherein the ionic surfactant is selected from the group consisting of alkyl ammonium salts; bile acids and salts, analogues, and derivatives thereof; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides; alginate salts; propylene glycol alginate; lecithins and hydrogenated lecithins; lysolecithin and hydrogenated lysolecithins; lysophospholipids and derivatives thereof; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; and mixtures thereof.
17. The pharmaceutical composition of claim 6, wherein the ionic surfactant is selected from the group consisting of bile acids and salts, analogues, and derivatives thereof; lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides; and mixtures thereof.
18. The pharmaceutical composition of claim 6, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, chenodeoxycholate, glycodeoxycholate, glycochenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate, tauroursodeoxycholate, glycoursodeoxycholate, cholylsarcosine, N-methyl taurocholate, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, and salts and mixtures thereof.
19. The pharmaceutical composition of claim 6, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, lysophosphatidylcholine, PEG-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, glycodeoxycholate, cholylsarcosine, caproate, caprylate, caprate, laurate, oleate, lauryl sulfate, docusate, and salts and mixtures thereof.
20. The pharmaceutical composition of claim 6, wherein the ionic surfactant is selected from the group consisting of lecithin, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, taurocholate, caprylate, caprate, oleate, lauryl sulfate, docusate, and salts and mixtures thereof.
21. The pharmaceutical composition of claim 1 wherein the hydrophobic surfactant is a compound or mixture of compounds having an HLB value less than about 10.
22. The pharmaceutical composition of claim 21, wherein the hydrophobic surfactant is selected from the group consisting of alcohols; polyoxyethylene alkylethers; fatty acids; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters; polyoxyethylene glycerides; lactic acid derivatives of mono/diglycerides; propylene glycol diglycerides; sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; transesterified vegetable oils; sterols; sterol derivatives; sugar esters; sugar ethers; sucroglycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
23. The pharmaceutical composition of claim 21, wherein the hydrophobic surfactant is selected from the group consisting of fatty acids; lower alcohol fatty acid esters; polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters; polyoxyethylene glycerides; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
24. The pharmaceutical composition of claim 21, wherein the hydrophobic surfactant is selected from the group consisting of lower alcohol fatty acids esters; polypropylene glycol fatty acid esters; propylene glycol fatty acid esters; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene vegetable oils; and mixtures thereof.
25. The pharmaceutical composition of claim 21, wherein the hydrophobic surfactant is a glycerol fatty acid ester, an acetylated glycerol fatty acid ester, or a mixture thereof.
26. The pharmaceutical composition of claim 25, wherein the glycerol fatty acid ester is a monoglyceride, diglyceride, or a mixture thereof.
27. The pharmaceutical composition of claim 26, wherein the fatty acid of the glycerol fatty acid ester is a C6 to C20 fatty acid or a mixture thereof.
28. The pharmaceutical composition of claim 21, wherein the hydrophobic surfactant is a reaction mixture of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
29. The pharmaceutical composition of claim 28, wherein the reaction mixture is a transesterification product of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
30. The pharmaceutical composition of claim 28, wherein the polyol is polyethylene glycol, sorbitol, propylene glycol, pentaerythritol or a mixture thereof.
31. The pharmaceutical composition of claim 21, wherein the hydrophobic surfactant is selected from the group consisting of myristic acid; oleic acid; lauric acid; stearic acid; palmitic acid; PEG 1-4 stearate; PEG 2-4 oleate; PEG-4 dilaurate; PEG-4 dioleate; PEG-4 distearate; PEG-6 dioleate; PEG-6 distearate; PEG-8 dioleate; PEG 3-16 castor oil; PEG 5-10 hydrogenated castor oil; PEG 6-20 corn oil; PEG 6-20 almond oil; PEG-6 olive oil; PEG-6 peanut oil; PEG-6 palm kernel oil; PEG-6 hydrogenated palm kernel oil; PEG-4 capric/caprylic triglyceride, mono, di, tri, tetra esters of vegetable oil and sorbitol; pentaerythrityl di, tetra stearate, isostearate, oleate, caprylate, or caprate; polyglyceryl 2-4 oleate, stearate, or isostearate; polyglyceryl 4-10 pentaoleate; polyglyceryl-3 dioleate; polyglyceryl-6 dioleate; polyglyceryl-10 trioleate; polyglyceryl-3 distearate; propylene glycol mono- or diesters of a C6 to C20 fatty acid; monoglycerides of a C6 to C20 fatty acid; acetylated monoglycerides of C6 to C20 fatty acid; diglycerides of C6 to C20 fatty acids; lactic acid derivatives of monoglycerides; lactic acid derivatives of diglycerides; cholesterol; phytosterol; PEG 5-20 soya sterol; PEG-6 sorbitan tetra, hexastearate; PEG-6 sorbitan tetraoleate; sorbitan monolaurate; sorbitan monopalmitate; sorbitan mono, trioleate; sorbitan mono, tristearate; sorbitan monoisostearate; sorbitan sesquioleate; sorbitan sesquistearate; PEG 2-5 oleyl ether; POE 2-4 lauryl ether; PEG-2 cetyl ether; PEG-2 stearyl ether; sucrose distearate; sucrose dipalmitate; ethyl oleate; isopropyl myristate; isopropyl palmitate; ethyl linoleate; isopropyl linoleate; poloxamers; and mixtures thereof.
32. The pharmaceutical composition of claim 21, wherein the hydrophobic surfactant is selected from the group consisting of oleic acid; lauric acid; glyceryl monocaprate; glyceryl monocaprylate; glyceryl monolaurate; glyceryl monooleate; glyceryl dicaprate; glyceryl dicaprylate; glyceryl dilaurate; glyceryl dioleate; acetylated monoglycerides; propylene glycol oleate; propylene glycol laurate; polyglyceryl-3 oleate; polyglyceryl-6 dioleate; PEG-6 corn oil; PEG-20 corn oil; PEG-20 almond oil; sorbitan monooleate; sorbitan monolaurate; POE-4 lauryl ether; POE-3 oleyl ether; ethyl oleate; poloxamers; and mixtures thereof.
33. The pharmaceutical composition of claim 1, wherein the clear aqueous dispersion has a particle size distribution having an average particle size of less than about 100 nm.
34. The pharmaceutical composition of claim 33, wherein the clear aqueous dispersion has a particle size distribution having an average particle size of less than about 50 nm.
35. The pharmaceutical composition of claim 33, wherein the clear aqueous dispersion has a particle size distribution having an average particle size of less than about 20 nm.
36. The pharmaceutical composition of claim 1, wherein the clear aqueous dispersion has an absorbance of less than about 0.1 at about 400 nm when the carrier is diluted with an aqueous solution in an aqueous solution to carrier ratio of 100:1 by weight.
37. The pharmaceutical composition of claim 36, wherein the absorbance is less than about 0.01.
38. The pharmaceutical composition of claim 1, wherein the hydrophobic therapeutic agent has an intrinsic water solubility of less than about 1% by weight at 25° C.
39. The pharmaceutical composition of claim 38, wherein the intrinsic water solubility is less than about 0.1% by weight at 25° C.
40. The pharmaceutical composition of claim 39, wherein the intrinsic water solubility is less than about 0.01% by weight at 25° C.
41. The pharmaceutical composition of claim 1, wherein the therapeutic agent is a drug, a vitamin, a nutritional supplement, a cosmeceutical, or a mixture thereof.
42. The pharmaceutical composition of claim 43, wherein the therapeutic agent is a polyfunctional hydrophobic drug, a lipophilic drug, a pharmaceutically acceptable salt, isomer or derivative thereof, or a mixture thereof.
43. The pharmaceutical composition of claim 41, wherein the therapeutic agent is selected from the group consisting of analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, erectile dysfunction improvement agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, β-Blockers, cardiac inotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastro-intestinal agents, histamine H,-receptor antagonists, keratolytics, lipid regulating agents, anti-anginal agents, nutritional agents, opioid analgesics, sex hormones, stimulants, muscle relaxants, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, anti-benign prostate hypertrophy agents, essential fatty acids, non-essential fatty acids, and mixtures thereof.
44. The pharmaceutical composition of claim 41, wherein the therapeutic agent is tramadol, celecoxib, etodolac, refocoxib, oxaprozin, leflunomide, diclofenac, nabumetone, ibuprofen, flurbiprofen, tetrahydrocannabinol, capsaicin, ketorolac, albendazole, ivermectin, amiodarone, zileuton, zafirlukast, albuterol, montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, dicoumarol, tirofibran, cilostazol, ticlidopine, clopidrogel, oprevelkin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, glipizide, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, nifedipine, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minoxidil, terzosin, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratiptan, rizatriptan, aminogluthemide, busulphan, cyclosporine, mitoxantrone, irinotecan, etoposide, teniposide, paclitaxel, tacrolimus, sirolimus, tamoxifen, camptothecan, topotecan, nilutanide, bicalutanide, pseudo-ephedrine, toremifene, atovaquone, metronidazole, furazolidone, paricalcitol, benzonatate, midazolam, zolpidem, gabapentin, zopiclone, digoxin, beclomethsone, budesonide, betamethasone, prednisolone, cisapride, cimetidine, loperamide, famotidine, lanosprazole, rabeprazole, nizatidine, omeprazole, citrizine, cinnarizine, dexchlopheniramine, loratadine, clemastine, fexofenadine, chlorpheniramine, acutretin, tazarotene, calciprotiene, calcitriol, targretin, ergocalciferol, cholecalciferol, isotreinoin, tretinoin, calcifediol, fenofibrate, probucol, gemfibrozil, cerivistatin, pravastatin, simvastatin, fluvastatin, atorvastatin, tizanidine, dantrolene, isosorbide dinatrate, a carotene, dihydrotachysterol, vitamin A, vitamin D, vitamin E, vitamin K, an essential fatty acid source, codeine, fentanyl, methadone, nalbuphine, pentazocine, clomiphene, danazol, dihydro epiandrosterone, medroxyprogesterone, progesterone, rimexolone, megesterol acetate, osteradiol, finasteride, mefepristone, amphetamine, L-thryroxine, tamsulosin, methoxsalen, tacrine, donepezil, raloxifene, vertoporfin, sibutramine, pyridostigmine, a pharmaceutically acceptable salt, isomer, or derivative thereof, or a mixture thereof.
45. The pharmaceutical composition of claim 1, wherein the hydrophobic therapeutic agent is selected from the group consisting of tramadol, celecoxib, etodolac, refocoxib, oxaprozin, leflunomide, diclofenac, nabumetone, ibuprofen, flurbiprofen, tetrahydrocannabinol, capsaicin, ketorolac, albendazole, ivermectin, amiodarone, zileuton, zafirlukast, albuterol, montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, glipizide, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratiptan, rizatriptan, aminogluthemide, busulphan, cyclosporine, mitoxantrone, irinotecan, etoposide, teniposide, paclitaxel, tacrolimus, sirolimus, tamoxifen, camptothecan, topotecan, nilutanide, bicalutanide, pseudo-ephedrine, toremifene, atovaquone, metronidazole, furzolidone, paricalcitol, benzonatate, midazolam, zolpidem, gabapentin, zopiclone, digoxin, cisapride, cimetidine, loperamide, famotidine, lanosprazole, rabeprazole, nizatidine, omeprazole, citrizine, cinnarizine, dexchlopheniramine, loratadine, clemastine, fexofenadine, chlorpheniramine, acutretin, tazarotene, calciprotiene, calcitriol, targretin, ergocalciferol, cholecaliferol, isotreinoin, tretinoin, calcifediol, fenofibrate, probucol, gemfibrozil, cerivistatin, pravastatin, simvastatin, fluvastatin, atorvastatin, tizanidine, dantrolene, carotenes, dihyrotachysterol, vitamin A, vitamin D, vitamin E, vitamin K, essential fatty acid sources, codeine, fentanyl, methdone, nalbuphine, pentazocine, clomiphene, danazol, dihydro epiandrosterone, mmedroxyprogesterone, progesterone, rimexolone, megesterol acetate, osteradiol, finasteride, mefepristone, amphetamine, L-thryroxine, tamsulosin, methoxsalen, tacrine, donepezil, raloxifene, vertoporfin, sibutramine, pyridostigmine, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
46. The pharmaceutical composition of claim 1, wherein the therapeutic agent is selected from the group consisting of tramadol, celecoxib, etodolac, refocoxib, oxaprozin, leflunomide, diclofenac, nabumetone, ibuprofen, flurbiprofen, tetrahydrocannabinol, capsaicin, ketorolac, ivermectin, amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, glipizide, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbenafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine, naratiptan, rizatriptan, aminogluthemide, busulphan, cyclosporine, mitoxantrone, irinotecan, etoposide, teniposide, paclitaxel, tacrolimus, sirolimus, tamoxifen, camptothecan, topotecan, nilutanide, bicalutanide, toremifene, atovaquone, metronidazole, furzolidone, paricalcitol, benzonatate, cisapride, cimetidine, loperamide, famotidine, lanosprazole, rabeprazole, nizatidine, omeprazole, citrizine, cinnarizine, dexchlopheniramine, loratadine, clemastine, fexofenadine, chlorpheniramine, acutretin, tazarotene, calciprotiene, calcitriol, targretin, ergocalciferol, cholecaliferol, isotreinoin, tretinoin, calcifediol, fenofibrate, probucol, simvastatin, atorvastatin, tizanidine, dantrolene, carotenes, dihyrotachysterol, vitamin A, vitamin D, vitamin E, vitamin K, essential fatty acid sources, danazol, dihydro epiandrosterone, medroxyprogesterone, progesterone, rimexolone, megesterol acetate, osteradiol, finasteride, mefepristone, raloxifene, L-thryroxine, tamsulosin, methoxsalen, pharmaceutically acceptable salts, isomers and derivative thereof, and mixtures thereof.
47. The pharmaceutical composition of claim 1, wherein the hydrophobic therapeutic agent is selected from the group consisting of sildenafil citrate, amlodipine, tramadol, celecoxib, refocoxib, oxaprozin, nabumetone, ibuprofen, terbenafine, itraconazole, zileuton, zafirlukast, cisapride, fenofibrate, tizanidine, nizatidine, fexofenadine, loratadine, famotidine, paricalcitol, atovaquone, nabumetone, tetrahydrocannabinol, megesterol acetate, repaglinide, progesterone, rimexolone, cyclosporine, tacrolimus, sirolimus, teniposide, paclitaxel, pseudo-ephedrine, troglitazone, rosiglitazone, finasteride, vitamin A, vitamin D, vitamin E, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
48. The pharmaceutical composition of claim 1, wherein the hydrophobic therapeutic agent is progesterone or cyclosporin.
49. The pharmaceutical composition of claim 1, which further comprises a solubilizer.
50. The pharmaceutical composition of claim 49, wherein the solubilizer is selected from the group consisting of alcohols, polyols, amides, esters, propylene glycol ethers and mixtures thereof.
51. The pharmaceutical composition of claim 50, wherein the alcohol or polyol is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives, and mixtures thereof.
52. The pharmaceutical composition of claim 50, wherein the amide is selected from the group consisting of 2-pyrrolidone, 2-piperidone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
53. The pharmaceutical composition of claim 50, wherein the ester is selected from the group consisting of ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof, and mixtures thereof.
54. The pharmaceutical composition of claim 49, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins, clodextrins and derivatives thereof, ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof, 2-pyrrolidone, 2-2 piperidone, ε-caprolactam, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethyl pyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, glycofurol, methoxy PEG, and mixtures thereof.
55. The pharmaceutical composition of claim 49, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, benzyl alcohol, ethylene glycol, propylene glycol, 1,3-butanediol, glycerol, pentaerythritol, sorbitol, glycofurol, transcutol, dimethyl isosorbide, polyethylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxypropylcyclodextrins, sulfobutyl ether derivatives of cyclodextrins, ethyl propionate, tributylcitrate, triethylcitrate, ethyl oleate, ethyl caprylate, triacetin, β-butyrolactone and isomers thereof, 2-pyrrolidone, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethylpyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
56. The pharmaceutical composition of claim 49, wherein the solubilizer is triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, dimethyl isosorbide, or a mixture thereof.
57. The pharmaceutical composition of claim 49, wherein the solubilizer is triacetin, ethanol, polyethylene glycol 400, glycofurol, propylene glycol or a mixture thereof.
58. The pharmaceutical composition of claim 49, wherein the solubilizer is present in the composition in an amount of about 400% or less by weight, based on the total weight of the surfactants.
59. The pharmaceutical composition of claim 58, wherein the solubilizer is present in the composition in an amount of about 200% or less by weight, based on the total weight of the surfactants.
60. The pharmaceutical composition of claim 59, wherein the solubilizer is present in the composition in an amount of about 100% or less by weight, based on the total weight of the surfactants.
62. The pharmaceutical composition of claim 60, wherein the solubilizer is present in the composition in an amount of about 50% or less by weight, based on the total weight of the surfactants.
62. The pharmaceutical composition of claim 61, wherein the solubilizer is present in the composition in an amount about 25% or less by weight, based on the total weight of the surfactants.
63. The pharmaceutical composition of claim 1, which further comprises an antioxidant, a preservative, a chelating agent, a viscomodulator, a tonicifier, a flavorant, a colorant, an odorant, an opacifier, a suspending agent, a binder, or a mixture thereof.
64. The pharmaceutical composition of claim 1 in the form of a preconcentrate, a diluted preconcentrate, a semi-solid dispersion, a solid dispersion, or a sprayable solution.
65. A dosage form comprising a capsule filled with the pharmaceutical composition of claim 1.
66. A dosage form comprising a multiparticulate carrier coated with the pharmaceutical composition of claim 1.
67. A dosage form comprising the pharmaceutical composition of claim 1 formulated as a solution, a cream, a lotion, an ointment, a suppository, a spray, an aerosol, a paste or a gel.
68. The dosage form of claim 65, wherein the capsule is a hard gelatin capsule, a soft gelatin capsule, a starch capsule or an enteric coated capsule.
69. The pharmaceutical composition of claim 1, which further comprises water or an aqueous buffer.
70. The pharmaceutical composition of claim 1, which further comprises an additional amount of a hydrophobic therapeutic agent, said additional amount not solubilized in the carrier.
71. A pharmaceutical composition comprising:
(a) at least one hydrophilic surfactant;
(b) at least one hydrophobic surfactant; and
(c) a hydrophobic therapeutic agent,
said pharmaceutical composition being in the form of a clear, aqueous dispersion which is substantially free of triglycerides.
72. The pharmaceutical composition of claim 71, wherein the hydrophobic surfactant is present in an amount of less than about 200% by weight, relative to the amount of the hydrophilic surfactant.
73. The pharmaceutical composition of claim 72, wherein the hydrophobic surfactant is present in an amount of less than about 100% by weight, relative to the amount of the hydrophilic surfactant.
74. The pharmaceutical composition of claim 73, wherein the hydrophobic surfactant is present in an amount of less than about 60% by weight, relative to the amount of the hydrophilic surfactant.
75. The pharmaceutical composition of claim 71, wherein the hydrophilic surfactant comprises at least one non-ionic hydrophilic surfactant having an HLB value greater than or equal to about 10.
76. The pharmaceutical composition of claim 71, wherein the hydrophilic surfactant comprises at least one ionic surfactant.
77. The pharmaceutical composition of claim 75, which further comprises at least one ionic surfactant.
78. The pharmaceutical composition of claim 75, wherein the non-ionic surfactant is selected from the group consisting of alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyethylene alkylethers; polyoxyethylene alkylphenols; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; sugar esters, sugar ethers; sucroglycerides; and mixtures thereof.
79. The pharmaceutical composition of claim 75, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
80. The pharmaceutical composition of claim 79, wherein the glyceride is a monoglyceride, diglyceride, triglyceride, or a mixture thereof.
81. The pharmaceutical composition of claim 79, wherein the reaction mixture comprises the transesterification products of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
82. The pharmaceutical composition of claim 79, wherein the polyol is glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol or a mixture thereof.
83. The pharmaceutical composition of claim 75, wherein the hydrophilic surfactant is PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, a poloxamer, or a mixture thereof.
84. The pharmaceutical composition of claim 75, wherein the hydrophilic surfactant is PEG-20 laurate, PEG-20 oleate, PEG-35 castor oil, PEG-40 palm kernel oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, polyglyceryl-10 laurate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, PEG-30 cholesterol, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, PEG-24 cholesterol, sucrose monostearate, sucrose monolaurate, a poloxamer, or a mixture thereof.
85. The pharmaceutical composition of claim 75, wherein the hydrophilic surfactant is PEG-35 castor oil, PEG40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, a poloxamer, or a mixture thereof.
86. The pharmaceutical composition of claim 76, wherein the ionic surfactant is selected from the group consisting of alkyl ammonium salts; bile acids and salts, analogues, and derivatives thereof; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides; alginate salts; propylene glycol alginate; lecithins and hydrogenated lecithins; lysolecithin and hydrogenated lysolecithins; lysophospholipids and derivatives thereof; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; and mixtures thereof.
87. The pharmaceutical composition of claim 76, wherein the ionic surfactant is selected from the group consisting of bile acids and salts, analogues, and derivatives thereof; lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides; and mixtures thereof.
88. The pharmaceutical composition of claim 76, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, chenodeoxycholate, glycodeoxycholate, glycochenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate, tauroursodeoxycholate, glycoursodeoxycholate, cholylsarcosine, N-methyl taurocholate, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, and salts and mixtures thereof.
89. The pharmaceutical composition of claim 76, wherein the ionic surfactant is selected from the group consisting of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, lysophosphatidylcholine, PEG-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, glycodeoxycholate, cholylsarcosine, caproate, caprylate, caprate, laurate, oleate, lauryl sulfate, docusate, and salts and mixtures thereof.
90. The pharmaceutical composition of claim 76, wherein the ionic surfactant is selected from the group consisting of lecithin, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, taurocholate, caprylate, caprate, oleate, lauryl sulfate, docusate, and salts and mixtures thereof.
91. The pharmaceutical composition of claim 71 wherein the hydrophobic surfactant is a compound or mixture of compounds having an HLB value less than about 10.
92. The pharmaceutical composition of claim 91, wherein the hydrophobic surfactant is selected from the group consisting of alcohols; polyoxyethylene alkylethers; fatty acids; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters; polyoxyethylene glycerides; lactic acid derivatives of mono/diglycerides; propylene glycol diglycerides; sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; transesterified vegetable oils; sterols; sterol derivatives; sugar esters; sugar ethers; sucroglycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
93. The pharmaceutical composition of claim 91, wherein the hydrophobic surfactant is selected from the group consisting of fatty acids; lower alcohol fatty acid esters; polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters; polyoxyethylene glycerides; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof.
94. The pharmaceutical composition of claim 91, wherein the hydrophobic surfactant is selected from the group consisting of lower alcohol fatty acids esters; polypropylene glycol fatty acid esters; propylene glycol fatty acid esters; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene vegetable oils; and mixtures thereof.
95. The pharmaceutical composition of claim 91, wherein the hydrophobic surfactant is a glycerol fatty acid ester, an acetylated glycerol fatty acid ester, or a mixture thereof.
96. The pharmaceutical composition of claim 95, wherein the glycerol fatty acid ester is a monoglyceride, diglyceride, or a mixture thereof.
97. The pharmaceutical composition of claim 96, wherein the fatty acid of the glycerol fatty acid ester is a C6 to C20 fatty acid or a mixture thereof.
98. The pharmaceutical composition of claim 91, wherein the hydrophobic surfactant is a reaction mixture of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
99. The pharmaceutical composition of claim 98, wherein the reaction mixture is a transesterification product of a polyol and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
100. The pharmaceutical composition of claim 98, wherein the polyol is polyethylene glycol, sorbitol, propylene glycol, pentaerythritol or a mixture thereof.
101. The pharmaceutical composition of claim 91, wherein the hydrophobic surfactant is selected from the group consisting of myristic acid; oleic acid; lauric acid; stearic acid; palmitic acid; PEG 1-4 stearate; PEG 2-4 oleate; PEG-4 dilaurate; PEG-4 dioleate; PEG-4 distearate; PEG-6 dioleate; PEG-6 distearate; PEG-8 dioleate; PEG 3-16 castor oil; PEG 5-10 hydrogenated castor oil; PEG 6-20 corn oil; PEG 6-20 almond oil; PEG-6 olive oil; PEG-6 peanut oil; PEG-6 palm kernel oil; PEG-6 hydrogenated palm kernel oil; PEG-4 capric/caprylic triglyceride, mono, di, tri, tetra esters of vegetable oil and sorbitol; pentaerythrityl di, tetra stearate, isostearate, oleate, caprylate, or caprate; polyglyceryl 2-4 oleate, stearate, or isostearate; polyglyceryl 4-10 pentaoleate; polyglyceryl-3 dioleate; polyglyceryl-6 dioleate; polyglyceryl-10 trioleate; polyglyceryl-3 distearate; propylene glycol mono- or diesters of a C6 to C20 fatty acid; monoglycerides of a C6 to C20 fatty acid; acetylated monoglycerides of C6 to C20 fatty acid; diglycerides of C6 to C20 fatty acids; lactic acid derivatives of monoglycerides; lactic acid derivatives of diglycerides; cholesterol; phytosterol; PEG 5-20 soya sterol; PEG-6 sorbitan tetra, hexastearate; PEG-6 sorbitan tetraoleate; sorbitan monolaurate; sorbitan monopalmitate; sorbitan mono, trioleate; sorbitan mono, tristearate; sorbitan monoisostearate; sorbitan sesquioleate; sorbitan sesquistearate; PEG 2-5 oleyl ether; POE 2-4 lauryl ether; PEG-2 cetyl ether; PEG-2 stearyl ether; sucrose distearate; sucrose dipalmitate; ethyl oleate; isopropyl myristate; isopropyl palmitate; ethyl linoleate; isopropyl linoleate; poloxamers; and mixtures thereof.
102. The pharmaceutical composition of claim 91, wherein the hydrophobic surfactant is selected from the group consisting of oleic acid; lauric acid; glyceryl monocaprate; glyceryl monocaprylate; glyceryl monolaurate; glyceryl monooleate; glyceryl dicaprate; glyceryl dicaprylate; glyceryl dilaurate; glyceryl dioleate; acetylated monoglycerides; propylene glycol oleate; propylene glycol laurate; polyglyceryl-3 oleate; polyglyceryl-6 dioleate; PEG-6 corn oil; PEG-20 corn oil; PEG-20 almond oil; sorbitan monooleate; sorbitan monolaurate; POE-4 lauryl ether; POE-3 oleyl ether; ethyl oleate; poloxamers; and mixtures thereof.
103. The pharmaceutical composition of claim 71, wherein the clear aqueous dispersion has a particle size distribution having an average particle size of less than about 100 nm.
104. The pharmaceutical composition of claim 103, wherein the clear aqueous dispersion has a particle size distribution having an average particle size of less than about 50 nm.
105. The pharmaceutical composition of claim 103, wherein the clear aqueous dispersion has a particle size distribution having an average particle size of less than about 20 nm.
106. The pharmaceutical composition of claim 71, wherein the clear aqueous dispersion has an absorbance of less than about 0.1 at 400 nm when the ratio of the weight of water to the total weight of the hydrophilic surfactant, the hydrophobic surfactant and the therapeutic agent is 100:1.
107. The pharmaceutical composition of claim 106, wherein the absorbance is less than about 0.01.
108. The pharmaceutical composition of claim 71, wherein the hydrophobic therapeutic agent has an intrinsic water solubility of less than about 1% by weight at 25° C.
109. The pharmaceutical composition of claim 108, wherein the intrinsic water solubility is less than about 0.1% by weight at 25° C.
110. The pharmaceutical composition of claim 109, wherein the intrinsic water solubility is less than about 0.01% by weight at 25° C.
111. The pharmaceutical composition of claim 71, wherein the therapeutic agent is a drug, a vitamin, a nutritional supplement, a cosmeceutical, or a mixture thereof.
112. The pharmaceutical composition of claim 111, wherein the therapeutic agent is a polyfunctional hydrophobic drug, a lipophilic drug, a pharmaceutically acceptable salt, isomer or derivative thereof, or a mixture thereof.
113. The pharmaceutical composition of claim 111, wherein the therapeutic agent is selected from the group consisting of analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, erectile dysfunction improvement agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, β-Blockers, cardiac inotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastro-intestinal agents, histamine H,-receptor antagonists, keratolytics, lipid regulating agents, anti-anginal agents, nutritional agents, opioid analgesics, sex hormones, stimulants, muscle relaxants, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, anti-benign prostate hypertrophy agents, essential fatty acids, non-essential fatty acids, and mixtures thereof.
114. The pharmaceutical composition of claim 111, wherein the therapeutic agent is tramadol, celecoxib, etodolac, refocoxib, oxaprozin, leflunomide, diclofenac, nabumetone, ibuprofen, flurbiprofen, tetrahydrocannabinol, capsaicin, ketorolac, albendazole, ivermectin, amiodarone, zileuton, zafirlukast, albuterol, montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, dicoumarol, tirofibran, cilostazol, ticlidopine, clopidrogel, oprevelkin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, glipizide, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, nifedipine, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minoxidil, terzosin, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratiptan, rizatriptan, aminogluthemide, busulphan, cyclosporine, mitoxantrone, irinotecan, etoposide, teniposide, paclitaxel, tacrolimus, sirolimus, tamoxifen, camptothecan, topotecan, nilutanide, bicalutanide, ephedrine, toremifene, atovaquone, metronidazole, furazolidone, paricalcitol, benzonatate, midazolam, zolpidem, gabapentin, zopiclone, digoxin, beclomethsone, budesonide, betamethasone, prednisolone, cisapride, cimetidine, loperamide, famotidine, lanosprazole, rabeprazole, nizatidine, omeprazole, citrizine, cinnarizine, dexchlopheniramine, loratadine, clemastine, fexofenadine, chlorpheniramine, acutretin, tazarotene, calciprotiene, calcitriol, targretin, ergocalciferol, cholecalciferol, isotreinoin, tretinoin, calcifediol, fenofibrate, probucol, gemfibrozil, cerivistatin, pravastatin, simvastatin, fluvastatin, atorvastatin, tizanidine, dantrolene, isosorbide dinatrate, a carotene, dihydrotachysterol, vitamin A, vitamin D, vitamin E, vitamin K, an essential fatty acid source, codeine, fentanyl, methadone, nalbuphine, pentazocine, clomiphene, danazol, dihydro epiandrosterone, medroxyprogesterone, progesterone, rimexolone, megesterol acetate, osteradiol, finasteride, mefepristone, amphetamine, L-thryroxine, tamsulosin, methoxsalen, tacrine, donepezil, raloxifene, vertoporfin, sibutramine, pyridostigmine, a pharmaceutically acceptable salt, isomer, or derivative thereof, or a mixture thereof.
115. The pharmaceutical composition of claim 71, wherein the hydrophobic therapeutic agent is selected from the group consisting of tramadol, celecoxib, etodolac, refocoxib, oxaprozin, leflunomide, diclofenac, nabumetone, ibuprofen, flurbiprofen, tetrahydrocannabinol, capsaicin, ketorolac, albendazole, ivermectin, amiodarone, zileuton, zafirlukast, albuterol, montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, glipizide, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratiptan, rizatriptan, aminogluthemide, busulphan, cyclosporine, mitoxantrone, irinotecan, etoposide, teniposide, paclitaxel, tacrolimus, sirolimus, tamoxifen, camptothecan, topotecan, nilutanide, bicalutanide, pseudo-ephedrine, toremifene, atovaquone, metronidazole, furzolidone, paricalcitol, benzonatate, midazolam, zolpidem, gabapentin, zopiclone, digoxin, cisapride, cimetidine, loperamide, famotidine, lanosprazole, rabeprazole, nizatidine, omeprazole, citrizine, cinnarizine, dexchlopheniramine, loratadine, clemastine, fexofenadine, chlorpheniramine, acutretin, tazarotene, calciprotiene, calcitriol, targretin, ergocalciferol, cholecaliferol, isotreinoin, tretinoin, calcifediol, fenofibrate, probucol, gemfibrozil, cerivistatin, pravastatin, simvastatin, fluvastatin, atorvastatin, tizanidine, dantrolene, carotenes, dihyrotachysterol, vitamin A, vitamin D, vitamin E, vitamin K, essential fatty acid sources, codeine, fentanyl, methdone, nalbuphine, pentazocine, clomiphene, danazol, dihydro epiandrosterone, mmedroxyprogesterone, progesterone, rimexolone, megesterol acetate, osteradiol, finasteride, mefepristone, amphetamine, L-thryroxine, tamsulosin, methoxsalen, tacrine, donepezil, raloxifene, vertoporfin, sibutramine, pyridostigmine, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
116. The pharmaceutical composition of claim 71, wherein the therapeutic agent is selected from the group consisting of tramadol, celecoxib, etodolac, refocoxib, oxaprozin, leflunomide, diclofenac, nabumetone, ibuprofen, flurbiprofen, tetrahydrocannabinol, capsaicin, ketorolac, ivermectin, amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, glipizide, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbenafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine, naratiptan, rizatriptan, aminogluthemide, busulphan, cyclosporine, mitoxantrone, irinotecan, etoposide, teniposide, paclitaxel, tacrolimus, sirolimus, tamoxifen, camptothecan, topotecan, nilutanide, bicalutanide, toremifene, atovaquone, metronidazole, furzolidone, paricalcitol, benzonatate, cisapride, cimetidine, loperamide, famotidine, lanosprazole, rabeprazole, nizatidine, omeprazole, citrizine, cinnarizine, dexchlopheniramine, loratadine, clemastine, fexofenadine, chlorpheniramine, acutretin, tazarotene, calciprotiene, calcitriol, targretin, ergocalciferol, cholecaliferol, isotreinoin, tretinoin, calcifediol, fenofibrate, probucol, simvastatin, atorvastatin, tizanidine, dantrolene, carotenes, dihyrotachysterol, vitamin A, vitamin D, vitamin E, vitamin K, essential fatty acid sources, danazol, dihydro epiandrosterone, medroxyprogesterone, progesterone, rimexolone, megesterol acetate, osteradiol, finasteride, mefepristone, raloxifene, L-thryroxine, tamsulosin, methoxsalen, pharmaceutically acceptable salts, isomers and derivative thereof, and mixtures thereof.
117. The pharmaceutical composition of claim 71, wherein the hydrophobic therapeutic agent is selected from the group consisting of sildenafil citrate, amlodipine, tramadol, celecoxib, refocoxib, oxaprozin, nabumetone, ibuprofen, terbenafine, itraconazole, zileuton, zafirlukast, cisapride, fenofibrate, tizanidine, nizatidine, fexofenadine, loratadine, famotidine, paricalcitol, atovaquone, nabumetone, tetrahydrocannabinol, megesterol acetate, repaglinide, progesterone, rimexolone, cyclosporine, tacrolimus, sirolimus, teniposide, paclitaxel, pseudo-ephedrine, troglitazone, rosiglitazone, finasteride, vitamin A, vitamin D, vitamin E, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
118. The pharmaceutical composition of claim 71, wherein the hydrophobic therapeutic agent is progesterone or cyclosporin.
119. The pharmaceutical composition of claim 71, which further comprises a solubilizer.
120. The pharmaceutical composition of claim 119, wherein the solubilizer is selected from the group consisting of alcohols, polyols, amides, esters, polyethylene glycol ethers and mixtures thereof.
121. The pharmaceutical composition of claim 120, wherein the alcohol or polyol is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives, and mixtures thereof.
122. The pharmaceutical composition of claim 120, wherein the amide is selected from the group consisting of 2-pyrrolidone, 2-piperidone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
123. The pharmaceutical composition of claim 120, wherein the ester is selected from the group consisting of ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof, and mixtures thereof.
124. The pharmaceutical composition of claim 119, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins, clodextrins and derivatives thereof, ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof, 2-pyrrolidone, 2-piperidone, ε-caprolactam, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethyl pyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, glycofurol, methoxy PEG, and mixtures thereof.
125. The pharmaceutical composition of claim 119, wherein the solubilizer is selected from the group consisting of ethanol, isopropanol, benzyl alcohol, ethylene glycol, propylene glycol, 1,3-butanediol, glycerol, pentaerythritol, sorbitol, glycofurol, transcutol, dimethyl isosorbide, polyethylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxypropylcyclodextrins, sulfobutyl ether derivatives of cyclodextrins, ethyl propionate, tributylcitrate, triethylcitrate, ethyl oleate, ethyl caprylate, triacetin, β-butyrolactone and isomers thereof, 2-pyrrolidone, N-methylpyrrolidone, N-ethylpyrrolidone, N-hydroxyethylpyrrolidone, N-octylpyrrolidone, N-laurylpyrrolidone, dimethylacetamide, polyvinylpyrrolidone, and mixtures thereof.
126. The pharmaceutical composition of claim 119, wherein the solubilizer is triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, dimethyl isosorbide, or a mixture thereof.
127. The pharmaceutical composition of claim 119, wherein the solubilizer is triacetin, ethanol, polyethylene glycol 400, glycofurol, propylene glycol or a mixture thereof.
128. The pharmaceutical composition of claim 119, wherein the solubilizer is present in the composition in an amount of about 400% or less by weight, based on the total weight of the surfactants.
129. The pharmaceutical composition of claim 128, wherein the solubilizer is present in the composition in an amount of about 200% or less by weight, based on the total weight of the surfactants.
130. The pharmaceutical composition of claim 129, wherein the solubilizer is present in the composition in an amount of about 100% or less by weight, based on the total weight of the surfactants.
131. The pharmaceutical composition of claim 130, wherein the solubilizer is present in the composition in an amount of about 50% or less by weight, based on the total weight of the surfactants.
132. The pharmaceutical composition of claim 131, wherein the solubilizer is present in the composition in an amount about 25% or less by weight, based on the total weight of the surfactants.
133. The pharmaceutical composition of claim 71, which further comprises an antioxidant, a preservative, a chelating agent, a viscomodulator, a tonicifier, a flavorant, a colorant, an odorant, an opacifier or a mixture thereof.
134. The pharmaceutical composition of claim 71, which further comprises an additional amount of a hydrophobic therapeutic agent, said additional amount not solubilized in the carrier.
135. A pharmaceutical composition comprising:
(a) a carrier,
 said carrier comprising:
(i) at least one hydrophilic surfactant; and
(ii) at least one hydrophobic surfactant,
 said hydrophilic and hydrophobic surfactants being present in amounts such that upon mixing with an aqueous solution the carrier forms a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants;
(b) a first amount of a hydrophobic therapeutic agent, said first amount being solubilized in the carrier; and
(c) a second amount of a hydrophobic therapeutic agent, said second amount not solubilized in the clear aqueous dispersion,
said composition being substantially free of triglycerides.
136. A method of treating an animal with a hydrophobic therapeutic agent, the method comprising:
providing a dosage form of a pharmaceutical composition comprising:
a hydrophobic therapeutic agent; and
a carrier,
 said carrier comprising:
at least one hydrophilic surfactant; and
at least one hydrophobic surfactant,
 said hydrophilic and hydrophobic surfactants being present in amounts such that upon mixing with an aqueous solution the carrier forms a clear aqueous dispersion of the hydrophilic and hydrophobic surfactants containing the hydrophobic therapeutic agent,
said composition being substantially free of triglycerides; and
administering said dosage form to said animal.
137. The method of claim 136, wherein the dosage form is a capsule, a cream, a lotion, an ointment, a suppository, a paste or a gel.
138. The method of claim 136, wherein the dosage form is administered by an oral, parenteral, topical, transdermal, ocular, pulmonary, vaginal, rectal or transmucosal route.
139. The method of claim 136, wherein the animal is a mammal.
140. The method of claim 139, wherein the mammal is a human.
US09/898,553 1999-02-26 2001-07-02 Compositions and methods for improved delivery of hydrophobic agents Expired - Lifetime US6451339B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/898,553 US6451339B2 (en) 1999-02-26 2001-07-02 Compositions and methods for improved delivery of hydrophobic agents
US10/074,687 US7374779B2 (en) 1999-02-26 2002-02-11 Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US10/158,206 US20030104048A1 (en) 1999-02-26 2002-05-29 Pharmaceutical dosage forms for highly hydrophilic materials

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/258,654 US6294192B1 (en) 1999-02-26 1999-02-26 Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US09/898,553 US6451339B2 (en) 1999-02-26 2001-07-02 Compositions and methods for improved delivery of hydrophobic agents

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/258,654 Continuation US6294192B1 (en) 1999-02-26 1999-02-26 Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US10/074,687 Continuation US7374779B2 (en) 1999-02-26 2002-02-11 Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/074,687 Continuation-In-Part US7374779B2 (en) 1999-02-26 2002-02-11 Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US10/158,206 Continuation-In-Part US20030104048A1 (en) 1999-02-26 2002-05-29 Pharmaceutical dosage forms for highly hydrophilic materials

Publications (2)

Publication Number Publication Date
US20020012680A1 true US20020012680A1 (en) 2002-01-31
US6451339B2 US6451339B2 (en) 2002-09-17

Family

ID=22981541

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/258,654 Expired - Lifetime US6294192B1 (en) 1999-02-26 1999-02-26 Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US09/898,553 Expired - Lifetime US6451339B2 (en) 1999-02-26 2001-07-02 Compositions and methods for improved delivery of hydrophobic agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/258,654 Expired - Lifetime US6294192B1 (en) 1999-02-26 1999-02-26 Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents

Country Status (12)

Country Link
US (2) US6294192B1 (en)
EP (2) EP1158959B1 (en)
JP (2) JP2002537317A (en)
AT (1) ATE537812T1 (en)
AU (1) AU771659B2 (en)
CA (1) CA2365536C (en)
CY (1) CY1112580T1 (en)
DK (1) DK1158959T3 (en)
ES (1) ES2379626T3 (en)
NZ (1) NZ513810A (en)
PT (1) PT1158959E (en)
WO (1) WO2000050007A1 (en)

Cited By (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020005437A1 (en) * 2000-06-08 2002-01-17 Ketcha Marcia Mary Methods and personal protection devices for repelling insects
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US20020107250A1 (en) * 2000-04-18 2002-08-08 Madhusudan Hariharan Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor
US20030138455A1 (en) * 1997-09-04 2003-07-24 Hertelendy, Pharm.D.,Ph.D Zsolt Istvan Urogential or anorectal transmucosal vaccine delivery system
US20030180244A1 (en) * 2001-12-21 2003-09-25 Soane David S. Use of oligomers and polymers for drug solublization, stabilization, and delivery
US20030224043A1 (en) * 2002-02-01 2003-12-04 Pfizer Inc. Immediate release dosage forms containing solid drug dispersions
US20040028728A1 (en) * 1999-03-11 2004-02-12 Fujisawa Pharmaceutical Company, Ltd. Liposome preparations
US20040071767A1 (en) * 2002-10-11 2004-04-15 Gregor Cevc NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20040167113A1 (en) * 2002-11-18 2004-08-26 Solomon Ugashe Bis-aryl sulfonamides
US20040175435A1 (en) * 1998-09-02 2004-09-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
US20040245662A1 (en) * 2000-12-22 2004-12-09 Mahesh Chaubal Method for preparing submicron particles of antineoplastic agents
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1501496A2 (en) * 2002-05-04 2005-02-02 Cydex Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
US20050137179A1 (en) * 2002-11-18 2005-06-23 Solomon Ungashe Bis-aryl sulfonamides
US20050137193A1 (en) * 2002-11-18 2005-06-23 Chemocentreyx Aryl sulfonamides
US20050209172A1 (en) * 2004-03-17 2005-09-22 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050220871A1 (en) * 2000-03-28 2005-10-06 Schwarz Franz X Taste masking granules
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US20050239905A1 (en) * 2002-05-22 2005-10-27 Tomonori Hamawaki Smooth muscle peristole inhibitor
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US20050250738A1 (en) * 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US20050266071A1 (en) * 2004-05-25 2005-12-01 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050271720A1 (en) * 2004-06-04 2005-12-08 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
KR100573289B1 (en) * 2002-07-20 2006-04-24 대화제약 주식회사 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20060147522A1 (en) * 2004-05-25 2006-07-06 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060204585A1 (en) * 2003-07-18 2006-09-14 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015710A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015694A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015692A1 (en) * 2005-07-13 2007-01-18 Chang James N Cyclosporin compositions
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US20070027072A1 (en) * 2005-07-27 2007-02-01 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1749528A1 (en) 2005-08-05 2007-02-07 Pharma C S.A. Pharmaceutical combinations containing a mu opioid agonist and an inhibitor of NO production
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US20070128298A1 (en) * 2005-11-22 2007-06-07 Cowley Michael A Compositions and methods for increasing insulin sensitivity
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US20070167358A1 (en) * 2005-10-14 2007-07-19 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
US20070232566A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070281021A1 (en) * 2006-06-05 2007-12-06 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1871384A2 (en) * 2005-04-15 2008-01-02 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US20080045583A1 (en) * 2006-08-18 2008-02-21 David Delmarre Stable levetiracetam compositions and methods
US20080057129A1 (en) * 2006-04-03 2008-03-06 Lerner E I Drug microparticles
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
US20080188540A1 (en) * 2007-02-05 2008-08-07 Wyeth Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US20080261966A1 (en) * 2007-04-23 2008-10-23 Solomon Ungashe Bis-aryl sulfonamides
US7459171B2 (en) 1999-07-05 2008-12-02 Idea Ag Method for the improvement of transport across adaptable semi-permeable barriers
WO2008147822A1 (en) 2007-05-22 2008-12-04 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20100196427A1 (en) * 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
WO2010117233A2 (en) * 2009-04-09 2010-10-14 한올바이오파마주식회사 Stable pharmaceutical composition containing fluvastatin and method for manufacturing the same
US20100280074A1 (en) * 2002-05-24 2010-11-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
WO2010140061A2 (en) 2009-06-03 2010-12-09 John Charles Mayo Formulations for the treatment of deep tissue pain
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US7867480B1 (en) 1999-01-27 2011-01-11 Gregor Cevc Non-invasive vaccination through the skin
US20110059170A1 (en) * 2006-11-09 2011-03-10 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
WO2011035332A1 (en) 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
US20110073518A1 (en) * 2003-12-31 2011-03-31 Cima Labs Inc. Generally Linear Effervescent Oral Fentanyl Dosage Form and Methods of Administering
US7927622B1 (en) 1999-01-27 2011-04-19 Gregor Cevc Methods of transnasal transport/immunization with highly adaptable carriers
EP2314590A1 (en) 2005-11-10 2011-04-27 ChemoCentryx, Inc. Substituted quinolones and methods of use
US20110098289A1 (en) * 2002-05-17 2011-04-28 Gadde Kishore M Method for treating obesity
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20110160168A1 (en) * 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20110172260A1 (en) * 2010-01-11 2011-07-14 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
EP2354126A1 (en) 2005-01-14 2011-08-10 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
US20110207803A1 (en) * 2010-02-19 2011-08-25 Kiichiro Nabeta Taxane Pro-Emulsion Formulations and Methods Making and Using the Same
US20110218246A1 (en) * 2005-12-29 2011-09-08 Depomed, Inc Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US20120046237A1 (en) * 1998-04-08 2012-02-23 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US20120148671A1 (en) * 2001-10-25 2012-06-14 Depomed, Inc. Gastric retained gabapentin dosage form
US20120177692A1 (en) * 2007-08-09 2012-07-12 Ems S/A Delivery systems for solubilising water-insoluble pharmaceutical active ingredients
WO2012039596A3 (en) * 2010-09-22 2012-08-16 Craun Research Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
US8440232B2 (en) 2001-10-25 2013-05-14 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
WO2013082429A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
US20130211195A1 (en) * 2010-10-22 2013-08-15 Fukuoka University Endoscopic observation method and composition for improving diagnostic performance involving applying useful white opaque substance to diagnosis of gastric epithelial tumors (adenoma or gastric cancer)
WO2013144289A1 (en) 2012-03-29 2013-10-03 Sequessome Technology Holdings Limited Vesicular formulations
WO2013171131A1 (en) 2012-05-14 2013-11-21 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
WO2013171132A1 (en) 2012-05-14 2013-11-21 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
US8629111B2 (en) 2003-09-15 2014-01-14 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20140030202A1 (en) * 2010-11-15 2014-01-30 L'oreal Solid cosmetic composition in compact powder form
US20140121178A1 (en) * 2011-06-24 2014-05-01 Acenda Pharma Inc. Method and improved pharmaceutical composition for improving the absorption of an ester prodrug
US20140193471A1 (en) * 2007-12-14 2014-07-10 L'oreal Solid antiperspirant and/or deodorant composition in the form of a water-in-oil emulsion based on silicone emulsifiers and on waxes; method for treating body odours
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20150093348A1 (en) * 2013-09-30 2015-04-02 L'oreal Self-foaming cleansing system
WO2015059466A1 (en) * 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
WO2015103447A1 (en) * 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
AU2013213706B2 (en) * 2005-11-07 2016-04-14 Murty Pharmaceuticals, Inc An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
WO2016105465A1 (en) * 2014-12-23 2016-06-30 Variant Pharmaceuticals, Inc. Oral compositions for insoluble compounds
US9452179B2 (en) 2009-08-21 2016-09-27 Sequessome Technology Holdings Limited Vesicular formulations
EP3078658A1 (en) 2008-12-22 2016-10-12 ChemoCentryx, Inc. C5ar antagonists
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20180092812A1 (en) * 2010-11-15 2018-04-05 L'oréal Solid cosmetic composition in compact powder form
WO2018091668A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
AU2016203127B2 (en) * 2005-11-07 2018-07-12 Murty Pharmaceuticals, Inc An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
US10391056B2 (en) 2011-11-03 2019-08-27 Taiwan Lipsome Company, LTD. Pharmaceutical compositions of hydrophobic camptothecin derivatives
US10617696B2 (en) 2010-04-12 2020-04-14 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
US20210330698A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers
WO2022040807A1 (en) * 2020-08-28 2022-03-03 Triple Hair Inc. Formulations for reducing hair loss and/or increasing hair regrowth
US11267790B2 (en) 2019-07-08 2022-03-08 Rezolute, Inc. Processes for preparing plasma kallikrein inhibitors
US11337987B1 (en) 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders
US11617758B2 (en) 2009-12-31 2023-04-04 Marius Pharmaceuticals Llc Emulsion formulations

Families Citing this family (543)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
IS4518A (en) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group New vaccine formulation
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
TR200101790T2 (en) 1998-12-23 2001-10-22 Idea Ag. Formula developed for uncommon in vivo topical applications
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6747058B1 (en) * 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US7648696B2 (en) * 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
ECSP003699A (en) * 1999-10-08 2002-04-23 Smithkline Beecham Corp FAB I INHIBITORS
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US6524623B1 (en) * 1999-11-12 2003-02-25 Milton Hodosh Therapeutic compositions and methods of use thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
SE0000773D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
FR2807662A1 (en) * 2000-04-12 2001-10-19 Cll Pharma PROCESS FOR STABILIZING THE SIZE OF AN ACTIVE INGREDIENT DISPERSE IN A LIQUID AND ITS APPLICATIONS
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US6596306B1 (en) * 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
ES2225600T3 (en) * 2000-09-22 2005-03-16 Galephar M/F SEMI-SOLID COMPOSITION OF ISOTRETINOIN.
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
AU2001293177A1 (en) * 2000-09-27 2002-04-08 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO2002026324A2 (en) * 2000-09-27 2002-04-04 Sonus Pharmaceuticals, Inc. Tocol-based compositions containing amiodarone
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
ATE414511T1 (en) * 2000-12-05 2008-12-15 Los Angeles Childrens Hospital PHARMACEUTICAL COMPOSITIONS OF FENRETINIDE WITH INCREASED BIOAVAILABILITY AND METHOD FOR USE THEREOF
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
FR2818905A1 (en) * 2000-12-28 2002-07-05 Cll Pharma MICELLAR COLLOIDAL PHARMACEUTICAL COMPOSITIONS COMPRISING A LIPOPHILIC ACTIVE INGREDIENT
EP2292211A3 (en) * 2001-02-14 2014-01-01 GW Pharma Limited Mucoadhesive pharmaceutical formulations
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
DK1560584T3 (en) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitors
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
SK14762003A3 (en) * 2001-05-31 2004-08-03 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase- 2 inhibitor a monohydric alcohol
JP2003063965A (en) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc Cilostazol aqueous composition for injection
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
EP1435781A4 (en) * 2001-06-23 2007-06-20 Lyotropic Therapeutics Llc Solvent system
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
EP1406594B1 (en) 2001-07-06 2019-06-05 Veloxis Pharmaceuticals A/S Controlled agglomeration
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
FR2827770B1 (en) * 2001-07-27 2005-08-19 Gattefosse Ets Sa ORAL PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT LIKELY TO BE SUBSTANTIALLY EFFECT OF FIRST INTESTINAL PASSAGE
WO2003016350A1 (en) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
SE0102855D0 (en) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
GB0121580D0 (en) * 2001-09-06 2001-10-24 Syngenta Ltd Novel compounds
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
BR0213661A (en) * 2001-10-19 2004-10-26 Isotechnika Inc Microemulsion preconcentrate and method for its preparation, pharmaceutical formulation and method for its preparation, method for producing immunosuppression, method for enhancing isatx247 immunosuppressive effects, use of pharmaceutical formulation
CN1606445A (en) * 2001-10-23 2005-04-13 兰贝克塞实验室有限公司 Process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2-enzyme inhibitors
WO2003035063A1 (en) * 2001-10-25 2003-05-01 Dinesh Shantilal Patel Novel preparation of selective cyclooxygenase ii inhibitors
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (en) 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
DE60225169D1 (en) * 2001-11-09 2008-04-03 Quadra Logic Tech Inc PHOTODYNAMIC THERAPY FOR THE TREATMENT OF HAIR LOSS
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
DE10159120B4 (en) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroid hormone-containing transdermal therapeutic systems containing propylene glycol monocaprylate and its use
JP2005515996A (en) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド Pharmaceutical composition comprising active vitamin D compound
US20050129718A1 (en) * 2001-12-20 2005-06-16 Sherman Bernard C. Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
KR100441167B1 (en) * 2001-12-27 2004-07-21 씨제이 주식회사 Composition of microemulsion preconcentrate
US20030129253A1 (en) * 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2003070281A1 (en) * 2002-02-15 2003-08-28 Nexmed (Holdings), Inc. Prostaglandin composition for the treatment of erectile dysfunction
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
BR0307913A (en) * 2002-02-25 2005-01-11 Lyfjathroun Hf Use of a composition, pharmaceutical composition for nasal administration, and methods to elicit a therapeutic, prophylactic and / or diagnostic effect in a mammal, to obtain a rapid onset of a therapeutic, prophylactic and / or diagnostic effect of an active substance in a mammal and to improve the bioavailability of a therapeutic, prophylactic and / or diagnostic effect of an active substance in a mammal
ES2286406T3 (en) * 2002-02-26 2007-12-01 Astrazeneca Ab PHARMACEUTICAL FORMULATION OF IRESSA THAT INCLUDES A WATER SOLUBLE CELLULOSE DERIVATIVE.
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
AU2003214538A1 (en) * 2002-03-01 2003-09-16 Novagali Pharma Sa Self emulsifying drug delivery systems for poorly soluble drugs
US6623780B1 (en) 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
WO2003082303A1 (en) * 2002-03-29 2003-10-09 Wisconsin Alumni Research Foundation Polymeric micelle formulations of hydrophobic compounds and methods
AUPS158502A0 (en) * 2002-04-08 2002-05-16 Dermcare-Vet Pty Ltd Allergic dermatitis composition and method of treatment
JP4599604B2 (en) * 2002-04-19 2010-12-15 カーギル テクスチュアライジング ソリューションズ ドイチュラント ゲゼルシャフト ミット ベシュレクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト Matrix containing bioactive phospholipid-containing components
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
GB0211949D0 (en) * 2002-05-23 2002-07-03 Glaxo Group Ltd Novel compounds compositions and processes
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20040034021A1 (en) * 2002-06-03 2004-02-19 Michaelis Arthur F. Intravenous rifalazil formulation and methods of use thereof
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
JP2005531606A (en) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド Nanoparticulate sterol formulations and sterol combinations
US7306819B2 (en) 2002-06-12 2007-12-11 The Coca-Cola Company Beverages containing plant sterols
CN100563466C (en) 2002-06-12 2009-12-02 可口可乐公司 The beverage that contains phytosterol
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
ITMI20021392A1 (en) * 2002-06-25 2003-12-29 Nicox Sa PHARMACEUTICAL FORMS FOR THE ORAL ADMINISTRATION OF LIQUID DRUGS AT AMBIENT TEMPERATURE EQUIPPED WITH BETTER BIOAVAILABILITY
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
AR039744A1 (en) * 2002-06-26 2005-03-09 Alza Corp METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
CA2491572C (en) 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2004006921A1 (en) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7608252B2 (en) * 2002-07-19 2009-10-27 The Gillette Company Shave gel composition containing polyglyceryl ester surfactant
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
KR100533458B1 (en) * 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
NZ537543A (en) * 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
AU2002950744A0 (en) * 2002-08-13 2002-09-12 Medihoney Pty Ltd Composition
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
DE10244847A1 (en) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medical device for drug delivery
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
CA2499819A1 (en) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
AU2003285012A1 (en) * 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
KR100508518B1 (en) * 2002-11-13 2005-08-17 한미약품 주식회사 Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby
IS6633A (en) * 2002-11-22 2004-05-23 Omega Farma Ehf. Compositions of finasteride tablets
WO2004047752A2 (en) * 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
US20040110828A1 (en) * 2002-11-27 2004-06-10 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
US7368418B2 (en) * 2002-12-02 2008-05-06 Diamond Chemical Company, Inc. Laundry compositions
US20080188392A1 (en) * 2002-12-02 2008-08-07 Diamond Chemical Company, Inc. Laundry Compositions
SI1575951T1 (en) * 2002-12-06 2014-10-30 Debiopharm International Sa Forum "Apres-Demain" Heterocyclic compounds, methods of making them and their use in therapy
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
US8003690B2 (en) * 2002-12-13 2011-08-23 Jagotec Ag Topical nanoparticulate spironolactone formulation
US6979672B2 (en) * 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
DE60336925D1 (en) * 2002-12-31 2011-06-09 Transdermal Biotechnology Inc STABLE COMPOSITIONS FOR TOPICAL DRUG DELIVERY
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
JP4567945B2 (en) * 2003-01-17 2010-10-27 太陽化学株式会社 Ubidecarenone formulation
US20040265291A1 (en) * 2003-01-24 2004-12-30 Flora Technology Inc. Compositions and methods for restoring bacterial flora
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
SI1603513T1 (en) * 2003-03-04 2021-04-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
DE602004016831D1 (en) 2003-03-17 2008-11-13 Affinium Pharm Inc PHARMACEUTICAL COMPOSITIONS INHIBITORS OF FAB I AND OTHER ANTIBIOTICS CONTAINED
CA2519195C (en) * 2003-03-18 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch containing non-steroidal anti-inflammatory agent
US20040185009A1 (en) * 2003-03-19 2004-09-23 Dexcel Pharma Technologies Ltd. Composition and device for treating periodontal diseases
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
EP1610742B1 (en) 2003-04-10 2015-01-21 Neurogesx, Inc. Uses and compositions for administration of capsaicin
WO2004093993A1 (en) * 2003-04-23 2004-11-04 Qlt Inc. Hair growth
BRPI0410646A (en) * 2003-05-20 2006-07-04 Ranbaxy Lab Ltd Acitretin pharmaceutical compositions and process for their preparation
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20040258754A1 (en) * 2003-06-18 2004-12-23 Valery Alakhov Compositions for oral administration of camptothecin and its analogs
EP1644004A4 (en) * 2003-06-20 2010-10-06 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
KR100581169B1 (en) * 2003-07-07 2006-05-17 한국유나이티드제약 주식회사 Formulation of terbinapine improved solubility and process for preparing the same
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
ATE540671T1 (en) * 2003-08-04 2012-01-15 Bend Res Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
BRPI0413353A (en) * 2003-08-06 2006-10-10 Nirmal Mulye pharmaceutical composition containing water soluble drug
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
GB2388581A (en) * 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070104809A1 (en) 2003-08-22 2007-05-10 Danisco A/S Composition comprising a bacteriocin and an extract from a plant of the labiatae family
JP2007503389A (en) * 2003-08-22 2007-02-22 アルザ・コーポレーシヨン Staged delivery of topiramate over long periods of time
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2564227A1 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
US20050123602A1 (en) * 2003-09-25 2005-06-09 Michaelis Arthur F. Rifalazil formulations
TR200301614A2 (en) * 2003-09-26 2005-10-21 Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş. New method for the preparation of atorvastatin calcium tablet formulation
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
KR20060085682A (en) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 A solid dosage form comprising a fibrate and a statin
KR20130103818A (en) 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 A solid dosage form comprising a fibrate
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
SI1530965T1 (en) 2003-11-11 2006-06-30 Mattern Udo Controlled release delivery system of sexual hormones for nasal application
WO2005046651A1 (en) * 2003-11-12 2005-05-26 Ranbaxy Laboratories Limited Liquid filled capsules of doxycycline
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CZ300438B6 (en) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Process for preparing solid medicament form for oral administration with instantaneous release of active substance and containing as the active substance finasteride polymorphous form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1706128B1 (en) 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
JP2007516259A (en) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー Method for preparing mixed phase co-crystal with activator
PE20050596A1 (en) * 2003-12-19 2005-10-18 Novartis Ag MICROEMULSION INCLUDING A RENIN INHIBITOR
JP2007516297A (en) * 2003-12-23 2007-06-21 アルザ・コーポレーシヨン Method and dosage form for increasing the solubility of a pharmaceutical composition for controlled delivery
CA2551815A1 (en) * 2003-12-29 2005-07-21 Alza Corporation Novel drug compositions and dosage forms
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
AU2005206084A1 (en) * 2004-01-09 2005-08-04 Wyeth Microemulsions for pharmaceutical compositions
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
JP2005255677A (en) * 2004-02-12 2005-09-22 Nof Corp Cyclosporine preparation
US7084247B2 (en) * 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
US20050202051A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical vehicle
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
ES2660172T3 (en) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injectable composition comprising sodium deoxycholate
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
EP1755720A1 (en) * 2004-05-20 2007-02-28 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
ES2515101T3 (en) * 2004-06-04 2014-10-29 Debiopharm International Sa Acrylamide derivatives as antibiotic agents
US20050271594A1 (en) * 2004-06-04 2005-12-08 Groenewoud Pieter J Abuse resistent pharmaceutical composition
GB2429916A (en) * 2004-06-07 2007-03-14 Strides Arcolab Ltd Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
EP1765300A2 (en) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
PT1765292T (en) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Abuse-deterrent drug formulations
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
DE102004038980A1 (en) * 2004-08-10 2006-02-23 Cognis Deutschland Gmbh & Co. Kg Anti-fogging agent for plastics
JP2008510804A (en) * 2004-08-23 2008-04-10 オークランド ユニサービシズ リミテッド Stomach therapy and composition therefor
US20060045914A1 (en) * 2004-08-26 2006-03-02 Isp Investments Inc. Matrix composition for stable microemulsions
JP4829120B2 (en) * 2004-10-01 2011-12-07 株式会社ヤクルト本社 Irinotecanic acid addition salt
US20060088590A1 (en) * 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
EP1812072B1 (en) * 2004-11-17 2008-10-22 Ares Trading S.A. Benzothiazole formulations and use thereof
EP1817012A2 (en) * 2004-11-24 2007-08-15 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
CN101132781A (en) * 2004-12-09 2008-02-27 茵西斯医疗公司 Room-temperature stable dronabinol formulations
CN101087589B (en) * 2004-12-24 2013-01-30 新梅斯托克尔克公司 Solid pharmaceutical composition comprising valsartan
JP2008525313A (en) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-dementia drug stabilization method
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
CA2600054A1 (en) * 2005-03-09 2006-09-21 Combe Incorporated Stable mixed emulsions
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
WO2006097938A1 (en) * 2005-03-16 2006-09-21 Strides Arcolab Limited Stable liquid suspension formulation comprising tibolone and process for producing the same
WO2006102157A1 (en) * 2005-03-21 2006-09-28 Ivax Pharmaceuticals S.R.O. Crystallization inhibitor and its use in gelatin capsules
US20060222671A1 (en) * 2005-03-30 2006-10-05 Astion Development A/S Dermatological compositions and salts for the treatment of dermatological diseases
MX2007012124A (en) * 2005-03-30 2007-11-21 Teva Pharma Formulations containing fenofibrate and surfacant mixture.
EP1707197A1 (en) * 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
DE102005017592A1 (en) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Dosage forms and combination preparations of pyrimidine biosynthesis inhibitors to achieve additional effects on the immune system
CN1853728A (en) * 2005-04-19 2006-11-01 上海天博生物科技有限公司 Method prescription and use for improving medicine or nutrient oral absorption
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
AU2006249349B2 (en) * 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
CA2612380C (en) * 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
CN101232869B (en) * 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 The gel combination of topical
KR100781882B1 (en) 2005-07-12 2007-12-05 주식회사유한양행 A pharmaceutical composition containing sibutramine
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007012022A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Unit dose form with ibuprofen-famotidine admixture
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
MXPA05009381A (en) * 2005-09-02 2007-03-01 Fernando Ahumada Ayala Skin-care preparations containing mupirocin and betamethasone dipropionate.
US20070065390A1 (en) * 2005-09-19 2007-03-22 Eric Spengler Stable emulsion systems with high salt tolerance
CN101316595A (en) * 2005-09-29 2008-12-03 利普生物药剂公司 Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
PT1937276E (en) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Improved testosterone gel and method of use
TW200800268A (en) 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
JP2009518399A (en) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Heterocyclic acrylamide compounds as FABI inhibitors and antibacterial agents
PE20110019A1 (en) * 2005-12-22 2011-01-27 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION CONTAINING AN INSULIN SENSITIZER AND AN INSULIN SECRETAGOG
JP5290582B2 (en) * 2005-12-28 2013-09-18 帝國製薬株式会社 Pharmaceutical composition for nail
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
AU2007215304B2 (en) 2006-02-09 2012-06-14 Alba Therapeutics Corporation Formulations for a tight junction effector
EP1818049A3 (en) 2006-02-10 2008-11-19 LifeCycle Pharma A/S Stabilized Atorvastatin
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
WO2007103555A2 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US20070225246A1 (en) * 2006-03-27 2007-09-27 Denu John M O-acetyl-ADP-ribose non-hydrolyzable analogs
CN101437518A (en) * 2006-04-06 2009-05-20 活跃生物药物学有限公司 Pharmaceutical compositions and uses thereof
FR2900048B1 (en) * 2006-04-21 2012-11-16 Oreal COMPOSITIONS COMPRISING A DIPHENYL-METHANE HYDROXYLATED DERIVATIVE
WO2007134219A2 (en) * 2006-05-11 2007-11-22 Living Proof, Inc. In situ polymerization for skin treatment
US20080063637A1 (en) * 2006-05-19 2008-03-13 The Trustees Of Tufts College Regulation of oncogenesis by Akt-specific isoforms
KR100917809B1 (en) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 Stable Pharmaceutical Composition containing Docetaxel
JP2009538901A (en) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． Dual unit pharmaceutical formulation
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
CA2657776C (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
WO2008008374A2 (en) * 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
JP5468899B2 (en) * 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Acrylamide derivatives as FABI inhibitors
US20100260691A1 (en) * 2006-07-31 2010-10-14 Narayanan Kolazi S Aqueous compositions containing a hydrophobic material
US20100239629A1 (en) * 2006-07-31 2010-09-23 Isp Investments Inc. Delivery system for delivering bioactive materials
BRPI0715328A2 (en) * 2006-08-04 2013-07-09 Insys Therapeutics Inc formulation and unit dose or multiple dose device for sublingual administration of a drug
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
HUE052378T2 (en) * 2006-09-01 2021-04-28 Fmc Corp Local topical administration formulations containing indoxacarb
JP4717769B2 (en) * 2006-09-20 2011-07-06 辻製油株式会社 Method for producing oil-soluble substance-containing solubilized composition
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US8747871B2 (en) * 2006-09-28 2014-06-10 Isp Investments Inc. Synergistic matrix composite for making stable microemulsions of active ingredients
ATE496617T1 (en) 2006-10-04 2011-02-15 M & P Patent Ag CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL USE OF NEUROTRANSMITTERS
EP1973528B1 (en) 2006-11-17 2012-11-07 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US20080131501A1 (en) * 2006-12-04 2008-06-05 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa Salts, prodrugs and polymorphs of fab i inhibitors
JP5452236B2 (en) * 2007-03-02 2014-03-26 ファーナム・カンパニーズ・インコーポレーテッド Sustained release composition using wax-like substance
GB0704709D0 (en) * 2007-03-12 2007-04-18 Croda Singapore P L Dispersion, gel and emulsification system
WO2008122965A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US8309222B2 (en) * 2007-04-25 2012-11-13 Covidien Lp Coated filaments
EP2061587A1 (en) 2007-04-26 2009-05-27 Sigmoid Pharma Limited Manufacture of multiple minicapsules
EP3766493B1 (en) 2007-04-27 2023-08-23 CyDex Pharmaceuticals, Inc. Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin
PT2155712T (en) 2007-05-22 2016-12-13 Chemocentryx Inc 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
NZ581099A (en) * 2007-05-22 2012-03-30 Otsuka Pharma Co Ltd A medicament comprising a carbostyril derivative and donepezil for treating Alzheimer's disease
EP2164518B1 (en) * 2007-05-25 2019-04-24 The University Of British Columbia Formulations for the oral administration of therapeutic agents and related methods
CN101801415B (en) 2007-05-25 2015-09-23 Rb医药品有限公司 The sustained delivery formulations of risperidone compounds
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
CN101820881B (en) 2007-07-12 2013-05-01 坎莫森特里克斯公司 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treament of inflammation
EP2184983A1 (en) * 2007-08-06 2010-05-19 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US20090062244A1 (en) * 2007-09-04 2009-03-05 Joseph Schwarz Pharmaceutical composition
JP2010539245A (en) 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
CN101918019B (en) * 2007-10-08 2014-11-26 奥里尼亚制药有限公司 Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
EP2220208A4 (en) * 2007-11-23 2010-12-29 Rappaport Family Inst For Res Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
EP2231144B1 (en) * 2007-12-24 2014-07-02 Sun Pharma Advanced Research Company Limited Nanodispersion
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
US7893097B2 (en) 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US9254264B2 (en) * 2008-02-06 2016-02-09 Biosuspensions Limited Compositions and uses thereof
US20110004148A1 (en) * 2008-02-08 2011-01-06 Terumo Kabushiki Kaisha Device for local intraluminal transport of a biologically and physiologically active agent
KR101259246B1 (en) 2008-03-17 2013-04-29 디스커버리 라보라토리스, 인크. Ventilation circuit adaptor and proximal aerosol delivery system
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
FR2932682B1 (en) * 2008-06-23 2013-07-12 Bionetwork NOVEL PHARMACEUTICAL FORMS WITH RAPID EFFECT AND USES OF PHARMACEUTICAL COMPOSITIONS THUS OBTAINED.
EP2306989A2 (en) * 2008-07-03 2011-04-13 Panacea Biotec Limited Fenofibrate formulation with enhanced oral bioavailability
CN102176913B (en) * 2008-10-08 2014-08-13 高田制药株式会社 Tacrolimus preparation for external applications
EP2179760B1 (en) 2008-10-22 2013-02-27 Trudell Medical International Modular Aerosol Delivery System
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100209475A1 (en) * 2009-02-19 2010-08-19 Biomet Manufacturing Corp. Medical implants having a drug delivery coating
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
KR20190071006A (en) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
GB2483815B (en) 2009-05-18 2013-12-25 Sigmoid Pharma Ltd Composition comprising oil drops
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
EP2255786A1 (en) * 2009-05-25 2010-12-01 HRA Pharma LLC Self-microemulsifying mitotane composition
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
TWI471321B (en) * 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
EP2442805A4 (en) 2009-06-19 2012-11-21 Sun Pharma Advanced Res Co Ltd Nanodispersion of a drug and process for its preparation
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
ME01718B (en) 2009-07-07 2014-09-20 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis C viral protease inhibitor
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
CA2775890C (en) * 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
AU2010316741A1 (en) 2009-11-09 2012-05-24 Capsugel Belgium Nv Delivery carrier
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8927009B2 (en) * 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
US8603568B2 (en) * 2010-01-15 2013-12-10 Kemin Industries, Inc. Hydrolyzed lecithin product to improve digestibility
JP5283654B2 (en) * 2010-03-30 2013-09-04 中日本カプセル 株式会社 Filling composition for soft capsules
UY33310A (en) 2010-03-31 2011-10-31 Pharmasset Inc ESTEREOSELECTIVE SYNTHESIS OF ASSETS CONTAINING PHOSPHORUS
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
PL2552930T3 (en) 2010-03-31 2016-02-29 Gilead Pharmasset Llc Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
EA027666B1 (en) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
EP2585051B2 (en) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
LT2600850T (en) 2010-08-04 2018-12-10 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
PT2600846E (en) * 2010-08-04 2016-02-09 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
KR101907225B1 (en) 2010-10-01 2018-10-11 마리 케이 인코포레이티드 Skin moisturizer and age fighting formula
US8865198B2 (en) 2010-10-25 2014-10-21 Dexcel Pharma Technologies Ltd. Method for treating a periodontal disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EA023996B1 (en) 2010-12-24 2016-08-31 КРКА, д.д., НОВО МЕСТО Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts with an organic acid
US20120172796A1 (en) 2010-12-30 2012-07-05 Chappa Ralph A Composition for intravascular delivery of therapeutic composition
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc Treatment of submental fat
CN103547258B (en) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 Local nitric oxide system and its application method
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
AR086400A1 (en) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp FORMULATIONS IN INTRANASAL GEL OF TESTOSTERONE IN DOSE OF LOWER POWER AND USE OF THE SAME FOR THE TREATMENT OF ANORGASMIA OR THE DISORDER OF HYPOACTIVE SEXUAL DESIRE
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
JP5885397B2 (en) * 2011-05-18 2016-03-15 東洋精糖株式会社 Method for dissolving poorly water-soluble substances and use thereof
EA201391742A1 (en) * 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. PHARMACEUTICAL COMPOSITION INCLUDING FEXOPHENADINE
EP2731460A1 (en) * 2011-07-15 2014-05-21 Prayon Formulation of transparent and nutritive microemulsions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
KR102180667B1 (en) 2011-09-29 2020-11-20 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
TW201330851A (en) * 2012-01-20 2013-08-01 Renascence Therapeutics Ltd Therapeutic compositions for intranasal administration of zolpidem
AU2013211876B2 (en) * 2012-01-26 2017-02-09 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
BR112014021148B1 (en) 2012-02-29 2022-07-26 Chemocentryx, Inc PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR9 ANTAGONISTS, THEIR COMPOSITION AND METHOD OF MODULATE CCR FUNCTION(9) IN A CELL
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EA028809B1 (en) 2012-05-09 2018-01-31 Вестерн Юниверсити Оф Хелт Сайенсиз Proliposomal formulations for delivery of testosterone
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
MX358435B (en) * 2012-06-18 2018-08-03 Therapeuticsmd Inc Soluble estradiol capsule for vaginal insertion.
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE043836T2 (en) 2012-06-19 2019-09-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
EP3446685A1 (en) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
AU2013355054B2 (en) 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2015007853A (en) 2012-12-21 2015-09-29 Chemocentryx Inc Diazole amides.
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2014204739B2 (en) 2013-01-14 2016-08-11 Infirst Healthcare Limited Compositions and methods for treating severe pain
WO2014117999A1 (en) 2013-02-04 2014-08-07 Biocopea Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US9040034B2 (en) 2013-04-09 2015-05-26 International Business Machines Corporation Vitamin functionalized gel-forming block copolymers for biomedical applications
CN105451551B (en) * 2013-08-14 2018-09-07 禾大公司 Auxiliary combination
WO2015084842A1 (en) 2013-12-02 2015-06-11 Chemocentryx, Inc. Ccr6 compounds
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10188611B2 (en) 2013-12-18 2019-01-29 Capsugel Belguim NV Stable liquid filled hard capsule comprising beta-hydroxy-beta methylbutyric acid
CA2973906C (en) * 2014-01-17 2022-07-26 Oncoral Pharma Aps Solid oral dosage form of irinotecan for the treatment of cancer
WO2015123272A1 (en) 2014-02-11 2015-08-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3122336A4 (en) 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
EA035866B1 (en) 2014-04-02 2020-08-21 Минорикс Терапьютикс С.Л. Use of 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders and method of treatment using such derivatives
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2016015528A (en) * 2014-06-11 2017-04-25 Mallinckrodt Llc Spray dried compositions having different dissolution profiles and processes for their preparation.
MX2016013693A (en) 2014-07-29 2017-10-31 Therapeuticsmd Inc Transdermal cream.
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
HUE053624T2 (en) 2014-11-07 2021-07-28 Sublimity Therapeutics Ltd Compositions comprising cyclosporin
JP6891118B2 (en) 2014-12-23 2021-06-18 インテレクチュアル プロパティ アソシエイツ エルエルシーＩｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ａｓｓｏｃｉａｔｅｓ， ＬＬＣ Methods and formulations for transdermal administration
PT3265140T (en) * 2015-03-02 2021-07-21 Medlab Clinical U S Inc Transmucosal and transdermal delivery systems
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP6605047B2 (en) 2015-05-28 2019-11-13 ドクター・レディーズ・ラボラトリーズ・リミテッド Celecoxib oral composition for the treatment of pain
BR112017027688A2 (en) 2015-06-22 2018-09-04 Lipocine Inc ORAL COMPOSITIONS CONTAINING 17- HYDROXYPROGESTERONE ESTER AND RELATED METHODS
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
GB201518172D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
TWI734715B (en) 2015-11-19 2021-08-01 美商卡默森屈有限公司 Modulators of chemokine receptors
KR101710441B1 (en) * 2015-12-28 2017-02-28 신풍제약주식회사 Tablet with improved stability and dissolution
JP6898334B6 (en) 2016-01-20 2021-07-28 ケモセントリックス，インコーポレイティド 2-Oxindole compound
KR20180114177A (en) 2016-02-26 2018-10-17 데비오팜 인터네셔날 에스 에이 Treatment of Diabetic Foot Infection
EP3426301A4 (en) * 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
US10286077B2 (en) * 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018049184A1 (en) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
KR101957585B1 (en) * 2016-09-23 2019-03-14 씨제이제일제당 (주) A fatty acid ethyl ester for cosmetics
EP4134080A1 (en) 2016-11-23 2023-02-15 ChemoCentryx, Inc. Ccr2 inhibitors for use in treating renal diseases
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. Oral testosterone undecanoate therapy
ES2867300T3 (en) 2016-12-01 2021-10-20 Minoryx Therapeutics S L 5 - [[4- [2- [5- (1-hydroxyethyl) pyridin-2-yl] ethoxy] phenyl] methyl] -1,3-thiazolidine-2,4-dione for treatment of nonalcoholic fatty liver disease
US20180207097A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force Non-toxic vehicle to solubilize, deliver, and obtain biological activity of steroid hormones at cell, tissue, and organ targets, in vitro and in vivo
BR112020007183A2 (en) 2017-10-11 2020-09-24 Chemocentryx, Inc. treatment of segmented focal glomerulosclerosis with ccr2 antagonists
GB2572126B (en) * 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
US10898434B2 (en) * 2018-05-14 2021-01-26 Texas Christian University Single-walled carbon nanotube-assisted antibiotic delivery and imaging techniques
EP3793535A1 (en) 2018-05-16 2021-03-24 Bayer Healthcare LLC High concentration suspension formulation for cold and flu soft gel capsule medications
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
ES2954907T3 (en) 2020-02-25 2023-11-27 Labomed Pharmaceutical Company S A Oral solutions comprising fludrocortisone acetate
WO2021257913A1 (en) * 2020-06-20 2021-12-23 Chavan Neha Compositions for solubilizing water-insoluble active ingredients
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
IL299845A (en) 2020-07-15 2023-03-01 Schabar Res Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
US11872320B2 (en) 2021-02-25 2024-01-16 Hisamitsu Pharmaceutical Co., Inc. Method for treating osteoarthritis
US20230083749A1 (en) * 2021-08-24 2023-03-16 Epalex Corporation Propofol compositions and methods of use
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (en) 1978-03-07 1979-09-13 Sandoz Ag NEW RESORBABLE GALENIC COMPOSITIONS
FR2502951B1 (en) * 1981-04-06 1985-12-06 Sandoz Sa TOPICAL PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A MICRO-EMULSION
US4731384A (en) 1983-07-01 1988-03-15 Troponwerke Gmbh & Co, Kg Etofenamate formulation
DE3406497A1 (en) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION
US4713246A (en) 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
JPS6112632A (en) * 1984-06-27 1986-01-21 Eisai Co Ltd Composition containing fat-soluble drug
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
DE3500103A1 (en) * 1985-01-04 1986-07-10 R.P. Scherer GmbH, 6930 Eberbach PHARMACEUTICAL PREPARATION WITH AN INTENSIVE SOLUTION IN WATER AND DIGESTIVE JUICES
JPS61189216A (en) * 1985-02-18 1986-08-22 Hisamitsu Pharmaceut Co Inc Water-soluble vitamin preparation
DE3611467A1 (en) * 1986-04-05 1987-10-08 Dolorgiet Gmbh & Co Kg HIGHLY RESORBABLE PREPARATION FOR THE HYMECROMON AND METHOD FOR PRODUCING THE SAME
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5244925A (en) 1987-12-18 1993-09-14 Kabi Pharmacia Aktiebolag Emulsion for parenteral administration
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (en) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 A multiphase cyclosporin composition
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5104656A (en) 1989-06-16 1992-04-14 Seth Pyare L Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
JP3273785B2 (en) 1990-08-13 2002-04-15 ダブリュー． イェスエア，デービッド Mixed lipid-bicarbonate colloid particles for drug or heat source delivery
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5300529A (en) 1991-02-12 1994-04-05 Isp Investments Inc. Stable, clear, efficacious aqueous microemulsion compositions containing a high loading of a water-insoluble, agriculturally active chemical
SE9200951D0 (en) 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
IT1255449B (en) 1992-06-30 1995-10-31 Fabio Berlati USE OF NOR- AND HOMO-DERIVATIVES OF BILE ACIDS AS DRUGS ABSORPTION PROMOTERS.
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH0717860A (en) * 1993-07-01 1995-01-20 Yoshitomi Pharmaceut Ind Ltd Liposoluble substance-containing solution agent and method for emulsifying and solubilizing liposoluble substance
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
JP3534199B2 (en) * 1993-11-10 2004-06-07 株式会社薬研 Surfactant composition
DE4340781C3 (en) 1993-11-30 2000-01-27 Novartis Ag Liquid preparations containing cyclosporin and process for their preparation
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5731355A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US5616330A (en) 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
PE52896A1 (en) * 1994-10-26 1996-12-12 Novartis Ag PHARMACEUTICAL COMPOSITION
KR0167613B1 (en) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
JP2740153B2 (en) 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー Mixed micelle
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
JPH1059862A (en) * 1996-08-16 1998-03-03 Meiji Seika Kaisha Ltd Cyclosporin preparation
PL193414B1 (en) * 1997-03-12 2007-02-28 Abbott Lab Hydrophilic two-component systems for use in administration of cyclosporine
CA2283780A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
NZ314702A (en) 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
ATE265847T1 (en) * 1997-07-29 2004-05-15 Upjohn Co SELF-EMULSIFABLE FORMULATION CONTAINING LIPOPHILIC COMPOUNDS
SI0989851T1 (en) * 1997-07-29 2003-04-30 Pharmacia & Upjohn Company Self-emulsifying formulation for acidic lipophilic compounds
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
WO1999056727A2 (en) 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

Cited By (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US20030138455A1 (en) * 1997-09-04 2003-07-24 Hertelendy, Pharm.D.,Ph.D Zsolt Istvan Urogential or anorectal transmucosal vaccine delivery system
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US20120046237A1 (en) * 1998-04-08 2012-02-23 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US20040175435A1 (en) * 1998-09-02 2004-09-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US7927622B1 (en) 1999-01-27 2011-04-19 Gregor Cevc Methods of transnasal transport/immunization with highly adaptable carriers
US7867480B1 (en) 1999-01-27 2011-01-11 Gregor Cevc Non-invasive vaccination through the skin
US6984397B2 (en) 1999-03-11 2006-01-10 Fujisawa Pharmaceutical Company, Ltd. Liposome preparations
US20040028728A1 (en) * 1999-03-11 2004-02-12 Fujisawa Pharmaceutical Company, Ltd. Liposome preparations
US7459171B2 (en) 1999-07-05 2008-12-02 Idea Ag Method for the improvement of transport across adaptable semi-permeable barriers
US7591949B2 (en) 1999-07-05 2009-09-22 Idea Ag Method for the improvement of transport across adaptable semi-permeable barriers
US20080095855A1 (en) * 2000-03-28 2008-04-24 Schwarz Franz X Taste Masking Granules
US20050220871A1 (en) * 2000-03-28 2005-10-06 Schwarz Franz X Taste masking granules
US20020107250A1 (en) * 2000-04-18 2002-08-08 Madhusudan Hariharan Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor
US7168630B1 (en) 2000-06-08 2007-01-30 S.C. Johnson & Son, Inc. Methods and personal protection devices for repelling insects
US7007861B2 (en) 2000-06-08 2006-03-07 S.C. Johnson & Son, Inc. Methods and personal protection devices for repelling insects
US7152809B2 (en) 2000-06-08 2006-12-26 S.C. Johnson & Son, Inc. Methods and personal protection devices for repelling insects
US20060226249A1 (en) * 2000-06-08 2006-10-12 S.C. Johnson & Son, Inc. Methods and personal protection devices for repelling insects
US20020005437A1 (en) * 2000-06-08 2002-01-17 Ketcha Marcia Mary Methods and personal protection devices for repelling insects
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040245662A1 (en) * 2000-12-22 2004-12-09 Mahesh Chaubal Method for preparing submicron particles of antineoplastic agents
US8333991B2 (en) 2001-10-25 2012-12-18 Depomed, Inc. Gastric retained gabapentin dosage form
US8475813B2 (en) 2001-10-25 2013-07-02 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8802157B2 (en) 2001-10-25 2014-08-12 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage form
US8529955B2 (en) 2001-10-25 2013-09-10 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8580303B2 (en) 2001-10-25 2013-11-12 Depomed, Inc. Gastric retained gabapentin dosage form
US8440232B2 (en) 2001-10-25 2013-05-14 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8333992B2 (en) 2001-10-25 2012-12-18 Depomed, Inc. Gastric retained gabapentin dosage form
US20120148671A1 (en) * 2001-10-25 2012-06-14 Depomed, Inc. Gastric retained gabapentin dosage form
US8409613B2 (en) * 2001-10-25 2013-04-02 Depomed, Inc. Gastric retained gabapentin dosage form
US7897563B2 (en) 2001-12-21 2011-03-01 Soane Family Trust Use of oligomers and polymers for drug solubilization, stabilization, and delivery
US20090156692A1 (en) * 2001-12-21 2009-06-18 Soane David S Use of oligomers and polymers for drug solubilization, stabilization, and delivery
US7482018B2 (en) * 2001-12-21 2009-01-27 Soane Family Trust Use of oligomers and polymers for drug solubilization, stabilization, and delivery
US20030180244A1 (en) * 2001-12-21 2003-09-25 Soane David S. Use of oligomers and polymers for drug solublization, stabilization, and delivery
US9211261B2 (en) 2002-02-01 2015-12-15 Bend Research, Inc. Immediate release dosage forms containing solid drug dispersions
US20080317851A1 (en) * 2002-02-01 2008-12-25 Pfizer Inc Immediate release dosage forms containing solid drug disbursions
US20030224043A1 (en) * 2002-02-01 2003-12-04 Pfizer Inc. Immediate release dosage forms containing solid drug dispersions
EP1501496A4 (en) * 2002-05-04 2006-05-31 Cydex Inc Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP2402008A1 (en) * 2002-05-04 2012-01-04 CyDex Pharmaceuticals, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP1501496A2 (en) * 2002-05-04 2005-02-02 Cydex Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20110098289A1 (en) * 2002-05-17 2011-04-28 Gadde Kishore M Method for treating obesity
US8367738B2 (en) 2002-05-22 2013-02-05 Nihon Pharmaceutical Co., Ltd. Smooth muscle contraction inhibitors
US20110028567A1 (en) * 2002-05-22 2011-02-03 Tomonori Hamawaki Smooth muscle contraction inhibitors
US20050239905A1 (en) * 2002-05-22 2005-10-27 Tomonori Hamawaki Smooth muscle peristole inhibitor
US7989503B2 (en) * 2002-05-22 2011-08-02 Nihon Pharmaceutical Co., Ltd. Smooth muscle peristole inhibitor
US8030517B2 (en) 2002-05-24 2011-10-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20100280074A1 (en) * 2002-05-24 2010-11-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US9035096B2 (en) 2002-05-24 2015-05-19 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20100324093A1 (en) * 2002-05-24 2010-12-23 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7999109B2 (en) 2002-05-24 2011-08-16 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
KR100573289B1 (en) * 2002-07-20 2006-04-24 대화제약 주식회사 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof
US20070031483A1 (en) * 2002-10-11 2007-02-08 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20090060989A1 (en) * 2002-10-11 2009-03-05 Idea Ag Nsaid formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20040071767A1 (en) * 2002-10-11 2004-04-15 Gregor Cevc NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20090060990A1 (en) * 2002-10-11 2009-03-05 Idea Ag Nsaid formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20090042989A1 (en) * 2002-10-11 2009-02-12 Idea Ag Nsaid formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US20090118307A1 (en) * 2002-11-18 2009-05-07 Chemocentryx, Inc. Aryl Sulfonamides
US20070203131A1 (en) * 2002-11-18 2007-08-30 Solomon Ungashe Bis-aryl sulfonamides
US20050137179A1 (en) * 2002-11-18 2005-06-23 Solomon Ungashe Bis-aryl sulfonamides
US8211896B2 (en) 2002-11-18 2012-07-03 Chemocentryx, Inc. Aryl sulfonamides
EP1798223A2 (en) 2002-11-18 2007-06-20 ChemoCentryx Inc Aryl sulfonamides
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US20050137193A1 (en) * 2002-11-18 2005-06-23 Chemocentreyx Aryl sulfonamides
US8642808B2 (en) 2002-11-18 2014-02-04 Chemocentryx, Inc. Bis-aryl sulfonamides
US20090163498A1 (en) * 2002-11-18 2009-06-25 Chemocentryx, Inc. Aryl Sulfonamides
EP2256116A2 (en) 2002-11-18 2010-12-01 ChemoCentryx, Inc. Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US10364240B2 (en) 2002-11-18 2019-07-30 ChemoCentryx. Inc. Aryl sulfonamides
US9890148B2 (en) 2002-11-18 2018-02-13 Chemocentryx, Inc. Aryl sulfonamides
US7335653B2 (en) 2002-11-18 2008-02-26 Chemocentryx, Inc. Bis-aryl sulfonamides
US20040167113A1 (en) * 2002-11-18 2004-08-26 Solomon Ugashe Bis-aryl sulfonamides
US7582661B2 (en) 2002-11-18 2009-09-01 Chemocentryx, Inc. Aryl sulfonamides
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
US20060204585A1 (en) * 2003-07-18 2006-09-14 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20100297220A1 (en) * 2003-07-18 2010-11-25 Santarus, Inc Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
US8648048B2 (en) 2003-09-15 2014-02-11 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8633162B2 (en) 2003-09-15 2014-01-21 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8685930B2 (en) 2003-09-15 2014-04-01 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8642556B2 (en) 2003-09-15 2014-02-04 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8629111B2 (en) 2003-09-15 2014-01-14 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US9248191B2 (en) 2003-09-15 2016-02-02 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20110073518A1 (en) * 2003-12-31 2011-03-31 Cima Labs Inc. Generally Linear Effervescent Oral Fentanyl Dosage Form and Methods of Administering
US8092832B2 (en) * 2003-12-31 2012-01-10 Cephalon, Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20050209172A1 (en) * 2004-03-17 2005-09-22 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US20060258617A1 (en) * 2004-04-15 2006-11-16 Allergan, Inc. Drug delivery to the back of the eye
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US20050250738A1 (en) * 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US20060147522A1 (en) * 2004-05-25 2006-07-06 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050266071A1 (en) * 2004-05-25 2005-12-01 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US8414920B2 (en) 2004-06-04 2013-04-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20050271720A1 (en) * 2004-06-04 2005-12-08 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US20070231358A1 (en) * 2004-10-29 2007-10-04 Tolmar, Inc. Intravaginal treatment of vaginal infections with metronidazole compositions
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US20090030060A1 (en) * 2004-10-29 2009-01-29 Tolmar, Inc. Intravaginal treatment of vaginal infections with metronidazole compositions
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
EP2354126A1 (en) 2005-01-14 2011-08-10 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
EP2474532A1 (en) 2005-01-14 2012-07-11 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
US20080085302A1 (en) * 2005-03-31 2008-04-10 Fairfield Clinical Trials, Llc Transdermal device for administration of antimicrobial medications
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
US11331325B2 (en) 2005-04-15 2022-05-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US11179402B2 (en) 2005-04-15 2021-11-23 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
EP2979699A1 (en) * 2005-04-15 2016-02-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
EP1871384A2 (en) * 2005-04-15 2008-01-02 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
EP1871384A4 (en) * 2005-04-15 2012-01-25 Clarus Therapeutics Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
EP2985026A1 (en) * 2005-04-15 2016-02-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8211855B2 (en) 2005-07-13 2012-07-03 Allergan, Inc. Cyclosporin compositions
US9101574B2 (en) 2005-07-13 2015-08-11 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US8536134B2 (en) 2005-07-13 2013-09-17 Allergan, Inc. Cyclosporin compositions
US8969307B2 (en) 2005-07-13 2015-03-03 Allergan, Inc. Cyclosporin compositions
US8969306B2 (en) 2005-07-13 2015-03-03 Allergan, Inc. Cyclosporin compositions
US10507229B2 (en) 2005-07-13 2019-12-17 Saint Regis Mohawk Tribe Cyclosporin compositions
US7276476B2 (en) 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US8563518B2 (en) 2005-07-13 2013-10-22 Allergan, Inc. Cyclosporin compositions
US20070015710A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US8575108B2 (en) 2005-07-13 2013-11-05 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US10456474B2 (en) 2005-07-13 2019-10-29 Saint Regis Mohawk Tribe Cyclosporin compositions
US20070015694A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015692A1 (en) * 2005-07-13 2007-01-18 Chang James N Cyclosporin compositions
US20080070834A1 (en) * 2005-07-13 2008-03-20 Allergan, Inc. Cyclosporin Compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US8906861B2 (en) 2005-07-27 2014-12-09 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US20070027072A1 (en) * 2005-07-27 2007-02-01 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1749528A1 (en) 2005-08-05 2007-02-07 Pharma C S.A. Pharmaceutical combinations containing a mu opioid agonist and an inhibitor of NO production
US20100266622A1 (en) * 2005-10-14 2010-10-21 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US8501174B2 (en) 2005-10-14 2013-08-06 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20070167358A1 (en) * 2005-10-14 2007-07-19 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
AU2013213706B2 (en) * 2005-11-07 2016-04-14 Murty Pharmaceuticals, Inc An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
AU2016203127B2 (en) * 2005-11-07 2018-07-12 Murty Pharmaceuticals, Inc An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
AU2006311818B2 (en) * 2005-11-07 2013-05-09 Murty Pharmaceuticals, Inc Improved delivery of tetrahydrocannabinol
AU2006311818B9 (en) * 2005-11-07 2013-05-16 Murty Pharmaceuticals, Inc Improved delivery of tetrahydrocannabinol
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
EP2314590A1 (en) 2005-11-10 2011-04-27 ChemoCentryx, Inc. Substituted quinolones and methods of use
US20070128298A1 (en) * 2005-11-22 2007-06-07 Cowley Michael A Compositions and methods for increasing insulin sensitivity
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8815889B2 (en) 2005-11-22 2014-08-26 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US8592481B2 (en) 2005-12-29 2013-11-26 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20110218246A1 (en) * 2005-12-29 2011-09-08 Depomed, Inc Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20110218247A1 (en) * 2006-03-28 2011-09-08 Curtis Wright Formulations of low dose diclofenac and beta-cyclodextrin
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
US20070232566A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US8946292B2 (en) 2006-03-28 2015-02-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
US20080057129A1 (en) * 2006-04-03 2008-03-06 Lerner E I Drug microparticles
US20070281021A1 (en) * 2006-06-05 2007-12-06 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US9504699B2 (en) 2006-08-03 2016-11-29 Hznp Limited Delayed-release glucocorticoid treatment of rheumatoid disease
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20080045583A1 (en) * 2006-08-18 2008-02-21 David Delmarre Stable levetiracetam compositions and methods
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US8722085B2 (en) 2006-11-09 2014-05-13 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US20110059170A1 (en) * 2006-11-09 2011-03-10 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US8318788B2 (en) 2006-11-09 2012-11-27 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US20080188540A1 (en) * 2007-02-05 2008-08-07 Wyeth Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US20080261966A1 (en) * 2007-04-23 2008-10-23 Solomon Ungashe Bis-aryl sulfonamides
WO2008147822A1 (en) 2007-05-22 2008-12-04 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20120177692A1 (en) * 2007-08-09 2012-07-12 Ems S/A Delivery systems for solubilising water-insoluble pharmaceutical active ingredients
US9278065B2 (en) * 2007-08-09 2016-03-08 Ems S/A Delivery systems for solubilising water-insoluble pharmaceutical active ingredients
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US10555878B2 (en) * 2007-12-14 2020-02-11 L'oreal Solid antiperspirant and/or deodorant composition in the form of a water-in-oil emulsion based on silicone emulsifiers and on waxes; method for treating body odours
US20140193471A1 (en) * 2007-12-14 2014-07-10 L'oreal Solid antiperspirant and/or deodorant composition in the form of a water-in-oil emulsion based on silicone emulsifiers and on waxes; method for treating body odours
US11324741B2 (en) 2008-05-30 2022-05-10 Nalpropion Pharmaceuticals Llc Methods for treating visceral fat conditions
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP3508477A1 (en) 2008-12-22 2019-07-10 ChemoCentryx, Inc. C5ar antagonists
EP3078658A1 (en) 2008-12-22 2016-10-12 ChemoCentryx, Inc. C5ar antagonists
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US20100196427A1 (en) * 2009-01-30 2010-08-05 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010117233A2 (en) * 2009-04-09 2010-10-14 한올바이오파마주식회사 Stable pharmaceutical composition containing fluvastatin and method for manufacturing the same
WO2010117233A3 (en) * 2009-04-09 2011-03-03 한올바이오파마주식회사 Stable pharmaceutical composition containing fluvastatin and method for manufacturing the same
WO2010140061A2 (en) 2009-06-03 2010-12-09 John Charles Mayo Formulations for the treatment of deep tissue pain
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
WO2010148288A3 (en) * 2009-06-19 2011-05-19 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US9452179B2 (en) 2009-08-21 2016-09-27 Sequessome Technology Holdings Limited Vesicular formulations
WO2011035332A1 (en) 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US11617758B2 (en) 2009-12-31 2023-04-04 Marius Pharmaceuticals Llc Emulsion formulations
US20110160168A1 (en) * 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US10576090B2 (en) 2009-12-31 2020-03-03 Marius Pharmaceuticals Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US10576089B2 (en) 2009-12-31 2020-03-03 Marius Pharmaceuticals Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US11590146B2 (en) 2009-12-31 2023-02-28 Marius Pharmaceuticals Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
WO2011082384A3 (en) * 2009-12-31 2011-11-10 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20110172260A1 (en) * 2010-01-11 2011-07-14 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US10322121B2 (en) 2010-01-11 2019-06-18 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US11033543B2 (en) 2010-01-11 2021-06-15 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
WO2011103413A3 (en) * 2010-02-19 2012-01-12 Teikoku Pharma Usa, Inc. Taxane pro-emulsion formulations and methods making and using the same
US8569357B2 (en) 2010-02-19 2013-10-29 Teikoku Pharma Usa, Inc. Taxane pro-emulsion formulations and methods making and using the same
US20110207803A1 (en) * 2010-02-19 2011-08-25 Kiichiro Nabeta Taxane Pro-Emulsion Formulations and Methods Making and Using the Same
US11179403B2 (en) 2010-04-12 2021-11-23 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US10617696B2 (en) 2010-04-12 2020-04-14 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US11426416B2 (en) 2010-04-12 2022-08-30 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2012039596A3 (en) * 2010-09-22 2012-08-16 Craun Research Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
JP2013537903A (en) * 2010-09-22 2013-10-07 クラウン リサーチ エスディーエヌ ビーエイチディー Pharmaceutical compositions for calanolide, derivatives and analogues thereof and process for preparing it
AU2011306573C1 (en) * 2010-09-22 2015-02-19 Craun Research Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
AU2011306573B2 (en) * 2010-09-22 2014-10-23 Craun Research Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US10463229B2 (en) * 2010-10-22 2019-11-05 Fukuoka University Endoscopic observation method and composition for improving diagnostic performance involving applying useful white opaque substance to diagnosis of gastric epithelial tumors (adenoma or gastric cancer)
US20130211195A1 (en) * 2010-10-22 2013-08-15 Fukuoka University Endoscopic observation method and composition for improving diagnostic performance involving applying useful white opaque substance to diagnosis of gastric epithelial tumors (adenoma or gastric cancer)
US10660826B2 (en) * 2010-11-15 2020-05-26 L'oréal Solid cosmetic composition in compact powder form
US20180092812A1 (en) * 2010-11-15 2018-04-05 L'oréal Solid cosmetic composition in compact powder form
US20140030202A1 (en) * 2010-11-15 2014-01-30 L'oreal Solid cosmetic composition in compact powder form
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US20140121178A1 (en) * 2011-06-24 2014-05-01 Acenda Pharma Inc. Method and improved pharmaceutical composition for improving the absorption of an ester prodrug
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
US10391056B2 (en) 2011-11-03 2019-08-27 Taiwan Lipsome Company, LTD. Pharmaceutical compositions of hydrophobic camptothecin derivatives
WO2013082429A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
US9555051B2 (en) 2012-03-29 2017-01-31 Sequessome Technology Holdings Limited Vesicular formulations
WO2013144289A1 (en) 2012-03-29 2013-10-03 Sequessome Technology Holdings Limited Vesicular formulations
WO2013171131A1 (en) 2012-05-14 2013-11-21 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
WO2013171132A1 (en) 2012-05-14 2013-11-21 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US10403170B2 (en) 2012-06-06 2019-09-03 Nalpropion Pharmaceuticals, Inc. Methods of treating overweight and obesity
US9539185B2 (en) * 2013-09-30 2017-01-10 L'oreal Self-foaming cleansing system
US20150093348A1 (en) * 2013-09-30 2015-04-02 L'oreal Self-foaming cleansing system
WO2015059466A1 (en) * 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
US11077061B2 (en) 2013-12-31 2021-08-03 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
AU2014373683B2 (en) * 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2015103447A1 (en) * 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2016105465A1 (en) * 2014-12-23 2016-06-30 Variant Pharmaceuticals, Inc. Oral compositions for insoluble compounds
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
EP3954361A1 (en) 2015-06-30 2022-02-16 Sequessome Technology Holdings Limited Multiphasic compositions
US11547665B2 (en) 2015-06-30 2023-01-10 Sequessome Technology Holdings Limited Multiphasic compositions
WO2018091668A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US11267790B2 (en) 2019-07-08 2022-03-08 Rezolute, Inc. Processes for preparing plasma kallikrein inhibitors
US20210330698A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers
WO2022040807A1 (en) * 2020-08-28 2022-03-03 Triple Hair Inc. Formulations for reducing hair loss and/or increasing hair regrowth
US11478485B1 (en) 2021-05-07 2022-10-25 Lipocine Inc. Compositions and methods for treating CNS disorders
US11337987B1 (en) 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders

Also Published As

Publication number Publication date
US6451339B2 (en) 2002-09-17
JP2002537317A (en) 2002-11-05
NZ513810A (en) 2004-02-27
ES2379626T3 (en) 2012-04-30
EP1158959A4 (en) 2004-12-08
US6294192B1 (en) 2001-09-25
CY1112580T1 (en) 2016-02-10
AU2224200A (en) 2000-09-14
EP1158959B1 (en) 2011-12-21
CA2365536C (en) 2012-05-15
CA2365536A1 (en) 2000-08-31
EP1158959A1 (en) 2001-12-05
EP2316427A1 (en) 2011-05-04
AU771659B2 (en) 2004-04-01
WO2000050007A1 (en) 2000-08-31
PT1158959E (en) 2012-03-19
ATE537812T1 (en) 2012-01-15
JP2012006931A (en) 2012-01-12
DK1158959T3 (en) 2012-03-19

Similar Documents

Publication Publication Date Title
US6294192B1 (en) Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) Clear oil-containing pharmaceutical compositions
US6761903B2 (en) Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6383471B1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20100136105A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU686767B2 (en) Delivery systems for hydrophobic drugs
JP2003503440A5 (en)
US20030104048A1 (en) Pharmaceutical dosage forms for highly hydrophilic materials
WO2003068186A1 (en) Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
MX2011007351A (en) Steroidal compositions.

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment

Year of fee payment: 11

AS Assignment

Owner name: LIPOCINE INC., UTAH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PATEL, MAHESH V.;CHEN, FENG-JING;REEL/FRAME:041734/0242

Effective date: 19990226